var title_f28_42_29344="Miliary sarcoidosis CT";
var content_f28_42_29344=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Miliary nodules in sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 342px; height: 227px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sarcoidosis with multiple nodules, 1 to 2 mm in diameter, in peribronchiolar location. Beading of the major fissures is characteristic of lymphatic involvement. There is also prominent bilateral hilar lymph node enlargement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_42_29344=[""].join("\n");
var outline_f28_42_29344=null;
var title_f28_42_29345="Chronic GVHD nail dystrophy";
var content_f28_42_29345=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F71229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F71229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic graft-versus-host disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dystrophic nails are present in this patient with chronic graft-versus-host disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_42_29345=[""].join("\n");
var outline_f28_42_29345=null;
var title_f28_42_29346="Lichen planus wrists fair skin";
var content_f28_42_29346=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76383&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD56xsG7AB5x69MVpaNcCDUVBkKoMDpzyKzGZP4MkfNup9qFW5Vs8Z5I+n86+xqR5ouPc4l3PVdMYztltp2Kcd62LGQFiFOMnA/xrlvC8w2IWP+tIVmx0NdGB5Mo+YEqD2xkV8fiIcr1PVoSujaEu5VYfLltp2/XrVmVlhMjSBtrAEAdvasi1aVlRwVG8kYA4+taP2gFSj4fGdvfntXG1qdcSu1sZrtTkgHOSRyoq1Y7I5tkS/vcYA/z+dNhZpp92cA4J9z6Vq2tuN5lICykHkdQKV+h1KdlY0rGJjGyOwZsY3dMf57VMAJAJGTdtHC5x9M0wXCx7li5LY7dMUsSF2YSghs/Ko4GPektTGTtqyxCwKnzFA4+QDr+NVZ5mdiFfZkYOB09qWIglnmbp044NKEXaJHyq/e96G3sStHcoOxtpAUdi+M4brUS3k8s5jLLuPIGePetWVI50yoOT932qkmmGOceW+xtucnsfahJdTqpTja73IGG+QlX2vjA75PpUZs8pukXYPc5P5VpxwNFu3BSBwB3ye9Vb1H2jJ46bR2IqlLSyNue+iCy2W0eyIZ9Aa0tzMC2evYVnWUMuWU429eatAEMAD0PrUXsc9RJsSSJWOCoJP8JAxUkEaQOG4HbPSsjU5ZFlIy6D2NW9J8ySJhL8yjnmqa6kunyxvcvX0aTRe/UHrVFIjwVIyOOOM1fjO9doXmqV8JI7ZzH+7IPfrSsnqKHZEsCqCwA5qrcBMgHrnIrOGpPHgHHPvipreb7RDnv2qk1sKpRlF8zI7hMhtvJPeuZ1GIqGI++O1dHfv5SZHQ1hXKGVd4OM9qVtSVtc8o8eNvtVPIG8HFcrpKE3DhTj5cnnHFdd4+j2w+2+uP07IuMDk4Ne1l7tVgzzMWtzb2vKzJySofAzjGKVwQ5UNuHOSvHVaTOGZZFAck5P1H86aCVdQ3T5T+GOtfVXPNCRyzKd2WIXkjrxikQqpB+7tVdo7HnFSAHEZZTwo6n0PWoiEyAX4x1x/tUmA6IrtJbJyo2g85weleueH0RLO3GBlFAIFeRuMKOCFyQGB75616/wCHYw1jCwwuVH8q8LO2+SNu56GB+Js6mALNIuTgL1GatBDGxwMK3A561UsEPQjjua0FdTMUIB6Ae1fLs9aK1I1hZ5Uac7VUYAHrV1YdkXysTk55PWlihO/5gOPepmcKuNnP8qi3c0vdhbI0jqVCqw6gUkyyPJhgBjnrjNIAMHadr9sUxlKMTNIXbt6VSehSvcklz8pxzT0CuTv/AJVE9wjINpJz6U2QrIQuecfTPtTfcTTsWo88/OPYDiq0+/dlhlen1z3qv56wh8gnB4PpStJwrJkv6GldERVncawVV2DJOMfSop4XcmIkjcOCRUh/fOc5V14IFSlHhG5wJo+MYPJFNIblYz7tpYo0kl3FiQoz0pkEgLOgQlD056Grl0iyDncA3I9qz4vMjl2BRx1Hr7/SrkQncS4ZI4y5cFtuGI6//rrLZ9vmsCXMoznpgj2q9fxpuLFyCRngcZqAJtwMhlI38d/ap8ixNxeOIkA7pAMDoM1i3LlGZTwykjP0rZgXMsgQr5ZAb6cVU1a2VImnQfNwCKtRurmcmk7MxJ3UoMneMZ49TmqKbIpWC8LjofpUtxmGGJU5fPAqmHMhG8hXI/L2ppGcjzl1MbFOpXPJpzZWQvGf4jgj6UjNuQqAzMc5JOBjNPKMUyMruDNheeOlffM+fOl8MXrRzPbSEZOJAd3cDoK7azmLRruGXIwM+ue9eVWkklpMpwDtckj6DkV6Ppc5khRgRtwMc8jvXzmZ0eWXMduGl0OnjxEmULHyxuVe3NX7MfKAwG72HFZ9tIryERABMcEjrTrO6KiUHlkPPPrXi1Nz0KZpR26jaI2Jbg/Q/X1rUiZ4mZzgjoD7+lYi3En2jaxJQEc+ma14gAHWQMZEOQOxzWTR0K9rGjFPGkm+URvGrDI7YFWPtQYnBCIx3bycfgB6VlfZvOOJlwvqp6k1XvFS12IWyH9TkKKE2gcU9DfllihjCxktzjcw6ioBIZpBIQWROOf8Kxo7uYP5ZYHccbs/1rSD/IWZ3Vj0I6fWhu4/ZuKNG2Vn+YEIB+FSKmZSHLFx0GKq2lws2FY8Hpgc1rrGBGCCx6cZ7e9Ct0J1iVHhZ+ShPPBFIYd77Sm0nuelXJGBUCJ1QDn5hnNQ/aQqNvQHuWHSqHeXQz5IhFLtQ8d8Gl8tSxI+8OOKsZt7klkGXXsaikdIGIkc7c5A7VFtbjTe3UgaGMLl1DehPUVDJfW9qNhdd3cVFf3u+PMZ+UHG4DvWPJbCa7J7kcN12mrRtGndXkdJbXCMQyspDdxUeruXt8Ku7sfaqNlG8DHPOaszS8YOKz5iErSujFOn+ccsDnpzV60tfJjKHk+tXc5GccEVVlkZM8kA09B1Kkp6FC/jBGCen61k3IEce3PI4Fat2+6A/Kd3WsW7RlicnPPrV9dDnV7WZ5n8QgDDJgAHcK4ewJW4zwcqePWu08fPmNuTycc1xenZ+2xgfSvWwX8SB5+J6mxnc+AASWHH4VKoVeTg4CZ49u1MRdxGO2Pw7UjHKbd3IVfu+mf6V9YeYKX/AHYKElcYCnkjmk/vDauBkbs9eaMIsfUkYIORyMGhiB8y8jJwAMc0MENC+YwjQFsttHHPNeyeHg0cESgdFGfSvKNPj23toV6mThieSOK9W09mjtenzAkH3FfPZ3L4YnpYCN2zchmIY4+6DzVxWIkJByOufas2xIdT1z3961IVwTjGfXtXzrV9D2+VI04ZyxGTTLt5Cy7CQD6U6GHcFcEDHarchRQvcD1rN9mQmkyjBICMscEdW7VfMSuBhwwxnIrHvkDEKvGTmrNosqrhSAU96E7I1lC8eZMnmt0XcyDDEdBUCsQxQJu9T61cBzzJjbnkZxTG8tgNo5OeAafKZ6pFeS2LwkLuXPqeaSJWSIDk5H3h1q0uVRgDzjIGM04AKmNufYcVSiiL2Kbo0SbgCWxkk9ab56+UPlxzkgHpTLkKNxfeVz685+tV4ZoCjEB+BgZx0qmi5K6uTXbSHLg+xGccVSbaxR9xBb5RjpirccgkiBDBivBB9KpTxGTzlAIUfMBnp9DUu+5MVbQj1CIMQHyFbqR2x3qk8LPIwL7PL+bcOhFXrOQ7TFcDIwT6ErVNt3zxHI2jt1bjrTQ3poZ7XXl3BHAxzu7EZ7VYvrpDbHJz5gKgep4qlMgaRCWBTGOeoqjM0iomcsyElc1UW1dEVEmRyRK0qhjt5OSO1YMpYysf4OSfUD1rXdi0kgZl+ZuDjjnms+4j8pc7gzMpyB6VpEwdup57uYL2BGDgd+akfdsx93g9T2z0ppbaFQ8qNpAA55NIWO3IAHy4we+Wr7o8DcnQ+ZnzAzHazcHJBrsvDFy7WDjpsbBH0/8A11xAZo13IcHJzge9dB4XmMUrICf3jldo+lcOPp+0pNmlKXLI9BtpGe2tmikwzEBl9hWgoVQfM53ntWDpY425wScY9OcVsOWjWMSfdB2h8dv8a+UqR1PWg9DSjjBYsrY6Oc9M+laMNwJZgFJBP8R56d6yhcK1uU7Meo7e1N06V/7T+Vsw9DnsPasGuh1xWl2dOksvl5DAkrkfX2/Cqt00bgtICW6jjoOmPzqwpRmaQHaAOvYD2pjIJpgiqS3GeOM9qQcwQaeZIiQ2ONxzz/k1rLZqY1Xnjgk1NbqqRfORz0Pv3JokZnIw+ewxxTv0FzykVrFBG7O24qOmOSaum9yx8liD7jkD3qs8iQlFbqD0FQFiXzGuN3JPXFZvTQuPvblpnmLcH5T1yafNGUiBKndjOD3FLEqtGGUlecEt3qUK0iYRSxHfOacRuRDGCArw9+uO1UdVLFRsQMOhPoauqDuwxwQeMDANTRRh2cbQAeRxVRCMuWXMzmIoyhJCMyv1U8Z/z61YhCiQNjBI6ZrXvrYeUcIM9RgVlQIz3GGXgfzFNm/PzpssBG5Kr8p6knpSXP8Aqhu6etW0QgYIySOvtUUkW5yCwwOgqGjmi9SCNh5QKtn2qK7KxRlwuTnOCKtzKOuMcVialNuyrSdDxTiioR5mU0dnuVLvhGbBPpVLWY5Le4RR/q5Acj096tGP5O4HXNUdVkCpuJ5A4rRbBWtfQ8v8dgm33HnD4/WuNsMreIR1+tdr455siTn72a4qxGb2PgnnoK9TBfHD1PJxPU2wG8ovwUXaCAc55ppViFbIjwPqOtJkLGgTPIGV9eaXnEwUHlSMenzV9aeaPV/ldcNkhlwOh5zn601lKyHkhs/eFLMWwTkAsTwB7ChwQpI+cnByO4I9KTYE9kjJqEBLBmMin6Zr1yzBaJVC539/SvJ9JjRtTtgxIwykDuTivYNFxtBPDDp7185nfxR+Z6WA0uy9p9s65BBPPB71tRQhWBPIqGyZyrswxk4Bq08oiO4c8dPWvn2z1buWhctuGYAZ/oKfKoB5G7jj2rPgvN3A6nsKth1CZ5yalu4rNMBGgUMVJJ4PtUqbVXZGvPc560wP5cRVuWY9xT0icv8AeBPahXLuQXEaBW3kZAwBkVnI7C43ABW7N0rRkiO+USYJ9M9KqtneCqEoB1x2qmWnZWL6SEJggEnqaUuki7Dwe5qqJDIR5IwAOc1JIjkgRdQMMPWlcyaK0ki+YY3LBcHnFUngKb2UK+8fdPcf55rSWAMxYlXZRyGP86jniIYtHt8wYIVhkVSV1qF7OxRikSC4bYN4YYBUc0x8SsoTvwD6HNWTahoRwQQ25QONp9PpVabMcbuNpAJ3J0yKbRd10K7hvMBkADDKZPuKzrhngwmNz4wanN4HgIdgzL2PX2qvLIJYyZMjbwT39qVxWZnTypHgsAS5bPtWdfzbXUjgEjnuOKtMGS7wGDAjbgiq14ihGZ23HsPSqTM5qxUlbzZAAvzbQx/2qrXMylQg+8FPUdPapI2cMpJXB4H4HiqV27FyVPzHr7kmtInLI4RCmV27uq5yO/tThkqrZ7Dt0Gae0Dcb9uMLgg8njvSIcxoyoQwKjOeor7tHh9RY8+XKBydhB46Dd2qxav5duZFJEscm9SeOfSq+0iLJbAAH5bu9LFkh1HQjgnv83FROPMmikz0nQ7lZXikXILhSeOn1rfcCSTa5z/Ew9+1cP4VnHlbRkMsmGUnkV11u4OQHBcnPuOa+TxVPkm0elQldXNjT7X5QGG4gA+2aFVYyXYDGeMeoqeylPkFQcNjjvn1NRwiJyW8zPPJPpXnz3O+Em1qathMpCmRgBn862vLdym0cgnP0rmbWJGmG3JII+YjoK6qCceUzHOzGScdaUbNWJqKzVhwi3Iqq/UgZ7CpxBht0YHHUmo/tEYjjc4BPRAP1NTSXKkL5aE567qSsUr2KVy6ySBVK+5x1+lJ5RaRAv3c4Jz/SrW2NSHC72YYB9B7CoZWWKNnZScc4FQ11LT6IlnWNCFDFm/lU0DOiZQHB6/41nWt2LuX5cAdM4xWsZFGQSPLxj0FOKu7oclbRlZyjys5PAP0Gae10iygFQqgZ47miQ7AQEGGGR61lzWjyOGyzqDk8/pTtbYIxjL4i+9y0mVixgHuP0oa3BcSAYJ+9TwhGNq4OPypkskig4GcDsKWt9SW2vhGyled386hEYI9z2HpTrcq5wwxnrmrKRpGWIGR3zVWuTexSkIClGyVPc1mXtnGSHU44/Ota6IA3qvSs+7JLZUZXvzU7XNISa2MuUARkDlR0NYWqAvG35AVv3gZY2J6DrWDer87buhqkRKVmeZeOSUtSCT8zAVx1hn7bGRnqOldh8QJgyKn+3XI6b8s+7pjGD+NexgI3qwXmebinuavzGIqF4Az83HftTTtAJIwTuwe55qabIhJIBHzAe2GzRJ8u/gn7+B2XOK+qPOFkKu53jagzhuuBt6UyMFERt2C3GDwcY9aflWXHzjnkZ/2euKiZkYqCuCAMAHOeP50gRqeGVEmtQZU4+97DivU7SUQ45IOK8v8ACILaujDjCEkV6Hbq29CudwwcN0NfM5y71UvI9nLocy+Z2mll3ty7fhVu6iZ4xtA3VSs3dLZUCElhzjtWijK0WMNjGK8J2O9pp3MtpBHJtC7X757/AErQSQsodmPy8HinPZRykHgtjr70qRLEpDnDZ7mh7GjlF7bkkEomj3YP3upqzD+95QkMOw6VVV4jGVQKcc5AoSZkYEYC9xUdSdy5JHvBBcFu+RVEqyMY1z/gatyS75f3Z28c55BqvK0kYkkAB9RVNroQm1oNUFER9uMHDL61OFkILDKkenpUcchZVLKAmOtSxToRs3tx1GOvvRe4ncZNG6KT1zyrDuPQmqqSsZCWwcDoev8A9er+WERwxKA9O4qlsw6hCABzg81aIT7jJWlUKEIwRyD2rNufNEvmqPlPJUdx3/GtK7ZV2bT8x4K56iqTMU3eV84PVD2PtTluXF9jGubNJfmLFTklT0yD/hUU0PlI0bAjjDD19625FUogQHaD3HIPcU26ClSdoIIxkU+UcqltDkwQ8rtKM5Pr61BqK+XAN0YAB4PrVrU7b7PK7xH5c79vtWdq93ugEQxjnqeRTirGdR3d0Y/mb0UkBcsePTnpWfcys7lMbQvRh6e9XnUPEvIDjn6nPWs69YRLIpRTvUgs3UEHgj0reEdTklKxyxyrnJAB5J+gp4OZFVDu+7nPOeKDIVdzyeSCP+A05MCVUCocBSPTpX3J4yGqQA/A/hx370oYLH/ePUDpgZ/WgKQgUNyQoIz1pcYjXqRtViSenzVLQI1/DNwf7YGW2eZ2HBz2r0CywZMnGTkZFeaaa32e/ilyGI3MMeufevRdMcfZ1IxtI4GelfO5nC00ztwz00OhtIl3ho3IZV2Mv61bihRpB/CMcegPfNUrTKT7933lycc/lVmJ2MwH3Yt2TnvXgyPVhc07QjjYfkAxzWoZjJG4V9qDqdvWsqwRnLOwJTPC+taE6tAEwf3bHG1e9StjTlVy7agom/JEg4qRiXwsQ2gDJY0W0qSAKvyYHfrVtJIBhdyg469cmq5VYjmdyFI28vnjoPrUVwsmD5ZDH6Vd3DAVcsp7980ksRZTjAPcDvSKTs7nPSu8EoRPmI4PGcGrVjdPK23cMg8jrj8KdLabGZpCRHjjB5z/AIU6GCHcZEkHmNw6AdappdDrbi4lzIP3+nYegqZFV16nGeMUsa4HTAqccowHGOg9amxxN6iYULlTz61CwUKQHye5pSfLRgp5PtTFDPyRhc8Ad6m4rFORFDnL4NCuEGCc56U+7Xg4X5ulVEUxqGk5Cnk02tRx1FuJBEAzuMdsVEDuRuwxmke4t5XXBGD609toTI+7ilrcpppWZkXy4Dbc89c1h6i4ETAEZrfuCHJZuvauV1YushccZPatIk2ueX+POLmMHuciue0wDfISQMAHn61ueOpN15Co/hyaxtI5llGAfkPB717WXfxonmYl7mmqrygyB85J68delKw3OSqkIeM54J200YDkhAAdwyR1yPWlLYcIMNg5Un7udvSvpzzwijy6FmbkDO76dM1HgMVIGVAAOOP8mnIWOzlggC5FOBI3FOU4wfQ7upqWUjZ8HqZNSkZRzHHj0PpXpmiW7SMGlB55964XwFHiWeR2D9AMdRz3r1K1Ih2EYAPp0FfKZvP9+16Hs4CXLT0NSJQcYPCjp0/Wpi2f4eB6UWzqybWxntxUyrzwVx0rxd2dt31JbdgqYz9awdQu2a7ZUHT1OAK3lXah2na3Xmubutst8425ycHjj3q+qR0YZJttli1uCB+9GzHf1rZhgSZSxXA29R396xkTGVyhYjGB0PtWpZJcG3QA5wMfSqcUtbDrRSV0XY4CFIQHjgiq11bS8AZAz/nNWUEgkO8kKeoz0qaQ7lCkt14NTypo47tMz4oWCKCdrdcE9aPLb7Rnb5ajofWrgK7BvAI5BIHFIRvAUH5eqiosiuYcI1ZT5hw3Tcvp71TvoyuMlWBGFYfyqcxyRsOrRDsf6e9Q3DLHC8coJU9wc4rRPSzM+tzHuTyrJ1HIJGfwqAO0ku7ISTP+rPc0+4kMe7Kkr6f1qpO6xg/MzhuUJHIPvSZvHYcLpQWwAMnBBP606R1a23AEnHP4daz3ulkBMqBeQMqPyNMt7pWygbJU4wOn+cVUHrYmcdCDVX3IXU5GAPeuY1WJmtWk3DcvykDuK2L9ZVlcO3yMDtI9PQ1m3gY2pDDk8Z/WtUrs55PlRkvOqwqFbJXAHGKxdTl/csc9FB+uTU0hL3WMkoGJLA9RWVq84Bw4bDcg47CuynHU5JtFNwpL/L8x3bi307U/e6L5gOPm4bp2xTE3bWaRgAQ3G3PfrSznLANsyM4HpxX2J5SFRyFjBK4G3oOvHelikJUINxUhOv1zgUDA2ooAbIye33emaWJmVY35BG0Bs8LnvUsB6hgdz5LYzgn/AGu9egaHK7WEW4YK5wOue1ecoxDAY+bjduHUZ612fhW8DwPHEciORgqkdQTXlZnBOHN2OihKzO3tQpUBiVHGOcmtqzhX5RKDx8vXrWNozRhpXZsRgY3epxWxZSq4U5IxyD618vUVnc9eDujUj/cXGGIGOCR2qxI8cn7xMeZ0TPTHeqqsmwySdfbrUGpXMiW+y3C7iMbh/CPSsbHRCLbJ577e+2NC4IwD0BNOg82SSIsAWY4znHTtWNpoeaZQVYZYbiOo/wAK7KHT4kkYsGbBBHzZwP8AGtUtNTWaVPQSKOZIg+TkNgKeDVgSEFeCDjJ+tWo1+Vs4B7E1XuGyRlSSB2qJLsc7k2U7yYE4ZgC3GT/KqavHbzfKAAMZweprWSJZ49rrgHqT1qnLYDf+7IJHb0FO2htTlG1iaSVkiUphVbpzUlpO7DazDdVIRPJIqckA84PBq8LTy2Vtu3jHr+NZ2e5nNKOhdQ5HzYz04qC42qmQBnPY1YiCpwDVW6t2LPzkenSr6GN9SlIcBigKj39aQQGS3IflSOSKmnJSEe3BJqNZDGo4O0nBqdtyotmHe2zRSLGQAV5DAdqfH5kUJDncOuK20AbO4An6dBVeRo2DKMZB59qrc6ZVuaNmjn5WQDqRn1rJ1SMTwkr97BNaWqRANhBsHr/Wuamnkg3LuJFVFGap31R5X40Ui5iY+64+lZGlFvOkCjqhzWx43kD3kYA4G41k6MP9IbqfkIwPpXs5d/GieTit2a7yb2AbJjB4UnI+7UcRGFLKzY28dhTkXgZAPI+Xv0puGK4ZSpwpABx3/WvqWecJuKgclicEA/XvSgAYJOCRnkd808bApxn5gBzz0PemkfNgYVSSBzmpY0dp8P4iJbgnDDdwQevNekxLuWLaQBngH1rzr4fbvIlYA8yED6V6XbRllRAVAAzk9a+NzV3xEj2sFpBGpbII493T1PUVPCiAEgj65qmt3EQIQRu6ZNT2rqmQxUZ6V5j3O7ldtS0vQ5wRVJrMpIwBARxycZzVxpkZApxnOOKeQhK7sEjoPWnqtUVCTgQWumru+fJJ6le9aMflxQkBvujkelTFF8nLYVQM4FUpSVVsKSrD061pdoxnUc3qM8xHlCqDyOjdaR/nOzcQgPQ9qjYpJyRiROasI27GQOBnJ71nzB1uixEFWIKpHHOc5zTFGJh5XDH7uPWnJuljyoC80wuzgMPur1PejQLClvNiYfdkU5IqldOp2/xGpxJ57FHPzKOCepqCXCsrxlQw6jHf2q7ogybm2Z5JGBOw/e/xFUb2MrtyxCjC71GevrWyihzI8Z+bPK1Ru4wyknLLn7ucbT/hTa0KU7M5y4TblWO4E/eA4NZG5ob4qg49+PpW/fxhYz5bDHU+maw70P8AKxZmA4GOxpR0NG7k93d+Ym4xnay+nQ96xr5sK6E71PTP6VK5aVgplfCfMMnvVG8UY2M5yo/P2reGpyVdDAvGEchaMYD/AMJOcCuf1a7kkDIOEY/xdOvb0rW1BminG4MAQRg9sdK5e+umeLyGwV37uexxXfSVlc4psvrgxHA7HGT707O45TdvBcnPfiowVIO0nOMZPf5qeCwLHkEbuvSvqzzyTA3ANkMDjGP9mkgT7jBh/DkHPHWmkr5hCn5SWOR0+7UgjdShyqElRy2f4aTQxjAskW87vlABznqa3/Bk3kak28ZbBIHrnNYKErEiF8ghcqO3NaOlF4NRUqw4xnPXk4FcuKhz02i4OzPTdH2hFBGeOQ1dNpmHRDwB6Yrn/DqjyCefLU8Z9e9bEV6qNEh+bksBmvjqysz2aLclZFu8G+TaDhRzVyyXZb5mK9NuetUjIrgFecHJI6mte1jBto9oyT8wDHoawS1udXwrUn0+yRmMmzr97A7+lacTCIKjkjJyFHNZ8c0gjVFwA3BA4JP+e9X7ZWRozKSMnGB1I96py0sZybk7stEbuRknPU9qSRCsgDtzjOBTmZchVbvk+ijuTTDIgjZd+4Kc9KV+4bjJbts7PkB9hnAqS3jRxhjuI9TjNVJXG4+UF3dc5qzESFUMyc+nOPx9aE7vUlqy0LSQJEC0aAtnnPamzSjDKpUY9KfgIQTkD69ahBBdjhOPzrSWmhF76sYyEgcc5ycdqV2TpwGHUE9KsLgr865H1qjcxgOWUYJ681LVtR3uV7kByNp/CmNGVjz2HSm7ecMfmB4JpPNDYSPtz9Kl6lxQy4YrA7KSGI6isBfONx5nzAHrW/IAFyeR3PrWfcRlV3g8Z6ZqOY3hNJWKV2f3b7zgEYz/AErldZiaNDIB14yOldROfMBDdOn41j6yEW12n8Qa0iyIz5XY8T8YDGpY7AcVQ0VtlyWAyRkAepIrQ8ZnOrt6Y4qjowUs5JAGR9a93LVetE8nFO7ZohTtztAB2nk0wMuVwp6AHnoM9BT2YkJhiANuCR1APWnBtocIAeGBBHU5r6U88jcnaAFwoyOecc0pxvLIeM8jscdaJslcH5cE/KOlHMchHygkHnPXIpD3PR/BNusdjEVX7xLjnsa9BiEjQMIwPu4rlvC1viwg4x8o/Diu2s0G0LkYNfDYufPWlLzZ7uHXLFGIsMwcDAx7d60xEwh3DkgYq40BQsRj5uOR0otIT0GMZ/i71xyl0PRlVUkZkLSEbiTkdsda3tOYtGmGyB14xTUtIt+SnHr61dto0jXABAB4qkrGdWopKyRO7nGCAA1QyHDDGdv6k0ksjAlSc8+lSy/MvI4AweKd7nM9NCi9viUy7NwPf0NSxBcKGBLdcmmLcHIXbuBbAJ/lVg7yQVIwRikl1K1W5BIwLAZ2nPHpQzbiQDz3BqR7fcmcjcCDkVDLFIqk79+OhFNXKuipMp83eCwI7iomcsyuy/MT823off61A88i3A/ugjcfb1ouN+9iApjAyduT+NNJWFJCw5UuQ3GeuKrXI3tufGTwwzjI9arNLJHI6Kd2RkHPJqMPKXYuwAP3S1HkQ463MrUEdbl0jxj7w9KzEzslyQZG46/dNad3tWVt+fL5wfQ1nzxpnCjfkZ/+uKEX0sZO7YNkgAfPXPNY93cES8gMNpHvmtq8CNGrE5Ve/cGuYnkH2p9w4PJ54rppI5qzMfWJVdrgKzDkBM9c1zTkSvuJ4757GtLVrkMzE/388HpVCIFgeAGLZzXqUIXkonBNmkAQudoJAzn1570twiquUDjO7jGe9NQ/KCeg28djzUmQFckZ+U5PfluBX0hxDXY73Vl5O4cdOnoKevyDBTgEZwM/NtpRllwAAMPz6/Wj72w543E4f2XqaQxbYpuQSAsCUzt796nt5ireaxB6HnjGCcVBG2wqZc7gFIGfapUYLaEEFnG04I4wT1FZ1Nhno3hy7ae1hj3ME+8QP4qvYY3CNuKrgjPUn2rF8DTZtCXJLKxUGu00e1G1pnQNwQDn19K+PxcOWbR7WDqWVzS0aNIoxKw4PArVuJVRCEwTngCspXWNoYxu+YgcdRWibckrIXChvfpXDudU2m7su2QEvMmNoA47/jV55MMTl8/wfSq9q0CRrGpG5wT68etXreE7VyQGHTPJq3F2M01fUiVnDs3RSOp5qWMsRu28kcgAYAqxJFsjJfB9fU0RqFChBgMPujvWTi76mjkU/LQHaEYDHPFK65YMGwegx/hVueQEcFevNNIURgyAYHQYxVctjNvUVAwTaXLDsTUCTBJCojJcdcmnRuSwXOPpTJU2nfjBx3PWnuGnUsC4XHI5B7U2XDjCjB9aijZVwVGWPYc1ZjhZsnaMHtTu2RypalBo87sg5J60PAQ4EYUt3PtV2ZxG+wrxxwKZOoYsUYL6UraFczTK0sKNHg9fQVRuIEXcNnykYxnmrxLFVbjHtWZNMxncYLjpu9KTsNNma8e3jBwDWD4jDGOToMLkYroLpeq7unOa5vVpfNZl4JI496aDfU8W8XMG1ZsHOFFV9EC/MW/vLz6DPb3p/icY1ST8qZowBjlBYqcDGPrX0GVr98vQ8vE7MvSMzMy7CzKCBj0BpzL8znIU/Nhey9+KYwA3pwCN4JHf0qTG9AVwX3EsB24r6Pc4RgwGwgODk885yOlSWiiS4RcbfnUAde1Rop4DcZIwe/IrR0OIPqMCJt/hYcehrKo+WLZUVd2PXtIi8uKJcYJA710tovlhRnJx+VYWlMrxqAMDHHrXRaepC5Pevg5vmZ78dFYnBZWBzlfQ05nGCSAMnrTioZwNu6kaMAhSM56e1ZtNaI0TRNA4kUoBwBzUsWQmcMT79MUsCAYxx3JxU0wDxhlyMelO3cm5BEqPKxx347YFSXZwdqcMOpojCuApyHPTPapDHtClskdzVIb3uyraxEkl+R2z2q68a7VJGPpUTsAmE6E5zRHnftLnJFDstieZvUrXG6NCFB3A8nHWqM++QHc5EhGRjtW1JGCmRISB3x0Poaz54iqtlCD1ytJJouMrGPMCYs7wGydxzx9aro3luv7zD/w4P5qc1dugJAFClGUcccYqheWzSL5h4ft/hVGkWnuQTxpu3RgBiMg/0rMLyXAIaT5uwatQBlt24xzxg9PpWVdNKq5KKdzZJxzUdRNEE+SuSBuUgMOxFUblvlBjAwOMDrV6Qu0RYKGboff8Ky7oMuM9uMHgYq4mUnYzriVfLlRlwxORg1yWqymMvt4XqRiunvHJIGAeoGODXIattYlixDZIOOa66COStI5m7jkl3TIjtDvC7wpK7j0XPr7VZv7ZLaWOBUuo7mOMC5juECFJAeijrjGOvNblu9nrXhnT9NGs22lzWM0jvBdBlinLHIlDKDlgMrg/hUPjC/gvbmxjhu21B7O0FvLfMpU3DAk5GeSACFBPJxXr4RXnc4ZlKJQ7IHY/MEwFGO9OYDbsZm+6cYH3ju6/SmxsoB8wA4Cd+velVmVFKFeVyVPXlq945R7Lgtl8MpcFewHrmmD97vwVUbjyRnPy08DKNhdx2N17c0SDYdy4LAvyp6AAUAOQ7tkSZ6rjA+YYWnQ4z84UZCqe3frUGN0iZwCSDgem2pDGinaASVCd+lSxnVeDXMTzR7uG5A9Sa9Ns3226Koxx0ryvwPKf7SZWJAKYwfQGvSbKVdjMT22ivk8yjy1WephX7p0FpkzK7IPY+gp+pSkKisMKfve47VFpziVRwRtFXjCsxcceua8s74vXUyoJ7i4uNyOUx6DpjoBXYafcMNm8FiVxyOtZem2SxYZVxjgA9K3LYKhBUZY81oncmq4t6FxI1Mn3Pc7ulQzLKkLBAAmevpU5laPczIxLdv61EZGdvMkHJGAoPH1qZChcqxryQy8gcf8A16hkfdmN3xVmJWDEjDCopYDLJkjdt/h7CkndaF6J3Zn3N0tumN26RugFOt7oSnZIMOB3pt9Yh0w4yp6gdT+NTW1n5SjcuFXuTzQomsvZ8t+pas3KphgMZ64q1vfaQMc9AaqCQRnaHPJwMU5CZF9wc5pXsZNX1HSqxlBkIGB+FQzZKkFgB3IqVpHQliGYDpWTdak3nthPlwcZFK6sONNy2LbN5alVCkEVSmYKheJcq3DUkN2JSCDjI7jiiRwVxgcjtQiZRcdDGuZAQQCD6f8A165rWN6o0gIDDkACuouoUXLFenesLVVVoW4PT+lMa0R4n4uTbqpI6EZqro/PnLkDKmtPxpEY7mJuxyAfWsnRwDcuG5BU5H4V7uWytWieViVuahALBQD8ueQeelLGm+QENhNynB9MdaWMFhkjJLKwOegxjn0pHKkZbO8hSABjGD/Wvp9jgEO0lGj+bkEgnBHNbHhJN+qI42kKpJ496yCGaNSq/KBkkHjG6uw8C2we4kckbd+BmuLH1PZ0JS8jfDx5qiR6Jo6tmNT0AyMCumt8qFDDC9RWNp8YEn3j0rfhZJApB6DBr4fY92xZt/mbBIzUxIKgDaPp1qlM2GXaCB2I61ZjcAYwNzcnJqlLUlplqIL3Iwe5pHXaMAblz1Bp28vF8vXtUKZRiMEZ/vHGPpRISHwxnaSQOOtV/tBDlTuJ6FW64q3gEjGSD3qnLE3nkuD67h1FJ+Ras9wijJLEHgdBjp61LNE3l8DnHY1GkhU5BBHTirETjcTIuW24ytOyJuVAJQCu0OpOMg9B71G7+Xw0ZHpnk49atz71G7PyHvjGKpXKu7KQTjPBPalsVuUrrJb5SuScj0pkYypDHfjuep9qtSIykEqTk8npmqsjolyY1BKsMn1FO/UVyleIEVyUIP14rKD7tzMvzD866G4fdGMruzxz3FYd0ojlII2sPSky07mf5bO0pBJxjOB1rJ1TYBskJxjhj2q7cSH7QsnzIP4vrWZq7+ZIzt948ECrgZzTuY8pUEkEgqOSOQfeuM1KVVuJBIWEW1gc9/TFdddMLYk/wEfMB71wWoXPl3sUrIs6RuGMUmdjjPQ47Gu+gupw1mdZ4aOr/wDCIad/wjN3p1pKJZvtQllhWWU7vlb5+doHGOP1rE8Vtqz6pCNfuYLqdYsJJC8bgLzwSnAOc8VNbeJbNiP+KV0AZJGBHJ6f71UdTvYr+5jli020sYwqjyrUEIeuSQSST/hXtYGk4xTaOOpK5WG4PuKq23YAOuOKew2omcgyAE456mpYiqEO4BDFfl/ColBG0joQrD357V65z3FfY+RtzwcEt3Jp7n53AJCncTgcdKHOUQkKSqnAI5HzUkuWbadxwz5wOMUmBKFXJUMG+blRxxtqFSocFRjbtGacWQuxPzAs3IHA+WkjUeYgQ5BK8t9KTGjd8Olo9RjKFRlOpOT+NekWO1bSHg7WPPvXmGk4XU4mj5PCnjGeDXpVqRJCmMgLgEdzxXzebR9+534OR0ukE8dCF5xnk1s2+CwYggEVh2cixL+7PUDJNbdgySnc4O7PQ9q8NLU9FvS5fCLDveRmLdv/ANVGnTuJCQdwBpbkfJhTuyev9Ks2qIkaErsI680pfFoODVtSWW6dnycq/r3xUkEjSD92vXjJpjSDllwxPBPpWjZRLFGD3PapS5palN2REYR5eehH3vWmFRn7xKkVelQJ7qR0HSs2+kEibYevrnoK15UtTNPmdinPdRqcHO4fxHpTPtyuCASwHBNRIqSBYxgY5Zsd/aoERIQzhhlicKeoz3+vtT5Xa51KlG1jSTbIo2nK9cmnRWzbflk3c1EW8mIIkewEdTVu0kzGquMjsRWV9bGLbS0G3KOUYLkH+dY11auyOsmMY5B4rp1ZFyGAGfU1Ru0RkY/e9+lVa2pdKpbQ5pLfyuA2cdBnpVkEFQg5Ydc1Tmk8uYhc5B6HvUhi3/vBuU46Vmr3NK0L6sS5izkk8npxXP6tF+4f+8Bya359yjLNlTwD71hai2VZX5B4OKteZz9Dx7x/EUWA44U9frXL6Xzexr83zf3Rk13PxAj/ANBbGMK+f1rhLBil4hBxg/1r18A7VIHn4lbm7G+7bhFG1Vzx6HHPvUBJZsjjnj6g1MifIwI+dVcg5+9g55o3eYCSVX74yxxjjNfWNnmjjIMEHJc7/ujAPfn8K9B8A26RWKOM7nO5c+9eewhmI+XIY8exI6V6h4eiNtDbIVPCgHP0rxs6qWpKPdnbgV77Z3NrF8igY5HJrQSH91lN3ToKzNNmyQuMnP5VrBwFJY8+1fKPU9hBHvbcCCzY6HtVmMLtw6+4p1sNwDLjYOTnvUkmRjJAJHpRGJNTcWBzxkYz0qUOCzbedvc9jVNnKHj9e9OjMjKQ6gHrx0p7EWvqXGYqN6kEg5xULSSPMNyjaepFNZC5XYSfUg9KeA0fzbuo5GOlIqysRsQhK4x70hYELg7sdh1oJcy54K+h4qS4hDhWhYq45OO9U9RR0Gli2WwGHp6UGHkMz7N3UjkY7UWkhCMGILDsR1p8lxtB4Xkc4Xp9RRBJ7jk+hUuBsTDD8uc1mO67mO3njbmtmYgAAMrIw5PpWXLGI96k7wwx9KqUbakRZnzzr5mzdyeTn0rOuJ13HkEZ69x7GrNyMT5l+fPGR3FZ17CrSKoyG9OxFZm6S6lC7QSqJAQ27I44rD1FPLAULyB2PSugMSqjqG+fPTPasDVVMaSMCWI4GetaQMJysYF/IfshA+8hx06givOdScNcMAxIBxk12+pyFYpSzZUYzt/lXDXGGncAcmTAHXvXpUY6W7nDUepYsIJpvL8mKSQl1RQik7mP8I9T7Vq6nawWcKWsun6haapCqGczsAMknPyYyBgjHPrXTeFtYtrTw9bMhunvdIjuHS2igZkaWThZ2ccLtBPX04rH8W3kNxLYWkE9xdGytPIkuZlKvM+4ueDzgBgBnqK9+i3pFrY45dzKEe6UqNpVWwQT049akj2OiAKdy7Af15FJGQ0x8wggEgDoT8vpTYnAmTooJTOee3p6V6DMLDsqVLFxuVeAeTndUbqAzA7lHzbSc5/H0p5YGEKBg7B90dee1OIPkMVAwituGevPWiwXCYMshWUYySeRj+HtUkPEqhvnYbcgjB6d6ZyyMxLYBYYz229aXdsl9WGz7wwOF9akCzYPtvInZlAIRuD156GvTrAtKiIMnc+cjsK8ytflhiLAb8KMEZOCT2r0vQwZgpVztYgAEYJ+vpXgZvHaR3YR2bOotiroF24YkAj0ArobdRFHnjPUNn9axkt1t5V55YbiR/KtGKf7sW0HHBOc5r53Z6nqbrQtRzhXC5Jywzx/OriuZM7SMN0z2qhIcMhCnaeWNWo2dgoRehx14+nvUPYtPl1HRRt5gaQnjoBxmta3lJVSAFVeu49aroUBG0gkceuT6VZhjJPQlvTFJRs9C5SuiR52O4sBgDqKzpNss2QxIxzxWk2MDj5umMd6hWAiRlznPJOOlXZsxuomeLF2ZtwdQem04/OrEVnsUhsk5znFTXErrtiVWJ7se9PjdgpDPj9aOZbIv2kuUovCfMClWEYPUnpV62hAwBn15FC2+STzzwPrUdzetblYkOX+nAoUbasSvPRFi7QsVA4XOfrWReO0jFMsoXoBxmh9WkRslQc9QvPFUri+iY71U7geVNJm9OlKO5RmUecobd19auMjZQIDjrn1qGV0lYPkRuB8q4z+v9Kms5JZIWaTA54HtR1sFaTaIruLdD8y8jng1zuodCQMAfpXQ30uyIkc9jiufu1LPsJBBPJ6YNNvU54nnfj2Mtps5UcDkmvNbVttzGc4GRXr/iu2Mmn3CfLhlI4rx1eJV9Qa9HBytKL8zjxKOjlBM0gbCkswIxzgjrUYVQwXcSMjOBzytTxFHlOXyGIG48HlaauXVSUxsCDIxyOn419lY8otaOrT3lsgXhthbHtmvVNMgHmKrAgZ45rzzwfGTqwHBCxkcD/ar1KyjxJGSMADmvmc6neoodkepgYaNmvbxFZDsOB3rUjOEXcRtzxjk1TjZETOcZ6CtG34XdlcHjpXgNa6HqbK5ZjUIhw/PXFSKhIG8dRzTIFMhG7nJx7irXlMCNh24655q46GUmVpEYHBGRiiNDnb0PoDTdQlMGEwWkPTFUhJcSMH4wnBX0qmEacpLQ1EwMqjAKB270gO9sdiOc0WoDxbsjJ7GqIllWVkEbbevr+tQ9NxpbotQSgMUIx7VNKowOCMVFaqhfeQQR/OrhCyqY1xuHXNWtjJv3jOu4gzq2/5uowcZ9qSWdWjJkG119eCDU8qRFxFjY+O/NV54PLyGwQcd81G2xq2misblGVMNhx1U1DPcDa5VcDPQ/56VVkCvO20/MDgVFdBo2JUErjkHvT520ZuKTGzBZGDZx9OxrMupC4C7eU7ng1chJCkq3yt0Oe9Z9+WJJZdoxyB/OluiyhIdzh1K7iDxWFqz7up+bqD/StSVgj7mXBz97+VYOpy5mYLld2W5Fa00YVDkdelRLRyv8ROfbFcdCplmfbnuxrovFEx8vaflLsSMdxisGxjJBc8Dla9nCQ5pxR59WW7PS/CE0c/h6Oxtb+2tjHbXsd1bTTiHzpJFxG5J4Ze3tj3rC8YTW8tzpdsbuO9u7WzFtdXUbbldxkgBv4toIXd7VsaYlx/wiOmyaRoFlqszyyi5mezFw8J/hQr1wRyCfoKveI7W3n0y9W50ewsZ7SwguHa2QI1tdM2PJJHXcvO08j8K9aFoTv5mDu0cEzKkj5QFzkEEZ28cYp6cgKoVQHTLdzx601x5kz7DwxPLDuBT9sZlUpjqgwTjAx3/GvQsc9yNcbSAAcBBnPHXtSvlVZWB4DYPqd1KQwXYMFcqAfxOP60hGNqgA/L65H3utA0h/yhHLOD8z8KOvFLGczgOoJ4JRTnA29ajaP95K3OBvIJHU+lTbmR8qCDuIypxn5elJjEjlZJY2X752qAfSvUPCrqbSJyT8nJJ5z6V5vFEskiKpO1FQlvoOa7vw44g0/5mxwMAD8q8XNleCOrC/Edfc3Z5YYxwRz1rT0lzcwrIEwPWufit3njilb5VY8r3IrsNMgEVsqhSFPQeg9q+Za1PabSikOigeVzjG08AZ6D1q3ZoY2XJO7ufSoTdJC6sc7TxgVbjO7a34gev1qVYhsvwqhAbGSPuirtv5gUDof72aisY1lUPJwx6kGppVEg2I21icYH86Grahe7sRXM6RphRkk8UqSssQ3nD47iq89u0UmYyMDp6/WpSAyctk460oN3dxTSshYiJnG/LH2pzwNuJ+UD0z+lRxkR4QHDdeKtllKdQCOvrQlfcJOyIhPsU5VTg49xWddN5rFyiiL0zzTb1pGcGIgqOWHt61HhThhx3BzgD6VXM3obU4cq5iu8aIm4MQxPHGMVTkOZAWULsHUd60LiUEY2k8dcZB/Gs27JKkqpZR+GKR1wbejKHnILvcjNg8Fcdfer11cpHbll+8OOPSsmZh5gIOdpznpz6H2pLhjJJtQEHqR2/Cm1cupR57F20mV1dcg7uec1TuAMnAyTxRYCSMuADjGfoaklwzHAPzDGPQ1KRxVI8srHN69B5ljKDycHFeF3oC30wAwA54r3/X7cvZMIzyB0rwbWhjU7kYwA/T0rsw7scWIjoma679scmF2bUOTzntzUmFaPIJ+6MjGMgN2qC1ybWIgsyhFJX33VKysHYErvG8YPIPPpX2sXeKZ4zWp2XgW2zPM6Ectt49M5r0F3W2XO3gL+lc14PtPJsoi4BYjccdq6t7druNmUZOMCvi8wq+1xEn5/ke9g4csI3II55HwWbPHGa6bS5A8UaZ+YetczHGcL2cd66HSYmB8wjpxzXEerVguU28EEfL7girJZmAwAKrQku6jJI60+R2Hyt97oTTuedKJDdx+YctjH0qrDb/vFKtj8ckfjV3O1CrfU89qYJk6Kq4PcDFWrMFNpWRYjMcIAONzUkv7tW8tQD6DrVWVyBuwuewPJ/CpLe6GC0i7dxwDjvUc13YXK2uYfDH8rNnJzyDxViOKMEsAQD+pqu7ooLKSCacZFEWAzbj0xVaIhpt6Cz2oO6RSW28qf6fX2qtKnmBGOAf4SK0IZQ0eCuB147+9QSso3AH6EjFDS3KbexiTQKsjMy4LcketUbwkkLk5A6VrXKqxIU5OOnY1kOR5ZIBGz1qWhJ63MyYFZOPlBHPPU1l3crGQITk89a1bjJVnVVyB29KyLqMtEGz359fcGp2NLmZfAqST/AKs9R3H0rmNWMjsdrA7SSTn06mulv3VhImRtA6d81zGrSqlvJIMLjhvyrqoq7Oeo3Y4TxDcNLMikDgYB9feobEAJF8pO4g4z1qHUm8ycEH0H0qxbDABBz1AAH3cGvfwEffbPNqvQ9C8HWGnw6bpzTWl7Pe6jHcSiaG6eFFMOcRfL1Jwc/UVz/i6KzUadcaZZyWlhe2i3IiaVncuJGV2Ynqc5wfStDTpLDSfD9hdX17q48+4knhisWUJbvG2Mkt/GR+hrN8T6pBq+rfaY5L+4JjKM14Uz6gDaMBcdvWu+CbqXMXsZq8owQD7ze+QB0pyKVlGTuUFcYHJ46U5OXfa7oAHwT/LFIpYyPtUjLZPOMYXpXcYIYz/PGCDwEXDdakZQ6Btw3Yyfl4PzcikDg+WQck7PnAyKYrfL0BYrxgcA76GUOlZFVmQ5GXAUdOtO27HYKCzFj83uF6U1ziFt0YGN43Y756e9Oc/NjBCq5JIHB+WkwL2nlPtjEglcoox0AIxyK6vRpFaBUbIyx6d+ev6Vx1m2JIyWz80THjnpXV+HZNzXBYDiT5M9BXkZmm6bOnDu00egWU4fYijJLAZHQdzXSR3amN920YG1Qetcbps4gOXbJQdPT1Na0MglKswGfv8AJxXyzR6y941DKFbMgBPp1wK04bvaqnaCDwM/4VhRqGLux7Z47CpbZ83IXBLH7o/rSSWx1QgpHZWUnzD5hgDp2qdceYWyDnrg/wAqxILgBW5HmAZ69RUsV0Zn2Kcoo5OeSfas2+hPsndtF28lJOE69OtQwxybwwzkdsYyKljt1VRkkHvnvVu3iUHLcnsDVRi5asxm0lZEZR1ZmO3aOdx60+NGmBJGB696sGETZw3y/WmSQtEpwQCO+etPlsyea6MzU4PKOYuM/wAI6H2rFluJ1Q42xkfKPlyfp7V0EoYs3mDPHArKupp/LMVt5KAnGMDP1ye9Nas7MO21ZmU2/afM35bnOeoqGNwqt5r5hBxuAyy+/wBKsiN3d/NRtwIwS3De4PrTZoHEbFVRfwxn8KrkR29bFE27ByODGwyCOh96dFbFXUnJA4xUsAR0wAA390ntWmIR5abgMDuKzlrojOtVcVYofNsxgDPt3qkxUzEAjHU4rXuEXJZSBH0+lZTRBJDtGSTg+9TqcN77mXfAbJFJ4I4rwjxKu3WrsYA+ft3r3vUUG08c4/KvCvFq7deuuMcg/pXVRepzV/hJrFlNlFt3bwjDPY85xWlbxtc3cMQG4vKRgn1HXNZmnANYw7QSw3DaD3x1rpfB9olxqZYj5Y8MMdQSK+wnW9lh/aPseRGHPU5T0vRYQtsoX7oAU/hXQ2karGADyazrCAosSKM9jW7BCF2l8CviG23dnvx0I47SPzFLpzkgAelajR7IwgGFxUBjVJO+T+tTocnABIx1zwKg1c2yNGJOEJJX0q0xbbuwR65psMW1xjj2HX61ZXlin3ifWhJsylIz5Mt84wecYPeo4oTExEgIHXGa1Gt8Kdx+b6c0sUW9NrAD0GOa1UH1Ic1YpPh5eBkkdOlJEEkkPy7Qp2nmrslsBhWBUjoev51SkKwTq/Pvjt9anls7suDUlZBNEQThsjPANOjds/NhcDBPrTnkilz8wwOn1qrcO2QEKMB2bv7UW1HFNuxbEmFIjIyv8LD+VVHnMsjFsbh29aoG5kEgVFYNnlCfu+4NXihmQFuvUMKT7FShybleRmkZgflGevrVC4QkMG4zV9hI0i+bz6MOhHuKhu4fMyhAXuCOaIs55uzOeZ2XJdMoOpqpdHCkbRkcgjnINbN3EsabRgg8GsO4kUyOFyAOVHv6VSjbcd76owb58ybhgEAj61xviGYRwy4IBxkr6ZrrL9nM7EDK57dc1w/jCXar8Z3c89a68PHUwrS0OPgw9wu4kDOSeuK0o1UNIHy0eWA7ZOMiqFpxNu6KD39607dxbzQTtEk4RkJicna47g9+a+iwEbU+Y82q9TvNDu7weFLGLRdX0nTZjLK1xFcyIrzsfuudwOMDjH41zfiWe+fUbc6pqFnqUiopEloyMqg5G0lQBnPNWV8Q6W6kt4U0cYCkjfKeAcf3qydXu4byQS22nW2nII9pit2O1trZ3HJJzzj8K6YRaldr8iG1axG+F3FQGb5vy4pFIErqCGwxJP8AwHrimOQEyvXDZJ+vWnh2MzlR8xY4IHT5a7DFbj1G7YekeUGSRxxmm/uygXG5gqkEcbstSDcx37QfLKBmXkDjrTU+U43KAApBTnPzdfpRYoe+TET0A3llPbn+dKqyMOpGWbvyPlpWZ3c7v9YSxZcfeJPenFSrEuT5hZl6dML/ADosIdCTGylfmPy9OM8V0XhuYfbJULjDopRQePrXOInzxhc5BUYz7Vf02bF7btHuXKYwK4cbT5qbNKUrSPSbWVHm3EggcYrorODzxuAGM8H2rnNFj3QKxUZOec11emN5a7YxwB1NfHVNHY9qMrrQvxx+S3zc56/SmyQBJwyEADnHcUhmUYQEk9c+9MV3dwJN+C3PbNc9zppXTuOUPLucDC5+8RyR6H0rSslk88uI1Lt1Ht/hTLVUMgiU7j94+/1rStkzIeQmeDjtTZvKpZWLCSFwFO0Mp6Z5qyjtwPveu01UYRREYDZbgKBy1aG6KFE2qwb0FWmcU7XFh3KyhWOe+aiuZJGmAEZ2DqTxVm2kjJLjAJ6ZFOlZXAwowepz1oWqJd09jMuXAQMPun2rBv5MlUjZSW/hJ3cfSum1KDdCqqCQcc1z1zZTO+9IwWycEDqKrl1O3C8trtmU1oFZZERd7DDEkkH2Ap8sxVdssQZSuPnPP4Gr5tJBEpPl+vB5rPu49oJYlh15FM61PmepnsJkkL4RSGyEHpWtbXaXCDDkSLwVNZMwI3YztJ6+n0qJS8UokjGTkcHuKzmVVgpo25i6qwPQ+lUvLLMSRj3q2jM6lgQfUUkZySWXipWp5knbQyb1fl3HBIBrwrxwuPEVxgYBAr37UIx5LFRwBXh3xFh8vX8gY3IDn1Nb0dJHPXXuFDSAGtF3HCq44z6ivRPAViy25nYqPMYYPqBXnGhhWiZWYhw6457GvcPB9iLfToIwMlQMkjnmvdx9f/YoRXW34HFhIXrN9jqdOtyFGUy2MmtIKCdxAP8AdxTLePgDvjj2HvTlUhAW47da+duerYYSfMYBTnHWmLDJ9oJ3HH86txIN/fPqKtpDzgcnrSKU+UW23cAAMMdacvyyfPtAPQ96kVEKZLbR6CoLmGQoTGWUerGtLWML3eo+ac8AA7e2TnmgS7QCzMfWqlpvRWWVc4NRzzuz7YeFPUEZpXb1Y/Z30RoRyls/NtHbNQXbJt5GPrzmp9OVZVBc/Si7tg5O0gkdMCk02rhFqLsZkMa+YQCAD0I5xSXNoSRtboOvXP0qzFCIM7V6jnvSxTAsVIGO/HFENNzTn1ujFaJvPXeWYjnntV5JFTJJA96lkVGc4yCetZF3E4YZBI6hjTeruOclPct3ZYBmjb3+tVnbES7m56kiq3nSBsSjMXqP6VXnkCYCsxyTzSXczcOgmoMAewyM5HesW5UkOzYLYzwOoq/fj91vRiWVeQay5ZSqrk7SehFOL1Iasjn76Up2Dc7gM85rz3xnIrgYOTnK/TvXeasV3TFOpG7ntjrivMvE8u++xnd8ueOK7qC0uclVlCxyHUgfxBhxnvWnbTRw3G+aLzYtw8xFbbuAfkA9RxVOzQ+WO3BI464xVxg2048sKC2G9zyK+owsOWkkefUep2mkaVaavZNdad4Md7cb0EjaqyBipyQNwGcdz2rF8ZWH2C+ig/sxNMcoWMC3P2jlh94t2JHRfTnvWjpmrRW1lpD3tteeXZyzWczRrmJorhCeG/56Anp3xVLxgsEd5ZWUSXO+wt44HluozFLKck5Kk8AAgD2op8yqW6fP/MTtYw2K7G+VmPzZx35HP0qSPILkAKpLA5HT5aavl4LbirAN93tz3FDHnYWUlnbk/wC71FdpiEi7RGDk7yu1hx2wR70yLCui84woB7D5vWpNzMwBBEYKhc8kcevpScsoBP3lX8s0ikKzsFZJMlsMp47Z5PvTyw3OrE7dzEHH+zTMqo27DuKsCfx605s8c85cLgE9qQMkyd0Sg7cOpxjrletPhfy5I+g+6w7kc1Gilj5gAO1kB3c847U1wreXtBUtg8n5evr9azqrmixx3PUtDkLopXlcc8966m1DCASsx2A4GP8APSuJ8Ky+ZartXkqRn3ruNNuB5OGHyKBtJ9K+IxEOWbTPbpSukzVUqkSTZQMeFUjlqqTsHHyMWYjnHGDUV7MBKpVAzEYAB6VetLb7RCkkeVkA5z3rjfY7ado6sXSQ5kbf8pA/E+9dPp9wp2mRRGF/X3rEtFy4VGXA4Ygcmp7hvMPyN8g4wOead2tSqnvs6JjH5mVAOf4h2qK5Yuyqpxzzmq0M37pMMudvOBio1uG81guDjnNauStY5VGzL9rbkyM3AB7YqwUVDgqPXI/lVBbiRE3IDnriq81xKTu28k8gmjRITvJmlJKHAVPkI755qAxyRMCMc9eMBvY96faJvQFwA5PTPUe1Wym5VTchHbcc4qrPcIz5XYxbnzJJMFQccDnJH41Ul0rdAQcFMcnGGzW+F8tihjHufWmXLEIcDnH4EUX7nQq76HB3NsiyDG7Hq3GKiS23yqhxx3z2rodQsUkG5e+az1swsWQx3DrisWdjrJxISrRqNi5X+LmpFyYSwzkN29KMsHUcFWODVpIwvOOenWmjz5N3KVypeI8YHavF/itbiO9tHGeQyn869qkO4uFI2A4ORXlXxZtybK3lxwspGfqKum/eQqsbwZwvhaNp9SjhXks68e2a+itAtgsagDA4/CvB/hxB5viWLIyqIW/wr6H0tVRF6ZPU+ldGJq80YQ7XMcLCylI2IoVVSM9epHU01lCn5vXp6VNtKoOCO+e5pm05yV5681yHVEWHanOQSRzVhX3njtUChSPmwFzzTkZQx2Atg/xdqBNXZejwDtG09xjgCnuq7Ms67iO1VlWRoyWO0+lHlsBn7wPUgZrRNmUooryHORHG3vVfBHVGH1q4yFcFQQxqRVJwZFOO5HX8jTUdSea2iKsE8cTfOhAPrSy3Ee7CuPYdKsXNnHIjEFMHkD3+lYt3YMjbhuH17U5xaWgoTTepqpIHG3J5qrchVOQwHP41QjuXhwCHBH5VfjuEnXJQn36VknfQ0s1qUJ7gRtg7DjjriqlzcMEOx8j0J5rTubSNzhd23+JWx+hrJmtFVht4HoetU047DTiyCNvNBIPAPIx0qCUeXllCg9we9WyoVWx1P6VVnXzCAwAycfWkDldmRcOy5Qk5cj8Kp6kQYMA4wc8VrXUS8A/w8g1i3rYRo1GCQfwNVFGc2cprBk8tyMbgwBPr715nqrtJeyK/8Pygeg9K9F1NGUOScqpwT6g+1ecTAvqbBjn5yM+9elhldW8zjrMvQKGRUkAb8emRT3O4qR82WU7RkdRjjvTYFYKFYZBK57dDjrToJpLSeK4s5WWaJlkV+8ZVuCtfUpWWh5/U6a0ey1PwzpthPqZ0yexeRyskDvDLvbO8FR98fd5HSqfim8guJ7GCCWe5SzsxB9smQo0xDFtwB52jO0Z7Ct3R9RbTvDdtc3fifVrH7ZLOY7aC3WQNh/mcHIxknv3zR4p0wX0Zvk1+61OeO0FzGLiAR77djtJRgTyrE5U1jF2nr5/1t+pTWhxSn5pQCNwLdO/NSBiZWPXLN8uPbGajRQASFbf82T+NSY3yuyttRScZ5Gcd67EYMa6k7NxwG2nrnIx6f0oCAkbQw+VWOeB14p0KFJk5G7cuOevFOwxCcYUqnBOO5596B3GzBDG2QwJUnr905/kaf86v5TlQpZsYOO3WkCuFZY0IYg49Dz2zSuMR+Y/zIGcHHU8UBccEOegzvHKn5SdtK2HijEm3cQuDjoM1HHuWQICRudQQe/H86lyAioAAylRnuOaTVyjvPh/xp0q7gzq5BOegrt7UmUiMLlSfTrXA+DGMNnIQ2C0xH1rvbF/3aMrEHoW7n6V8dmStWkl3PUwz9xFnyJPNQFhtBy3HathB5SK2SADgAGqNuhE+5iXDDgH+dbdpbbETKbxivLcTt5giiZ7feQQxycD0pbWA87zwe2Klh857l1CkKo5ParEi7QvIPv70macz2IGlaKMrGRk9z/hVzTIS8ZLHJ9cdapQw+fcMGzsH863LaKKO3IDBAvOMZJq6avqYVJW0HQqRuIQ8c050jZB5ihiOSR1qvPcbY/3XUc8mq9vevdRs0qlCDxnjP0q1NPQnkaVzQSKJn+TDZ6DpTkkCMSikjOPm/pUNuxZSRtI/nUzbVI3q350rsE+jEEiMRuUg+u2mTgYO1vrUigFlwSOerdqLhMYAKn1xVboq6TMSQHcdoIOemKpyqyk8DrzWldgYIbIPZhWZh2YkseO3Y1k9DoT0uQyRq/3V79qcFIAGM9sHrUZaTI8sYx39auJhgARh+o96FqRLRXM64XaS4HBHIxXAfFG3EvhueReSrq2B6Z5r0mZflIzz6jrXE+O7UDwzfRrkExs1P4WmNe8mjgfhLa+ZqV3MACyqqDPvzXumlxiOIZGeeM/zryL4RW4+x3MpIAaT+Qr2TTAcDKkegqqmsgoK1NGtErMoyBn1zVaV1DEg5ParJyFKr06ZJ5//AFVSfkkADOeDUsqI1AWcljz+lXYAABkcfzqKOPjJx9TUiHaBtBJHGaaRMmXUIChiOPcZoaU7WZBsYdDjj8qbGVxuk4wMfNTZR8vXK9M4yMmq1M7akBlZ2+dj9B3p25SvzeZj2zmoWVw5HJ4xnApE8zfxK3B6E80JkOKuJIYyMrOxPYMMY9qCqmP75Y+jdKkaFWA+Zmx1zg/lQ1uAe7KeeD/Sr5vITgu5VNoZ5MttUenY09rRVYgE5HfNWooQxxuIBPVun0zUU0WSeCP91qnkXYpS6DXjCJnP581mzKrMcjPvip7hSqEENg8ZFUJZ1QgHcF9R1obtoJRvqVrobGL5zjjgVRuvkAOSyHkYq9PKsgPllW/Q1QmJKtuXAP61PUu1jOmZgS2QQ3GPSsHVSVIx2OD7+1aN67KznPAOR7VmXkkcysRnOPmGauGpM11OV1y5MKtJ0XbgnqfYkfpXncJ83UTIoxls7R65rsvEM262nilciRQVX/aB6VyFlEPNkLcDaRn6c17OChzTijzqz3NB5CAUIIZQV+X1DZpNu1mjDddwHt3pdpkb5VBLZ2+oyuaeiKdxdhkyAZA65Wvo0cZ1vh5410K3bXpdJ/sp5nFit9DJJJkgb9nlkELnrnjNQeItTv7Oa4t5TpstvfW0IhmtIyIxaqxAjj/urkfMDzkVQsdU0+bSLay1vT7m6WzJME1tOIpFDHlDkEEZ5B60nimbzBpjC0Sy077GRaQo/mMIg7csT/Fu3E1goe/qv68ir6GThMsMluo6nA9qPmR2UjLO55HAIx6U1QpRtox9759/6U5UZeOSQcFVbBztrrMR0YiV1MqSAZXAUj0pFMjoof7yKoVmboMnn6VJncqqyckqSw/zxUcShVjywxx0PH3uaAHMxCc/Mqhtpxwfm7UMcD5VGAzDvxxSgiZyBtDDcB2VRnv+FEvHJ5U5AHtikCJFAM67x3XaCf4sUqPuCgjaeCRjk802NcurblHzqPl+lTxRghd7cIo2gDnGaGO9mdl4ajxYoOF+d2/3Qfb8K7bSlUbe47D0ritBJNqSo5JLZru9IgIX5+GK18Xj23Wk/M9nDL3EbFhEWlJzkY6101rGI4sggnHeua055BMYwnGeT6Ct8NJjAJUdiK8+L0bN5R1JJbtQm3gMevH6VBMxYKBy3YDtTHg3y7+pPUVbgCoMMp39OfSs9ZbmukUFm6bAoPTqfer5mVIl6tvOOn61FFa7mXy1IycketTXsZUKqjNa2aRk2pSIDt8zBUe3PFPwBzu69PT8qjCBVyRgeuasebFhQVx704LqKo7aEcOMDHysPyqxGJeGJJz6c1DP5KNhW96sKMKriTntjimvML6DGLIrcEv35oEgVfn6H8x+NNaQ9G2k9iv9ajkjLgnJ56baduwadSred9h+nGc1mShlVgO/p2rVMJX3988ioJ7ZSjN0PSs2nuaqSWhiWcjncrjocVdO5k5OB0qNISJiD06cetXYYSqfPgA8c1Mdi5PqZM5dI1ySTnqaxvEUZn0y4TAJaJwD26V091CxUx4HpzWJqkWLWRSD0P8AKk1qOLRxXwjiX+yScDBlY5PtXrVj/qxgc4/H615j8J4lXS2Bz8szjA+tep2JGcngmtG7u4krRsXi22P5RjHBJqg5y5C+vftV59rLlmG0Vms48xsk9eB60mOI8OWdUXOTwTVmNHVsDBwevbFVo2ABZuCP4RVyCXzcADafU81UURIlyfMzxj64J+lPdoYwA0m4+gPSmtbF8eY4Y9hU0UKxbTIqn12sM/rVozbRUn2sxMasw9QMVHJHLHGshVFDc8dTWlNPGUAYlscc9vxqlNKJAASzBTgKRxTaViLu+w1Xby/uj3IpD5jgAHPHBHUVKBgZLZB9eMU5V3lSqD2waixpcqAyKduSTUu3glk2N/fHNWGh24IzkcfLxmmkbg25Vz16cj8a0SZi2Zd6xOTu3A9fese4GEIAw3oea2NQVVOMhvf0rJlZWOAwJ7npiokaRfU5e9muUlLncvPHanxX7SLumOcjr2rTv0DtiTDEenest7dMEBR047VNuxvOalHbUq3YDBn+8PQVy9+rRrI6/dD/AJVq3sM9qxZTvjBPAPT6VmalIPsbSR4ZTwwPb1/GtYLU5pvQ878Uz7WVwDnlMn0/+tVC0jxjC8uNw56ZGaueLApukjicMCnSoLUkrEwbkhScnjrivocujed+yPMrsezOqoM9QrDjOcgin2skTPB9p8wW48vzTGAWVQeSPfHrQCphKhSGwM9RtIb+uaIoWM6QKURnYx7mYKgbIwWPTHNe3Y5tzedPCOCN3iLkMD8kOSAeM1V8SajYXz6bHpguRa2dv9mzchRIcszZwvHetC68FatFdvHPLpiTE5eNr+JcbhkYGehrE1PTp9MaOG7a1eZgsmbedZFxkjkrwCMdKxgoSatK7Kd7FaZTtcKo8v5lBzhh0NNVTuOzklvmJ7HFKVEXAB8tixOe/FOEgZwDksOQQO23pn1roMhiMSQu07iVyfU+v1pYkDhmAHygYJHv/OnRso4PzGTYc9l9v6UgYJlSDnABz1PNAC45AMbHaX3At19sU7aMoQQIzuJYnjp+tEnzySsCSV3YwMEinSqHl+bkngbeB93+dA0P3Ekjk/cwoXaOn86epAihf5lXaAT+NQoc4bAU5Uc/TriltkdnVY8MuBkjv81Sw6ne+EEkmhcsAEVuB6139ioUoS2WHyhQa4zw7sOmbosqTISfb0rt9HjUkBWO8cE4718Zj3+/kezhr8iNi1UKd23B9a0ldjjP3ep5qBQqxqD0xVmKSMoCAT6kVwNHTuTRxyHa0Y+Xoc96sxxMFDMMUyN5BGNhA9xU3JA3gHHbNCSBtlm2kIUgBvqBx+FE7lyAByfzquk+1zuOB0xVjIdxgECtHtoYxTUrspNCFfliR1PpVzYrbAvT17UycFcE9R696aVLODHwB6ZqY7FS1ZZ8hMfdz67RniqssbICUU7+mc8VpAPnecHAHApjKrHggMexFO1wT7mUY5sjzFDe44IpyGWLJXkHrzg1dKjGDuHpUEsWPuMWx+lFrCbuQGQsDk4wPpVWYyAHGCOtTShhyevoRVcvgkEZzwDmlcpLsJCI2Yhwdx65q28Q2gFsKRmq0aFnGOCOD7VZw0Yxt3L0IPUe9EUOTZTmVQB3I71i6onysQMdfxrZvBtBKHjuPWsjUH3R5PIxg+1TPY1p33OT+GBWOyuQeouHG38a9DhLEhgpPHftXnfw/jCy36k/cun6/WvSUG1AcZHQGpWxq1Z2JZWdogzMEHTOMYqkiASE/Nk+vU1Jcyb22k5IHA7AU23T5vY0DSsieK2BO4YzV2FREwC8k98dKg8xFPyMxOOcdvpUitv4I2r1A/z3q0ZSXcuF4i+0MxbucHmobgbCVySepHQU+FJSxKKAQO1SMV2bdoYnsW4NUtTK1ik23BYq4XHQYxSfuduGVlPXnjP41IY/mEgjyB+IFQvMrZBALdAewoTsDVx4KYxG5x+n51Krrn922cdjUCLLgAg4x93jFOeMjOCQcelZ3KaRM8ykcyopPYEkiqpeIgfM7t6DnFTLCuwF/wBRUcqYJwucDp3rS/cyaKlw8ZXp26Y5rKvI4igIQknvitVgVGTgnuMVRuYw5wqdeo7ClowWjOfnhjLbcFT61mXMBQFlkbPbBwa3bu0BByzIfasK+WaNCsbBl77qNCnIyL2eYKSW3qPvDHOK5zU2VWEkR3Ry4VxnGPetfUdQUBvOUxsOx6Vy2v3CIj3EB+RQNwz94V00o3MJs4vViy6u0bkbFYIPoalVEjgBG4sCw744IxVW5l+130jnJRe+PToK0RhHC4zySOccEZ5r6TLoNQcmedWd3YSYsTJzuOWHA9RnNORGuJFjgSR2cqEQc7ywxgDuSaYu3GDgglW+gxg0oLiIFw28KDHgdCGr01sYm1e6J4hvVtftOkak/wBmiWFC1qdwQH7pOOcZ6msnUtNvNPZIb20ltJCh2RTJsJXPB569662/0zxXqQgmu1EFyIPKIkvliklA+6zIW4bGB2z1Nczq1nqNpe/ZtTW4+1KeI5juIBGeCc8fpWVOblpdfIctCnwwYkAOxYHPI6dqMFQyF12hhggZPSmYQu3+s25IGB6inOSXZizcMN3QgnFbmYrCNio9ApBA4GfWnBgYR1Zivzf7XzcfWkGCkbrk7SgyBxn605wE3Mzt0O3AwTzzx6UASM6mMlhwpcYB6cdqUkAndjcpyDn1X+VRzfu4/LT5iC2AD0zj9ae+/KiRWYBtuR1Y7eaAHqxflyo24APXP40QOTA8anAdRlj2wen0pm4EBcjfhdrHufQ1YibYsSsoKhT/AD6frSYHoPg145LJV4xknAOfau8sJPLiV3IVM8nrXBeEXS308jaOSScH3rsbOWFkBLDnt2FfF4/+PL1PawztTRsJcGTdIAQg6A96vWSjA7MeOaoxTq0OEQFunFXLaJgm6TIPYA15z30OpeZs2wBHHA6ZPf8ACpm2oPvE1m2qyE4DHB6mrToxI6le/rT3BuwkkyvKoUFsdxxWvbFlQNlSTwDn+dULeFVIdkIHfmpbm4CjZGi/j2rTZGT1YapMq7QeWqWDc0SbepPc8ioLWxaeQNIwBOee1XYV5VSvyJwCBg59aaVldg9XoWYlkBwGKsDjJb71SsgkOHCKB0+vvUlvH5hBZkx2J5/Kp2hwSm1SRyGXuPUUJMmU9bGZONvyyHI/vAVTuEwMrwR39q1J12rjAOPXis2UZbK5x3pdbFKxQeRhnjJ7j2qkSGlIIznqKuTASZ2jleOO1VGjwCWbnPHvSkXEtWak9TjH3WzzirjY2hXyT0DD9M1n2bbZlycgetX36MccenrREU1qUr6PB4HHp61z2ooqhmU49Qf5V09yMxBeqtyMdq53Vl2Rvk5zUzNaJy/gFQDf4z/x9P1rv95S3JUDj7xPIH/16858E3Iia+UE7vtL811LzyzqqLnYD+BrO9lqdfJdmnHJGpwrZY9RjODV+2MauAWBLdc9qy7aB1OccH9a0Y1O0KEAHp60J3JmiyjQlhllRQeoHNWrcwM/ytGOOspyagjtUYAsce1T/ZQF+VV/EZrWJhNosiIgYWTzM/3TwKljs2Tl41UY/P61n+W6jKlgewXjFEc1wrffJPqTmndGbT6MuyqfLKMZNnXCDrVMoqYVA2CeOaUXFwM4fj3FUrmSYq2Cy+4GBVJohRZYMeNwyST7/pU6PDGu3cASMY9KylMzgbmzx9aljZwAIyMA+neoej0LdrastSzKE/dgAepOTUEtyTjYFUkZyzdahmhkl5kY/TpVdrfZ1U0WbJdiRrgYIyWI96pXEpPQFT2IqzwvYCoJ5E2dVGO5NAJ2ZQlWR13sc9qyLuLAIPNas15AoOWzj0B5rLvb2BgW/eA+ymhCcvI5TXbNZYm3KOe1eZeJrSS0hcoXMTDBHoa9V1C4QlsEn6jFcjrSxXKvG6hww7GuuhKzMKuqPOtHdfO8r5dzNwTz2rQCMmDt2kbSSTx0wfxrIuU+w6kQAwVWBXPXFa4lDIrx7ymCRnpwa+my6pzU+R9Dzays7ilCIunCjkrx0bg1Z024m0+/tr1NjNDMHwxwrAENg/XFVZhu/iLDLDqPTOcVY02a3j1ewlvEaa0WeJ5Y+pZMjIA+leg9jI3tRs/Dl5ePfXWoanaG8kM4iuLEux3c4D5wwBPX0qj4ov7eU6bHZm7S2tLRIIZbgYkmTcxLHHQZJAA4AFa+oa7Kus3dnr14mt6DdN5u6J93kIWO2SLP3GUYyntg1n+NPs6Jo0FpdQX6waf5QngJ2n94xGR2OCOD0rng2mk/l/Vimro52PdHISV6EjpznFOgUO4Zhldw3ZOCOP5VL5anYd4zySDwRx096jJR3Q5bPyqR3XjmuoxFXl1B3BTtOBznnrSncpY4Jxkgseo3UqIUXamc4GPfJpCiD7zAlQxI7/SgBJV8xCyAAbmHXHb+VThsAjIGSCWDf7NROu+UopUqQWwTjt+tEa4xsOTlc4zgcUDJQUZRhhldn407mQMXkBJDBix6c9BUK5SFCrx4YDAx23cg1LkthCFXlhyMZGfT1pPYDs/CbSzkwDCoP73oR1r0PR7KFVRXGR1w1cl4d0tY445hLtkZcMeigHtiuyspUi+WNTKR1bt+dfHZhOEq0vZ7HsYZNQ1N6GGFCuFwvoKv7kdAuCvoay4JbiUDaka/XmrayXa/wRMPUEivNszpuacCJs+T5h0PrVyFRjjJPrWXBduWAaHA9Qea0YnVyNkpjfrtOatOxEk2yRvlb73I7GmwIry/vCeep9KeVkHZXHrTkdY13Mh3epFNSV7iadrFyVYfJURgk55OeOPSpQiRxqA6kHn5l61mj5mV1bcPY1pl96AgBSODg9ac5XCEeVFy08yP95HCWQ8YBxg1YjCTRncdrL/CeoNQQtKEUKxxnoB0pZZSpIflj371SdjOXvMju4Cw6AelZdx+7wrJh/71aM1xIgPlspHaqpj3R73z5nXmlZblJtLUzDGFYseGNZ1yxUsoA/AVp3DcnHBHY1QuSNpDDis5GtPRkdn98EdQK0ZGMmWA5XkCsy0GO/ynrWrEFaNjgj3Bojc0na5TL71KgZUAmsHV3DRuG7jGa6R4MqxUgMfXvWBrUO23Zs8YJNRPRF0rXOG8E25Ed1IQRm4cZP1rt4DFCOSeOnHWsLwpAF0/jJJZm/Ek10CwFgu7IOMGsj0LLYsw3UIGN30yKsrqVqBt3njrxVM2vydCMjjNN+ynBz1GKfMyXCJsx6raiIkSD2z1qaDV4GcB3jB6jHT9axRZHZyoFQG2w2AePSrU2YSpwZ1r39rKwxJHg9T3FSNNZMn7tlBxyWI/SuVSzHDDOPenLbkHkD61Sm+xzypR6M35Lq0PeJcDP3+tVJLm3bAEq4xyAc1lC2VmyV/SrUFqgP3RVqTIcEid5YCQsKMc9eMCrKTRIdwRc4/iOTmq8VvlsdDTmj2uFOOR19KeplYme43EnaFGMELx+tULlS6/Km36nJNWpCoX72T71EzZztHBqXpuUlbVGX5LK3JOffpTGtA2cgZ9TWusAGc8nuaZOUhXcwGKhFORgyWoUkBR+NVLq1jRSWwDWnPNJMSIF2r6sKqSaZ5h3Sktnrk0uawONzltT8oK37yOuU1eKCRSGWJx/s8GvR7rSYyu0KAfasHUdBLhtuzPutbU6lnqZypdjxTxJpxPzIzNjoG6j/GsXTLnDi3mJCkEDngH3r0fxLoMqK/7pkxzlOR9cV5lqcDwXD7vvA9R3r1sPiHBqpHocdWn0N3JZ1Iz8zDAXjGRx+FRO25QiqwzgHcMksDziqWn3YcCOR8EAYJ9jW7o1xDaatZT3Lb7aC4EhYDPAOeB+v4V9LTqqpDnicDvF2ZO+hxWjrb32sWltcDdmBo3k2d9sjKCFPqOcd6zr6xuNPu3gvMLOHDcHcrBhkOGHBUjoR1rtLq1ePVtHna9uLeeyIASG1eX7TlixkhZRtfzM5OSOSQawvFkpjubO12+W0CESxoQRCzSM4iz0JRWAOOh4qITcnYqWiOYWdvLLhV3K3FEVwxHmFVLDbRRTuyLaFhZnecM2CWXcfqKZDctLJIHRMFSTx1yRmiirTZJdVAb9Y+2Dz34Wo7UmeWWRyd3y9PaiirQIUkpEZF4Yrkn8a2PDdul7qVvHcZZS0hPPpRRWdd2gy6fxI9S062i85Bt4I6V0lmihMhR93NFFfEVN2e3DZGpbcjB9q0Io1O3IoorKI5EsXEuBVl41PXJPqT0oopS2NI7i28h3shAIHTIqzJhlII4B4oopLYch9rbRvAz4IYc5BxU0cjKwCnGM0UUS6GUdb3NJAZIgWZj+NRTZjcBScUUVozJDLlAmWUncBmiICa2LuAWzjpRRSkUjJuwAHA6A1j3rsigg96KKzka09xqHDEDp1qa3lfgbjg0UUR3NWXXlc7VzxWNrpzZyH/ZNFFKew6XxIpeGEX+z4uP4c1sFR8x9aKKx6HofaY+Ikkgn5cDipkUHJx0YiiiqRL6izMcCqwALEGiiqMOhfiUAqMd6ZcqFkwPQUUVfQx+0QADBXsalgJbAJNFFERsc8rlyoOAB271G0jA5B74oorRGMlsCAM5LcmpgAMD3oorPqN7BM2wnGOazCPOkzISeM47UUVMgjuTxxIDwKZOoCnHrRRSH1MssRuPGc9ayryVgpxjNFFECnuc9qUrFSTg8dxXmPjqxt3sTd+WFm7leM/hRRXdhfjOKsedoxVsg8iuggY/ZCfQgj8RRRX0GVPRnnV+hqWl5e2+nyx219dwxgKdkczKvPXgHFZxOBGBwCrDA9jmiivYslscx//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Violaceous polygonal papules are present on the ventral wrists.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_42_29346=[""].join("\n");
var outline_f28_42_29346=null;
var title_f28_42_29347="Acute appendicitis ultrasound";
var content_f28_42_29347=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 625px\">",
"   <div class=\"ttl\">",
"    Acute appendicitis ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 605px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient is a 19-year-old female who presented to the emergency department with right lower quadrant pain. The gray scale ultrasound of the appendix is projected in the longitudinal (A) and transverse planes (B). A noncompressible appendix measures almost 20 mm in diameter, consistent with a diagnosis of acute appendicitis. The echogenic mucosal and submucosal portions of the wall have become discontinuous (red arrows) suggesting disruption as a result of sloughing. Luminal air (yellow arrows) results in posterior shadowing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_42_29347=[""].join("\n");
var outline_f28_42_29347=null;
var title_f28_42_29348="Neomycin: Pediatric drug information";
var content_f28_42_29348=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Neomycin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"    see \"Neomycin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/63/36852?source=see_link\">",
"    see \"Neomycin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1048863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Ammonium Detoxicant",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Aminoglycoside",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Topical",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Hyperammonemia Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11443897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral: Diarrhea: 100 mg/kg/day divided every 6 hours (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1048856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"      see \"Neomycin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Oral: 50-100 mg/kg/day in divided doses every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preoperative bowel antisepsis: 90 mg/kg/day divided every 4 hours for 2 days; or 25 mg/kg at 1, 2, and 11 PM on the day preceding surgery as an adjunct to mechanical cleansing of the intestine and in combination with erythromycin base",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic coma: 2.5-7 g/m",
"     <sup>",
"      2",
"     </sup>",
"     /day divided every 4-6 hours for 5-6 days not to exceed 12 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diarrhea caused by enteropathogenic",
"     <i>",
"      E. coli",
"     </i>",
"     : 50 mg/kg/day divided every 6 hours for 2-3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adults: Topical: Apply ointment 1-3 times/day; topical solutions containing 0.1% to 1% neomycin have been used for irrigation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Oral: 500-2000 mg every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preoperative bowel antisepsis: 1 g each hour for 4 doses then 1 g every 4 hours for 5 doses; or 1 g at 1 PM, 2 PM, and 11 PM with oral erythromycin on day preceding surgery as an adjunct to mechanical cleansing of the bowel; or 6 g/day divided every 4 hours for 2-3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic coma: 4-12 g/day divided every 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diarrhea caused by enteropathogenic",
"     <i>",
"      E. coli",
"     </i>",
"     : 3 g/day divided every 6 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F200451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as sulfate: 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F200437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1048859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reconstituted neomycin solution is stable for 7 days when refrigerated",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1048866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administered orally to prepare GI tract for surgery; treat minor skin infections; treat diarrhea caused by",
"     <i>",
"      E. coli",
"     </i>",
"     ; adjunct in the treatment of hepatic encephalopathy",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F200504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, irritation or soreness of the mouth or rectal area, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Dyspnea, eosinophilia, nephrotoxicity, neurotoxicity, ototoxicity (auditory), ototoxicity (vestibular)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1048869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to neomycin or any component, or other aminoglycosides; patients with intestinal obstruction, inflammatory or ulcerative gastrointestinal disease",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1048855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment, pre-existing hearing impairment, neuromuscular disorders; modify dosage in patients with renal impairment. Oral doses of 12 g/day may produce a malabsorption syndrome for a variety of substances (fat, nitrogen, cholesterol, carotene, glucose, xylose, lactose, sodium, calcium, cyanocobalamin, and iron).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1048854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Neomycin is more toxic than other aminoglycosides when given parenterally;",
"     <b>",
"      do not administer parenterally",
"     </b>",
"     ; topical neomycin is a contact sensitizer with sensitivity occurring in 5% to 15% of patients treated with the drug; systemic absorption can occur when neomycin is utilized for irrigation of wounds or surgical sites. Systemic absorption occurs following oral administration; toxic reactions may occur",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Concurrent and/or sequential use of any form of other aminoglycosides should be avoided because toxicity may be additive",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . May cause nephrotoxicity",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; usual risk factors include pre-existing renal impairment, concomitant nephrotoxic medications, advanced age, and dehydration. Discontinue treatment if signs of nephrotoxicity occur; renal damage is usually reversible. May cause neurotoxicity",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; usual risk factors include pre-existing renal impairment, concomitant neuro-/nephrotoxic medications, advanced age, and dehydration. Ototoxicity is proportional to the amount of drug given and the duration of treatment. Tinnitus or vertigo may be indications of vestibular injury and impending bilateral irreversible damage. Discontinue treatment if signs of ototoxicity occur; risk of hearing loss continues after drug withdrawal. Avoid concurrent use of potent diuretics due to risk of ototoxicity",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; intravenous use of diuretics may enhance neomycin toxicity by altering concentration in serum and tissue. May cause neuromuscular blockade and respiratory paralysis",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     , especially when given soon after anesthesia or muscle relaxants.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F200446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acarbose: Neomycin may enhance the adverse/toxic effect of Acarbose. Neomycin may enhance the therapeutic effect of Acarbose. Neomycin may decrease the metabolism of Acarbose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Aminoglycosides may enhance the hypocalcemic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CARBOplatin: Aminoglycosides may enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Aminoglycosides may decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (2nd Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (3rd Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (4th Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CISplatin: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Aminoglycosides may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gallium Nitrate: Aminoglycosides may enhance the nephrotoxic effect of Gallium Nitrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Aminoglycosides may enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: Neomycin may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Neomycin may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F200447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5722064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aminoglycosides cross the placenta; however, neomycin has limited maternal absorption. Therefore the portion of an orally administered maternal dose available to cross the placenta is very low. Teratogenic effects have not been observed following maternal use of neomycin. Because of several reports of total irreversible bilateral congenital deafness in children whose mothers received another aminoglycoside (streptomycin) during pregnancy, the manufacturer classifies neomycin as pregnancy category D.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1048862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function tests",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1048853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with bacterial protein synthesis by binding to 30S ribosomal subunits",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1048868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Poor orally (3%) or percutaneously; readily absorbed through denuded or abraded skin and body cavities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.36 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 2-3 hours (age and renal function dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Within 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In urine (30% to 50% as unchanged drug); 97% of an oral dose eliminated unchanged in feces",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Dialyzable (50% to 100%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1048861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/63/36852?source=see_link\">",
"      see \"Neomycin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if ringing in the ears, hearing impairment, or dizziness occurs",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12634 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.65.66-BC5B390E05-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_42_29348=[""].join("\n");
var outline_f28_42_29348=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709169\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048863\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11443897\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048856\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200451\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200437\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048859\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048866\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200504\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048869\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048855\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048854\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299750\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200446\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200447\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5722064\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048862\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048853\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048868\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048861\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12634\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12634|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=related_link\">",
"      Neomycin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/63/36852?source=related_link\">",
"      Neomycin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_42_29349="ECG digoxin toxicity in AF 2";
var content_f28_42_29349=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76154&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1126px;\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Single-lead electrocardiogram (ECG) showing atrial fibrillation with an accelerated junctional pacemaker",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 79px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The 4 electrocardiograms in this sequence demonstrate increasing severity of digoxin toxicity in a patient with atrial fibrillation.",
"    <br>",
"     <br>",
"      In this strip, the R-R intervals are constant, as the ventricles are controlled by an accelerated junctional pacemaker, resulting in a regular tachycardia at 115 beats per minute. Physical examination at this time might lead to the erroneous diagnosis of a regular sinus mechanism.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       The four electrocardiograms are adapted from Childers, R, Med Clin North Am 1976; 60:3.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_42_29349=[""].join("\n");
var outline_f28_42_29349=null;
var title_f28_42_29350="Nasolacrimal duct obstruction (dacryostenosis) in children";
var content_f28_42_29350=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nasolacrimal duct obstruction (dacryostenosis) in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/42/29350/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/42/29350/contributors\">",
"     Evelyn A Paysse, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/42/29350/contributors\">",
"     David K Coats, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/42/29350/contributors\">",
"     Michael Cassidy, COT",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/42/29350/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/42/29350/contributors\">",
"     Richard A Saunders, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/42/29350/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/42/29350/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/42/29350/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasolacrimal duct (NLD) obstruction (dacryostenosis) is the most common cause of persistent tearing and ocular discharge in children. Other causes range from mild self-limited conditions to sight-threatening ocular emergencies (",
"    <a class=\"graphic graphic_table graphicRef63904 \" href=\"UTD.htm?40/30/41452\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The clinical features, evaluation, and treatment of NLD obstruction will be discussed below. The anatomy of the lacrimal system, other causes of persistent tearing, and the approach to the child with persistent tearing are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7079?source=see_link\">",
"     \"Approach to the child with persistent tearing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EMBRYOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nasolacrimal apparatus appears in the third to fifth week of embryonic life. The nasolacrimal apparatus gradually forms a cord of epithelium that extends from the eyelids to the nose. Canalization of the cord begins at the punctum in the eyelid during the third month of intrauterine life and extends toward the nose. Incomplete canalization can result in obstruction of the nasolacrimal duct.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasolacrimal duct (NLD) obstruction is the most common cause of persistent tearing and ocular discharge in children, occurring in up to 20 percent of all normal newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29350/abstract/1\">",
"     1",
"    </a>",
"    ] and causing symptoms in up to 6 percent of children during the first year of life [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29350/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     NLD obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasolacrimal duct (NLD) obstruction can occur anywhere in the lacrimal drainage system. It most commonly occurs at the distal end of the nasolacrimal duct at the membrane of Hasner (ie, the unopened valve of Hasner) (",
"    <a class=\"graphic graphic_figure graphicRef53429 \" href=\"UTD.htm?20/48/21252\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Infants with NLD obstruction present with a history of chronic or intermittent tearing, debris on the eyelashes (mattering), and occasionally redness of the conjunctiva (",
"    <a class=\"graphic graphic_picture graphicRef62518 \" href=\"UTD.htm?29/6/29806\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef52654 \" href=\"UTD.htm?40/60/41935\">",
"     picture 2",
"    </a>",
"    ). On physical examination, there is often an increase in the size of the tear meniscus. Palpation of the lacrimal sac may cause reflux of tears",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mucoid discharge onto the eye through the puncta. If tearing is intermittent, and none of the above signs are present at the time of examination, the dye disappearance test can be performed to help confirm the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7079?source=see_link&amp;anchor=H20#H20\">",
"     \"Approach to the child with persistent tearing\", section on 'Dye disappearance test'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other causes of persistent tearing in infants and young children that must be considered in the differential diagnosis of NLD obstruction are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef63904 \" href=\"UTD.htm?40/30/41452\">",
"     table 1",
"    </a>",
"    ). Associated signs and symptoms usually help to narrow the differential diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7079?source=see_link&amp;anchor=H5#H5\">",
"     \"Approach to the child with persistent tearing\", section on 'Etiology of persistent tearing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Dacryocystocele",
"    </span>",
"    &nbsp;&mdash;&nbsp;A dacryocystocele (also known as dacryocele, amniotocele, or nasolacrimal duct cyst) is produced when both the proximal and distal portions of the nasolacrimal system are obstructed. The distal obstruction is generally at the level of the membrane of Hasner. The proximal obstruction typically occurs in the common canaliculus or at the valve of Rosenmuller (",
"    <a class=\"graphic graphic_figure graphicRef53429 \" href=\"UTD.htm?20/48/21252\">",
"     figure 1",
"    </a>",
"    ). The proximal obstruction is a one-way valve that permits tears to enter, but not to reflux out of the canaliculi of the lacrimal drainage system.",
"   </p>",
"   <p>",
"    Dacryocystoceles usually are noted at or shortly after birth. A bluish swelling of the skin overlying the lacrimal sac and superior displacement of the medial canthal tendon is typical (",
"    <a class=\"graphic graphic_picture graphicRef62273 \" href=\"UTD.htm?40/28/41422\">",
"     picture 3",
"    </a>",
"    ). The diagnosis can be confirmed by neuroimaging (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50760 \" href=\"UTD.htm?28/42/29358\">",
"     image 1",
"    </a>",
"    ), though it is usually obvious clinically and further work-up generally is not necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous resolution occurs by six months of age in up to 90 percent of children with congenital nasolacrimal duct (NLD) obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29350/abstract/2\">",
"     2",
"    </a>",
"    ]. The chance of spontaneous resolution decreases between 6 and 12 months of age, but still occurs. By some accounts, fewer than 1 percent of NLD obstructions that are present at 12 months of age resolve spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29350/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     NLD obstructions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of nasolacrimal duct (NLD) obstruction may entail lacrimal sac massage (sometimes called \"Crigler\" massage)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lacrimal duct probing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Massage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lacrimal sac massage typically is the first line of treatment for NLD obstruction. Lacrimal sac massage forces tears from the lacrimal sac into the nasolacrimal duct, theoretically increasing the hydrostatic pressure enough to relieve the distal membranous obstruction.",
"   </p>",
"   <p>",
"    Lacrimal sac massage is performed by applying moderate pressure over the lacrimal sac in a downward direction. Parents are requested to perform this maneuver two to three times per day. Demonstrating the technique for lacrimal sac massage on both the child and the parents (so the parents understand how much pressure to apply) is helpful. Parents should be instructed to keep their fingernails trimmed and to wash their hands before performing lacrimal sac massage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Probing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lacrimal duct probing may be necessary for unresolved NLD obstruction. Lacrimal duct probing is performed by an ophthalmologist. It may be performed in the office or the operating room, depending upon the age of the child and the experience and preference of the ophthalmologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715890109\">",
"    <span class=\"h4\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small blunt probe or irrigation cannula is introduced into the punctum and advanced through the lacrimal drainage system until it abuts the obstruction (",
"    <a class=\"graphic graphic_picture graphicRef76279 \" href=\"UTD.htm?38/59/39858\">",
"     picture 4",
"    </a>",
"    ). The probe then is pushed gently through the obstruction into the nose. Irrigation with fluorescein-stained saline is often performed to ensure patency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715890116\">",
"    <span class=\"h4\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The timing of initial probing depends upon the preference of the ophthalmologist. Some ophthalmologists advocate deferring the procedure until the child is at least 12 months of age because of the high rate of spontaneous resolution; exceptions can be made for children who have recurrent infection or lid irritation, or who need anesthesia for some other procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29350/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. When performed after 12 months of age, general anesthesia is usually necessary.",
"   </p>",
"   <p>",
"    Other ophthalmologists advocate probing between 6 and 12 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29350/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. They suggest that prolonged tearing annoys the infant and the parents, and that delayed probing may increase the risk of infections, lacrimal duct scarring, and failure. Probing between 6 and 12 months of age has an advantage of being able to be performed in the office with topical anesthesia.",
"   </p>",
"   <p>",
"    In a multicenter trial evaluating immediate versus six-month deferral of probing for NLD obstruction in infants who remained symptomatic at 6 to 10 months of age (mean age 7.8 months), 107 infants (133 eyes) were randomly assigned to the deferral group and treated with lacrimal massage and topical antibiotics as needed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29350/abstract/7\">",
"     7",
"    </a>",
"    ]. Four patients underwent early surgery because of worsening symptoms, parent request, or development of cellulitis. Among the 117 eyes that were examined at the six-month follow-up, NLD obstruction had resolved in 77 (66 percent, 95% CI 56-74 percent). Among the 25 patients with bilateral NLD obstruction, 14 (56 percent, 95% CI 37-74 percent) had resolution in both eyes without surgery.",
"   </p>",
"   <p>",
"    Whether delaying probing until &gt;12 months of age results in increased rate of failure is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29350/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. In a prospective observational study of NLD probing of 900 eyes in 672 children between six months and four years of age, probing was successful in 78 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29350/abstract/13\">",
"     13",
"    </a>",
"    ]. For patients younger than 36 months, success was unrelated to age; there were too few patients between 36 and 48 months of age for adequate assessment of age effect in this group. The probability of success was slightly lower when the procedure was performed in an office rather than a surgical facility (72 versus 80 percent, adjusted relative risk [RR] 0.88) and when performed on both eyes (adjusted RR 0.88). Many ophthalmologists utilize a tube to temporarily stent the lacrimal drainage system or a balloon to dilate the lacrimal drainage system intraoperatively as an adjunct to simple probing to improve the success rate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Other procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who are older or have tight obstructions, anatomic abnormalities, or recurrence of obstruction after primary nasolacrimal duct probing may require the placement of a silicone stent or balloon dilation of the nasolacrimal duct (balloon dacryocystoplasty) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29350/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Both of these procedures are performed with the child under general anesthesia. Stents usually are removed in the office after two to six months. Stents typically are not necessary with balloon dacryocystoplasty.",
"   </p>",
"   <p>",
"    Other procedures that may be indicated in children with NLD obstruction include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The creation of a window between the lacrimal sac and nasal cavity (dacryocystorhinostomy); this procedure preserves the active drainage mechanism. Dacryocystorhinostomy is reserved for children who have failed to achieve resolution of symptoms after more typical treatments (as outlined above) and is uncommonly required. Children with abnormal anatomy are more likely than children with normal anatomy to require dacryocystorhinostomy.",
"     </li>",
"     <li>",
"      The placement of a Pyrex glass tube between the caruncle and the nasal cavity (conjunctivodacryocystorhinostomy); this procedure relies solely on gravity drainage, and is indicated in children with significant anatomical abnormalities proximal to the lacrimal sac that cannot be addressed with the procedures described above. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Dacryocystoceles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with dacryocystoceles should be seen urgently by an ophthalmologist. They may require early intervention because of two potential complications [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29350/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute dacryocystitis, indicated by erythema and tenderness of the dacryocystocele, swelling and fever, poor feeding, or altered behavior. Acute dacryocystitis is a medical emergency in a newborn infant, and it must be treated promptly to prevent the development of secondary preseptal or orbital cellulitis, sepsis, meningitis, or brain abscess. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Acute dacryocystitis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Distension of the mucosal lining of the nasolacrimal duct through the entrapment of tears. The swelling may distend into the nose, forming a mucocele, which can lead to nasal obstruction and respiratory distress in infants who are obligate nose breathers [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29350/abstract/18-21\">",
"       18-21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Decompression of a dacryocystocele usually can be achieved with digital massage or probing of the lacrimal canaliculus and duct. Untreated, infection often ensues. The NLD obstruction component is treated as it is in older children. In addition, the intranasal component, if present, must be opened to prevent recurrence of the obstruction. The intranasal component can be opened in the office, but more complex cases are best managed in the operating room under general anesthesia, sometimes with the aid of a nasal endoscope. The opening of the intranasal component of the lesion can sometimes be accomplished with probing, but marsupialization may be required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasolacrimal duct (NLD) obstruction may be complicated by acute or chronic dacryocystitis (inflammation or infection of the lacrimal sac). In a review of 54 cases of dacryocystitis in children, two-thirds were chronic, and one-third were acute [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29350/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Acute dacryocystitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute dacryocystitis is indicated by erythema, swelling, warmth,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tenderness of the lacrimal sac (",
"    <a class=\"graphic graphic_picture graphicRef65777 \" href=\"UTD.htm?6/21/6480\">",
"     picture 5",
"    </a>",
"    ). Acute dacryocystitis can be complicated by preseptal or orbital cellulitis, sepsis, or meningitis and should be treated promptly with systemic antibiotics. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    The choice of antibiotic depends upon the age of the child, the severity of the infection, and the presence and type of complications. The most common organisms isolated from children with acute dacryocystitis include alpha-hemolytic streptococci,",
"    <em>",
"     Staphylococcus epidermidis",
"    </em>",
"    , and",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29350/abstract/22\">",
"     22",
"    </a>",
"    ]. Because of the great increase in methicillin-resistant",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    (MRSA) in many areas of the United States, oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    , or, if more severe, intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    is often a first-line antibiotic in combination with a third-generation cephalosporin to cover a broader spectrum. Empiric antimicrobial therapy should be altered as indicated when culture results are available. The duration of antimicrobial therapy varies depending on response, but is usually 7 to 10 days.",
"   </p>",
"   <p>",
"    Infants and children with acute dacryocystitis should be managed in consultation with an ophthalmologist. If NLD probing is to be performed, preoperative antibiotics should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29350/abstract/23\">",
"     23",
"    </a>",
"    ]. Mucopurulent material obtained during drainage should be sent for culture to guide definitive antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29350/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Chronic dacryocystitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic dacryocystitis, due to bacterial growth in the stagnant tear pool of the lacrimal sac, is indicated by mucopurulent drainage from the puncta.",
"   </p>",
"   <p>",
"    Children with NLD obstruction and chronic dacryocystitis can be treated with topical antibiotics. Appropriate agents may include topical",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/11/38064?source=see_link\">",
"     erythromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/27/35248?source=see_link\">",
"     sulfacetamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/39/22129?source=see_link\">",
"     tobramycin",
"    </a>",
"    , or fluoroquinolones (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/15/38128?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/35/37424?source=see_link\">",
"     ofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    , etc) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29350/abstract/24\">",
"     24",
"    </a>",
"    ]. The organisms most commonly isolated from the lacrimal sac in a study of 47 young children with chronic NLD obstruction included",
"    <em>",
"     Streptococcus pneumoniae",
"    </em>",
"    (35 percent),",
"    <em>",
"     Haemophilus influenzae",
"    </em>",
"    (20 percent),",
"    <em>",
"     Pseudomonas aeruginosa",
"    </em>",
"    (11 percent), and",
"    <em>",
"     Streptococcus viridans",
"    </em>",
"    (11 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29350/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/54/25441?source=see_link\">",
"       \"Patient information: Blocked tear duct (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nasolacrimal duct (NLD) obstruction is the most common cause of persistent tearing in infants, occurring in up to 20 percent of newborns and causing symptoms in up to 6 percent of infants during the first year of life. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical features of NLD obstruction may include chronic or intermittent tearing, debris on the eyelashes, increased tear meniscus, reflux of tears",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mucoid discharge through the puncta with palpation of the lacrimal sac, and redness of the conjunctiva (",
"      <a class=\"graphic graphic_picture graphicRef62518 \" href=\"UTD.htm?29/6/29806\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef52654 \" href=\"UTD.htm?40/60/41935\">",
"       picture 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'NLD obstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical features of dacryocystoceles include a bluish swelling of the skin overlying the lacrimal sac and superior displacement of the medial canthal tendon (",
"      <a class=\"graphic graphic_picture graphicRef62273 \" href=\"UTD.htm?40/28/41422\">",
"       picture 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Dacryocystocele'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Spontaneous resolution of congenital NLD obstruction occurs by six months of age in 90 percent of children. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lacrimal sac massage (\"Crigler\" massage) is the first line of treatment for NLD obstruction. Lacrimal duct probing (",
"      <a class=\"graphic graphic_picture graphicRef76279 \" href=\"UTD.htm?38/59/39858\">",
"       picture 4",
"      </a>",
"      ) may be necessary if NLD obstruction does not resolve with lacrimal massage. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'NLD obstructions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with dacryocystoceles should be seen urgently by an ophthalmologist. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Dacryocystoceles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NLD obstruction may be complicated by acute or chronic dacryocystitis. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute dacryocystitis, manifest by erythema, swelling, warmth,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tenderness of the lacrimal sac (",
"      <a class=\"graphic graphic_picture graphicRef65777 \" href=\"UTD.htm?6/21/6480\">",
"       picture 5",
"      </a>",
"      ), should be managed in consultation with an ophthalmologist. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Acute dacryocystitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic dacryocystitis may be managed by the primary care provider with topical antibiotics. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Chronic dacryocystitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29350/abstract/1\">",
"      Petersen RA, Robb RM. The natural course of congenital obstruction of the nasolacrimal duct. J Pediatr Ophthalmol Strabismus 1978; 15:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29350/abstract/2\">",
"      MacEwen CJ, Young JD. Epiphora during the first year of life. Eye (Lond) 1991; 5 ( Pt 5):596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29350/abstract/3\">",
"      Robb RM. Congenital nasolacrimal duct obstruction. Ophthalmol Clin North Am 2001; 14:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29350/abstract/4\">",
"      Wagner RS. Management of congenital nasolacrimal duct obstruction. Pediatr Ann 2001; 30:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29350/abstract/5\">",
"      Baker JD. Treatment of congenital nasolacrimal system obstruction. J Pediatr Ophthalmol Strabismus 1985; 22:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29350/abstract/6\">",
"      Chiesi C, Guerra R, Longanesi L, et al. Congenital nasolacrimal duct obstruction: therapeutic management. J Pediatr Ophthalmol Strabismus 1999; 36:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29350/abstract/7\">",
"      Pediatric Eye Disease Investigator Group. Resolution of congenital nasolacrimal duct obstruction with nonsurgical management. Arch Ophthalmol 2012; 130:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29350/abstract/8\">",
"      Robb RM. Probing and irrigation for congenital nasolacrimal duct obstruction. Arch Ophthalmol 1986; 104:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29350/abstract/9\">",
"      Paul TO, Shepherd R. Congenital nasolacrimal duct obstruction: natural history and the timing of optimal intervention. J Pediatr Ophthalmol Strabismus 1994; 31:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29350/abstract/10\">",
"      Katowitz JA, Welsh MG. Timing of initial probing and irrigation in congenital nasolacrimal duct obstruction. Ophthalmology 1987; 94:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29350/abstract/11\">",
"      el-Mansoury J, Calhoun JH, Nelson LB, Harley RD. Results of late probing for congenital nasolacrimal duct obstruction. Ophthalmology 1986; 93:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29350/abstract/12\">",
"      Maini R, MacEwen CJ, Young JD. The natural history of epiphora in childhood. Eye (Lond) 1998; 12 ( Pt 4):669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29350/abstract/13\">",
"      Pediatric Eye Disease Investigator Group, Repka MX, Chandler DL, et al. Primary treatment of nasolacrimal duct obstruction with probing in children younger than 4 years. Ophthalmology 2008; 115:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29350/abstract/14\">",
"      Pediatric Eye Disease Investigator Group, Repka MX, Melia BM, et al. Primary treatment of nasolacrimal duct obstruction with balloon catheter dilation in children younger than 4 years of age. J AAPOS 2008; 12:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29350/abstract/15\">",
"      Repka MX, Chandler DL, Holmes JM, et al. Balloon catheter dilation and nasolacrimal duct intubation for treatment of nasolacrimal duct obstruction after failed probing. Arch Ophthalmol 2009; 127:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29350/abstract/16\">",
"      Paysse EA, Coats DK, Bernstein JM, et al. Management and complications of congenital dacryocele with concurrent intranasal mucocele. J AAPOS 2000; 4:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29350/abstract/17\">",
"      Wong RK, VanderVeen DK. Presentation and management of congenital dacryocystocele. Pediatrics 2008; 122:e1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29350/abstract/18\">",
"      Edmond JC, Keech RV. Congenital nasolacrimal sac mucocele associated with respiratory distress. J Pediatr Ophthalmol Strabismus 1991; 28:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29350/abstract/19\">",
"      Duval M, Alsabah BH, Carpineta L, Daniel SJ. Respiratory distress secondary to bilateral nasolacrimal duct mucoceles in a newborn. Otolaryngol Head Neck Surg 2007; 137:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29350/abstract/20\">",
"      Yee SW, Seibert RW, Bower CM, Glasier CM. Congenital nasolacrimal duct mucocele: a cause of respiratory distress. Int J Pediatr Otorhinolaryngol 1994; 29:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29350/abstract/21\">",
"      Leonard DS, O'Keefe M, Rowley H, Hughes JP. Neonatal respiratory distress secondary to bilateral intranasal dacryocystocoeles. Int J Pediatr Otorhinolaryngol 2008; 72:1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29350/abstract/22\">",
"      Campolattaro BN, Lueder GT, Tychsen L. Spectrum of pediatric dacryocystitis: medical and surgical management of 54 cases. J Pediatr Ophthalmol Strabismus 1997; 34:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29350/abstract/23\">",
"      Baskin DE, Reddy AK, Chu YI, Coats DK. The timing of antibiotic administration in the management of infant dacryocystitis. J AAPOS 2008; 12:456.",
"     </a>",
"    </li>",
"    <li>",
"     Yen KG, Chilakapati MC, Coats DK, et al. Ocular infectious diseases. In: Feigin and Cherry's Textbook of Pediatric Infectious Diseases, 6th, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders Elsevier, Philadelphia 2009. p.811.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29350/abstract/25\">",
"      Kuchar A, Lukas J, Steinkogler FJ. Bacteriology and antibiotic therapy in congenital nasolacrimal duct obstruction. Acta Ophthalmol Scand 2000; 78:694.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6274 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-59E8FFCE15-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_42_29350=[""].join("\n");
var outline_f28_42_29350=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EMBRYOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NLD obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Dacryocystocele",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      NLD obstructions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Massage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Probing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H715890109\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H715890116\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Other procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Dacryocystoceles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Acute dacryocystitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Chronic dacryocystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6274\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6274|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/42/29358\" title=\"diagnostic image 1\">",
"      Nasolacrimal duct cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6274|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/48/21252\" title=\"figure 1\">",
"      Anatomy of lacrimal system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6274|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/6/29806\" title=\"picture 1\">",
"      Nasolacrimal duct obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/60/41935\" title=\"picture 2\">",
"      NLD obstruction mattering",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/28/41422\" title=\"picture 3\">",
"      Dacryocele",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/59/39858\" title=\"picture 4\">",
"      Nasolacrimal duct probing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/21/6480\" title=\"picture 5\">",
"      Dacryostenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6274|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/30/41452\" title=\"table 1\">",
"      Causes persistent tearing in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7079?source=related_link\">",
"      Approach to the child with persistent tearing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/54/25441?source=related_link\">",
"      Patient information: Blocked tear duct (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_42_29351="Hepatic toxocariasis";
var content_f28_42_29351=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 581px\">",
"   <div class=\"ttl\">",
"    Hepatic toxocariasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 561px; height: 469px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 43-year-old man with hepatic toxocariasis. Contrast-enhanced arterial (A), portal phases (B), and equilibrium phase (C). CT images display two small triangular and oval nodules in the periphery of the liver. The nodules are clearly seen on portal venous phase image, but not clearly seen on arterial and equilibrium phase images.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Lim JH. Toxocariasis of the liver: visceral larva migrans. Abdom Imaging 2008; 33:151, with kind permission of Springer Science + Business Media B.V. Copyright &copy; 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_42_29351=[""].join("\n");
var outline_f28_42_29351=null;
var title_f28_42_29352="Overview of the treatment of chronic lymphocytic leukemia";
var content_f28_42_29352=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the treatment of chronic lymphocytic leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/42/29352/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/42/29352/contributors\">",
"     Kanti R Rai, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/42/29352/contributors\">",
"     Michael J Keating, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/42/29352/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/42/29352/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/42/29352/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/42/29352/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/42/29352/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic lymphocytic leukemia (CLL) is one of the chronic lymphoproliferative disorders (lymphoid neoplasms). It is characterized by a progressive accumulation of functionally incompetent lymphocytes, which are monoclonal in origin.",
"   </p>",
"   <p>",
"    CLL is considered to be identical (ie, one disease at different stages) to the mature (peripheral) B cell neoplasm small lymphocytic lymphoma (SLL), one of the indolent non-Hodgkin lymphomas. The term CLL is used when the disease manifests primarily in the bone marrow and blood, whereas the term SLL is used when involvement is primarily nodal. While there is some difference to the treatment of early stage CLL and SLL, the treatment of advanced stage disease is the same. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=see_link\">",
"     \"Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    General issues regarding the treatment of",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    will be reviewed here. Further details regarding the selection of initial therapy for advanced stage or symptomatic disease, the treatment of",
"    <span class=\"nowrap\">",
"     relapsed/refractory",
"    </span>",
"    disease, the use of hematopoietic cell transplantation, and the management of complications of",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    and its treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6362?source=see_link\">",
"     \"Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=see_link\">",
"     \"Treatment of relapsed or refractory chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35800?source=see_link\">",
"     \"Hematopoietic cell transplantation in chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=see_link\">",
"     \"Overview of the complications of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathophysiology, clinical manifestations, diagnosis, staging, and prognosis of CLL and SLL are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24680?source=see_link\">",
"     \"Epidemiology and clinical manifestations of chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=see_link\">",
"     \"Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15466?source=see_link\">",
"     \"Staging and prognosis of chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42361?source=see_link\">",
"     \"Pathophysiology and genetic features of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all patients with CLL require treatment at the time of diagnosis. This is principally because:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CLL is an extremely heterogeneous disease with certain subsets of patients having survival rates without treatment that are similar to the normal population [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29352/abstract/1-4\">",
"       1-4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      With the possible exception of allogeneic hematopoietic cell transplantation (HCT), CLL cannot be cured by current treatment options. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15466?source=see_link&amp;anchor=H17#H17\">",
"       \"Staging and prognosis of chronic lymphocytic leukemia\", section on 'Low and intermediate risk groups'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prospective, randomized trials evaluating immediate versus delayed treatment strategies have found no improvement in long-term survival with early treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29352/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Spontaneous regression of variable duration is a rare occurrence [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29352/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5621835\">",
"    <span class=\"h2\">",
"     Asymptomatic early stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among newly diagnosed patients with early stage asymptomatic CLL we recommend observation rather than immediate treatment. In contrast, localized radiation therapy is the treatment of choice for patients with localized (stage I) SLL. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Treatment of localized SLL'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This approach is supported by several prospective, randomized trials that have evaluated the treatment of early stage disease. A meta-analysis of 2048 patients with asymptomatic Rai stage I or II or Binet stage A disease enrolled in six prospective, randomized trials of immediate versus delayed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    -based chemotherapy found no benefit with immediate therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29352/abstract/4\">",
"     4",
"    </a>",
"    ]. There was a nonsignificant trend towards decreased rates of 10-year overall survival with immediate treatment (44 versus 47 percent).",
"   </p>",
"   <p>",
"    The development of newer agents with significant activity in CLL has resulted in much higher rates of complete remissions with therapy. As such, prospective, randomized trials of aggressive therapy with these newer agents in patients with early stage disease and poor-risk prognostic markers (eg, ZAP-70, 17p deletion, CD38, unmutated immunoglobulin Vh genes) are underway. While we acknowledge that persons with asymptomatic CLL that displays poor-risk prognostic markers can have increased psychological stress that affects their emotional well-being and creates a push to start therapeutic interventions right away, there is no evidence that earlier treatment benefits the patient. Until studies demonstrate a benefit, early treatment of asymptomatic persons should be reserved for patients enrolled on these clinical trials. We do routinely perform FISH for del17p, del11q, trisomy 12, and del13q in asymptomatic patients at the time of diagnosis to predict time to progression. (See",
"    <a class=\"local\" href=\"#H5625565\">",
"     'Pre-treatment evaluation'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42361?source=see_link\">",
"     \"Pathophysiology and genetic features of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5621842\">",
"    <span class=\"h2\">",
"     Symptomatic or advanced stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;While patients with asymptomatic early stage (Rai stage &lt;3, Binet stage A or B) CLL have a median survival greater than 10 years, patients with more advanced stage CLL or those who demonstrate symptoms or progressive disease have a median survival without treatment between 18 months and three years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29352/abstract/6\">",
"     6",
"    </a>",
"    ]. Treatment of the underlying CLL is indicated for patients who develop disease-related symptoms or evidence of progressive disease. With therapy, median survival improves to approximately five years.",
"   </p>",
"   <p>",
"    Therapy is indicated for patients with the following disease-related complications [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29352/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weakness, night sweats, weight loss, painful lymphadenopathy, or fever. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24680?source=see_link&amp;anchor=H5#H5\">",
"       \"Epidemiology and clinical manifestations of chronic lymphocytic leukemia\", section on 'Symptoms'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Symptomatic anemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      thrombocytopenia (Rai stages III or IV; Binet stage C) (",
"      <a class=\"graphic graphic_table graphicRef56284 graphicRef80421 \" href=\"UTD.htm?8/35/8764\">",
"       table 1A-B",
"      </a>",
"      ). Autoimmune mediated anemia or thrombocytopenia is treated with therapy directed at the autoimmune process before treatment of the underlying CLL is initiated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=see_link&amp;anchor=H13#H13\">",
"       \"Overview of the complications of chronic lymphocytic leukemia\", section on 'Autoimmune hemolytic anemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Autoimmune hemolytic anemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      thrombocytopenia poorly responsive to corticosteroid therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=see_link&amp;anchor=H13#H13\">",
"       \"Overview of the complications of chronic lymphocytic leukemia\", section on 'Autoimmune hemolytic anemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Progressive disease, as demonstrated by increasing lymphocytosis with a lymphocyte doubling time less than six months,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      rapidly enlarging lymph nodes, spleen, and liver. In contrast, transient localized lymphadenopathy, occurring in response to localized infections, is not necessarily an indication for treatment.",
"     </li>",
"     <li>",
"      Repeated episodes of infection. Hypogammaglobulinemia without repeated episodes of infection is not a clear indication for therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=see_link&amp;anchor=H2#H2\">",
"       \"Overview of the complications of chronic lymphocytic leukemia\", section on 'Infection'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is premature to use newer, adverse prognostic features (eg, ZAP-70, CD38, unmutated immunoglobulin Vh genes) as the basis for deciding when to initiate treatment, except in the context of prospective clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29352/abstract/9,11\">",
"     9,11",
"    </a>",
"    ]. At this time, we consider the patient's clinical presentation and course to be of greater weight and importance than the results of specific prognostic markers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15466?source=see_link&amp;anchor=H3#H3\">",
"     \"Staging and prognosis of chronic lymphocytic leukemia\", section on 'Clinical staging and prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5625291\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF CLL/SLL",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Management of asymptomatic CLL",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, immediate treatment is indicated in patients with advanced stage disease, high tumor burden, severe disease-related \"B\" symptoms, or repeated infections. Otherwise, a period of observation is recommended. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Indications for treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    During the observation period, we perform blood counts at three-month intervals along with a clinical examination. At the end of 12 months, a clear decision as to whether the patient has aggressive disease can be made based upon these evaluations.",
"   </p>",
"   <p>",
"    Of particular importance is the rate of increase in blood lymphocyte count and any evidence indicating emergence of progressive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptomatic disease. If the patient has a blood lymphocyte doubling time less than 12 months, survival is significantly shorter than in patients with longer doubling times [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29352/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Some clinicians choose to offer treatment in this setting, although it is our preference not to treat based on the doubling time alone. In addition, the initial level of blood lymphocyte count should be considered. For example, a doubling of the white cell count from 10,000 to 20,000 in less than 12 months in an early stage patient who is free of symptoms does not have the same weight in deciding to initiate therapy as a rapid doubling of the white cell count from 75,000 to 150,000.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Treatment of localized SLL",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with localized (stage I) SLL, we recommend treatment with involved-field radiation therapy alone rather than systemic chemotherapy. Patients with stage II or more advanced SLL are treated with chemotherapy regimens used for symptomatic CLL as discussed below. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Treatment of symptomatic CLL or advanced SLL'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Our preference for radiation therapy in patients with localized SLL is principally based upon retrospective analyses that have demonstrated prolonged freedom from relapse with localized radiation therapy alone and extrapolation of data from other indolent non-Hodgkin lymphoma subtypes. As an example, a retrospective series of 54 patients with SLL included 14 patients with stage I or II disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29352/abstract/15\">",
"     15",
"    </a>",
"    ]. Among patients with stage I or stage II SLL treated with radiation therapy alone (40 to 44 Gy given as involved or extended-field), 10-year freedom from relapse rates were 80 and 62 percent, respectively.",
"   </p>",
"   <p>",
"    Although there have been no prospective trials comparing radiation therapy to chemotherapy or observation in patients with early stage SLL, such studies have been performed in patients with other indolent non-Hodgkin lymphoma subtypes and found localized radiation therapy to be superior to the other options. These trials are described in detail separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Treatment of symptomatic CLL or advanced SLL",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, therapy is offered to patients with symptomatic CLL or advanced stage SLL with the goals of ameliorating symptoms and improving progression-free and overall survival. With the possible exception of allogeneic hematopoietic cell transplantation, CLL cannot be cured by current treatment options. (See",
"    <a class=\"local\" href=\"#H5621842\">",
"     'Symptomatic or advanced stage'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5625565\">",
"    <span class=\"h3\">",
"     Pre-treatment evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the initiation of active therapy for patients with symptomatic disease, patients with CLL should undergo a pre-treatment evaluation to determine the extent of disease, patient performance status (",
"    <a class=\"graphic graphic_table graphicRef58785 graphicRef72901 \" href=\"UTD.htm?43/16/44300\">",
"     table 2A-B",
"    </a>",
"    ), and assessment of comorbidities that are likely to have an impact upon treatment options. Details on the Rai and Binet staging systems used in CLL are presented separately (",
"    <a class=\"graphic graphic_table graphicRef56284 graphicRef80421 \" href=\"UTD.htm?8/35/8764\">",
"     table 1A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15466?source=see_link\">",
"     \"Staging and prognosis of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to a history and physical examination, it is our practice to perform the following pretreatment studies in patients with CLL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laboratory studies include a complete blood count with differential, chemistries with liver and renal function and electrolytes, alkaline phosphatase, lactate dehydrogenase (LDH), beta-2 microglobulin, and direct antiglobulin test (DAT).",
"     </li>",
"     <li>",
"      All patients should undergo testing for HIV, hepatitis B, and hepatitis C. For patients being treated with agents associated with cytomegalovirus (CMV) reactivation (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      or allogeneic hematopoietic cell transplantation), consider obtaining serology for CMV (IgM and IgG). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"       \"Hepatitis B virus reactivation associated with immunosuppression\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19974?source=see_link\">",
"       \"Evaluation for infection before hematopoietic cell transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Unilateral bone marrow aspirate and biopsy is recommended for all patients who have cytopenias of unknown cause. This sample should be sent for pathologic review, immunophenotyping, cytochemistry, and fluorescence in situ hybridization (FISH) for del17p, del11q, trisomy 12, and del13q. While testing for t(11;14), CD38 expression, and Zap70 expression are performed by many clinicians, we do not perform these routinely since treatment decisions are not made on the basis of these results. Some physicians also choose to perform a bone marrow biopsy in all patients at the time cytotoxic therapy is initiated",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      in those with cytopenias, in order to determine the cellularity and degree of CLL infiltration [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29352/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Men and women with childbearing potential should receive counseling about the potential effect of treatment on their fertility and options for fertility-preserving measures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link\">",
"       \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A chest x-ray should be obtained to evaluate for hilar and mediastinal adenopathy. Computed tomography (CT) of the chest, abdomen, and pelvis are not required for the pre-treatment evaluation, and are usually reserved for patients enrolled in clinical trials [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29352/abstract/10,16\">",
"       10,16",
"      </a>",
"      ]. However, a CT should be performed in any patient in whom enlarged abdominal or pelvic nodes are suspected based upon evidence of complications such as obstructive jaundice, or obstruction of the inferior vena cava or ureters.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5625744\">",
"    <span class=\"h3\">",
"     Selection of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no agreed upon standard front-line treatment regimen for symptomatic CLL or advanced SLL. There are several initial treatment options. Most have not been directly compared. While overall survival rates with the different available regimens are similar, they differ in their rates of complete remission, time to progression, and associated toxicities. A choice between these therapies is made based upon patient characteristics and goals of therapy. While most patients with symptomatic or advanced stage CLL are treated similarly, older patients and patients with del(17p) or del(11q) require particular consideration. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6362?source=see_link\">",
"     \"Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5625429\">",
"    <span class=\"h2\">",
"     Management of the complications of CLL and its therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    commonly develop complications associated with an intrinsic immune dysfunction resulting in immunodeficiency and autoimmune disorders. The most common complications are infection, anemia, and thrombocytopenia. Rare, but potentially life-threatening complications include leukostasis, tumor lysis syndrome, and second cancers. These are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=see_link\">",
"     \"Overview of the complications of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     EVALUATING RESPONSE TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Workshop on CLL (IWCLL) published a revised version of guidelines initially developed by the National Cancer Institute Working Group",
"    <span class=\"nowrap\">",
"     (NCI/WG)",
"    </span>",
"    on CLL for the diagnosis of",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    and the evaluation of treatment response. This response evaluation and criteria are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17671?source=see_link\">",
"     \"Evaluating response to treatment of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DURATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals and duration of therapy for",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    are poorly defined, and there is no evidence that intensification or maintenance therapy is of benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29352/abstract/17\">",
"     17",
"    </a>",
"    ]. In addition, it is not known if attainment of minimal residual disease negativity is a proven and established goal of treatment for some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29352/abstract/18\">",
"     18",
"    </a>",
"    ]. If patients are tolerating and responding to treatment, it appears reasonable to continue therapy until one of the following three endpoints has been reached:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete remission (CR) has been obtained",
"     </li>",
"     <li>",
"      Continued improvement is no longer noted",
"     </li>",
"     <li>",
"      An unacceptable degree of toxicity develops",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While most experience has been obtained with the use of purine analogs given as six monthly courses, many patients receiving these treatments as initial therapy achieve CR after two to three courses. For patients treated off protocol, we evaluate the response with a clinical examination and blood work prior to each scheduled chemotherapy cycle. If this evaluation demonstrates a continued beneficial response compared with the preceding cycle without unacceptable levels of toxicity, we continue with the planned chemotherapy cycle. If, on the other hand, we see a plateau in the response level compared with the prior cycle, we discontinue treatment. This way we stop at the maximum achievable response and avoid any unnecessary toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5625951\">",
"    <span class=\"h1\">",
"     RELAPSED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients undergoing chemotherapy for",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    will have an initial complete or partial response. However, with the exception of some of those treated with allogeneic hematopoietic cell transplantation, disease relapse invariably occurs after treatment has been discontinued. The treatment of relapsed or refractory",
"    <span class=\"nowrap\">",
"     CLL/SLL",
"    </span>",
"    is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=see_link\">",
"     \"Treatment of relapsed or refractory chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     TREATMENT OF CLL VARIANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major variants of CLL seen in clinical practice are prolymphocytic leukemia (PLL), which may be B cell or T cell in type, and T cell CLL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Prolymphocytic leukemia",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     B cell PLL",
"    </span>",
"    &nbsp;&mdash;&nbsp;B cell PLL (B-PLL) is a very rare B cell neoplasm comprised of so-called prolymphocytes, typically with involvement of the peripheral blood, bone marrow, and spleen. The name \"prolymphocyte\" in this case is also a misnomer, as the tumor cells in this disease are mature activated B cells. By definition, these prolymphocytes comprise greater than 55 percent of the cells in the blood and bone marrow.",
"   </p>",
"   <p>",
"    Survival of patients with B-PLL is usually three to five years despite therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29352/abstract/19\">",
"     19",
"    </a>",
"    ]. The clinical course is variable, with some patients having an indolent course and others, especially those with anemia (hemoglobin concentration &lt;11",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    and extreme lymphocytosis",
"    <span class=\"nowrap\">",
"     (&gt;100,000/microL),",
"    </span>",
"    having shorter survival. The most appropriate treatment of this disease variant is unclear and most treatment reports are anecdotal. B-PLL is commonly treated with combination regimens used for CLL such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (FCR). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6362?source=see_link&amp;anchor=H5622436#H5622436\">",
"     \"Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia\", section on 'Fludarabine, cyclophosphamide, and rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Responses to varying regimens have been reported, although they are most frequently partial responses. Individual chemotherapy regimens have not been directly compared, and a choice among regimens is made largely based upon the side effect profile and the clinician&rsquo;s experience with the regimen.",
"   </p>",
"   <p>",
"    A retrospective analysis of 35 patients with B-PLL followed for a median of 63 months reported responses to the following regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29352/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of 17 patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (CP) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , prednisone (COP), eight achieved a partial response with a median response of 32 months.",
"     </li>",
"     <li>",
"      Of six patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (CHOP), one achieved a complete remission and two achieved partial response with a median response time of 30 months.",
"     </li>",
"     <li>",
"      Three patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"       cladribine",
"      </a>",
"      achieved a partial remission. Another case series of eight patients with B-PLL treated with cladribine reported five complete remissions and three partial responses [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29352/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Case reports and small case series have also reported responses to single-agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29352/abstract/21-24\">",
"     21-24",
"    </a>",
"    ], splenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29352/abstract/25\">",
"     25",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29352/abstract/26,27\">",
"     26,27",
"    </a>",
"    ], and single-agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29352/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     T cell PLL",
"    </span>",
"    &nbsp;&mdash;&nbsp;T cell PLL (T-PLL) is a rare T cell neoplasm composed of lymphoid cells, typically with involvement of the peripheral blood, bone marrow, lymph nodes, and spleen. The name \"prolymphocyte\" is a misnomer, as the tumor cells in this disease are of post-thymic T cell origin. This class of neoplasms includes many cases previously classified as T cell chronic lymphocytic leukemia, a category no longer included in the current World Health Organization (WHO) classification.",
"   </p>",
"   <p>",
"    The clinical course of T cell prolymphocytic leukemia (T-PLL) is more aggressive than CLL and B-PLL. T-PLL is primarily treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    -based chemotherapy. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18680?source=see_link\">",
"     \"Treatment of T cell prolymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     T cell CLL",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not clear that T cell CLL exists as a true or distinct disease. The management of T cell CLL, which accounts for approximately 1 to 5 percent of all CLL cases, is less satisfactory than is the management of B cell CLL [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29352/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In one series, the majority of patients were refractory to treatment, with a median survival of 13 months [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29352/abstract/31\">",
"     31",
"    </a>",
"    ]. While purine analogs decrease normal T cell numbers, they are less effective in the management of T-CLL. However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    may be more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    in the management of mature T cell lymphoproliferative disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29352/abstract/29,32\">",
"     29,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    T-CLL is uncommon and no clear treatment recommendation can be made. Affected patients are usually treated as if they had typical B cell CLL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6362?source=see_link\">",
"     \"Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/39/12914?source=see_link\">",
"       \"Patient information: Chronic lymphocytic leukemia (CLL) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/13/38098?source=see_link\">",
"       \"Patient information: Leukemia in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/10/6309?source=see_link\">",
"       \"Patient information: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic lymphocytic leukemia (CLL) is one of the chronic lymphoproliferative disorders and is characterized by a progressive accumulation of functionally incompetent lymphocytes, which are monoclonal in origin. CLL is considered to be identical (ie, one disease at different stages) to the mature (peripheral) B cell neoplasm small lymphocytic lymphoma (SLL). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CLL is an extremely heterogeneous disease and not all patients require treatment at the time of diagnosis. Therapy is indicated for patients with advanced stage disease, high tumor burden, severe disease-related \"B\" symptoms, or repeated infections. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with newly diagnosed early stage asymptomatic CLL, we recommend observation rather than immediate treatment (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Management of asymptomatic CLL'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with localized (stage I) SLL, we recommend treatment with involved-field radiation therapy alone rather than systemic chemotherapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Patients with stage II or more advanced SLL are treated with chemotherapy regimens used for symptomatic CLL (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment of localized SLL'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to the initiation of active therapy for patients with symptomatic disease, patients with CLL should undergo a pre-treatment evaluation to determine the extent of disease, patient performance status, and assessment of comorbidities that are likely to have an impact on treatment options. (See",
"      <a class=\"local\" href=\"#H5625565\">",
"       'Pre-treatment evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no agreed upon standard front-line treatment regimen for symptomatic CLL or advanced SLL. There are several initial treatment options and most have not been directly compared. While overall survival rates with the different available regimens are similar, they differ in their rates of complete remission, time to progression, and associated toxicities. A choice between these therapies is made based upon patient characteristics and goals of therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6362?source=see_link\">",
"       \"Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients are evaluated periodically to determine the response to treatment. The specific evaluation used varies depending upon whether the patient is enrolled in a clinical trial or is being treated off protocol. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17671?source=see_link\">",
"       \"Evaluating response to treatment of chronic lymphocytic leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The goals and duration of therapy for CLL are poorly defined, and there is no evidence that intensification or maintenance therapy is of benefit. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29352/abstract/1\">",
"      Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients. The French Cooperative Group on Chronic Lymphocytic Leukemia. Blood 1990; 75:1414.",
"     </a>",
"    </li>",
"    <li>",
"     Montserrat E, Vinolas N, Reverter JC, et al. Chronic lymphocytic leukemia in early stage \"smoldering\" and \"active\" forms in chronic lymphocytic leukemia. In: Scientifc Advances and Clinical Developments, Cheston BD (Ed), Marcel Decker, New York 1993. p.281.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29352/abstract/3\">",
"      Natural history of stage A chronic lymphocytic leukaemia untreated patients. French Cooperative Group on Chronic Lymphocytic Leukaemia. Br J Haematol 1990; 76:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29352/abstract/4\">",
"      Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. J Natl Cancer Inst 1999; 91:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29352/abstract/5\">",
"      Del Giudice I, Chiaretti S, Tavolaro S, et al. Spontaneous regression of chronic lymphocytic leukemia: clinical and biologic features of 9 cases. Blood 2009; 114:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29352/abstract/6\">",
"      Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29352/abstract/7\">",
"      Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87:4990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29352/abstract/8\">",
"      Chronic lymphocytic leukemia: recommendations for diagnosis, staging, and response criteria. International Workshop on Chronic Lymphocytic Leukemia. Ann Intern Med 1989; 110:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29352/abstract/9\">",
"      Binet JL, Caligaris-Cappio F, Catovsky D, et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 2006; 107:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29352/abstract/10\">",
"      Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111:5446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29352/abstract/11\">",
"      Gribben JG. How I treat CLL up front. Blood 2010; 115:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29352/abstract/12\">",
"      Molica S, Alberti A. Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia. Cancer 1987; 60:2712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29352/abstract/13\">",
"      Montserrat E, Sanchez-Bisono J, Vi&ntilde;olas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 1986; 62:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29352/abstract/14\">",
"      Pepper C, Majid A, Lin TT, et al. Defining the prognosis of early stage chronic lymphocytic leukaemia patients. Br J Haematol 2012; 156:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29352/abstract/15\">",
"      Morrison WH, Hoppe RT, Weiss LM, et al. Small lymphocytic lymphoma. J Clin Oncol 1989; 7:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29352/abstract/16\">",
"      Blum KA, Young D, Broering S, et al. Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria. J Clin Oncol 2007; 25:5624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29352/abstract/17\">",
"      Keller JW, Knospe WH, Raney M, et al. Treatment of chronic lymphocytic leukemia using chlorambucil and prednisone with or without cycle-active consolidation chemotherapy. A Southeastern Cancer Study Group Trial. Cancer 1986; 58:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29352/abstract/18\">",
"      Nabhan C, Coutr&eacute; S, Hillmen P. Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime? Br J Haematol 2007; 136:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29352/abstract/19\">",
"      Shvidel L, Shtalrid M, Bassous L, et al. B-cell prolymphocytic leukemia: a survey of 35 patients emphasizing heterogeneity, prognostic factors and evidence for a group with an indolent course. Leuk Lymphoma 1999; 33:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29352/abstract/20\">",
"      Saven A, Lee T, Schlutz M, et al. Major activity of cladribine in patients with de novo B-cell prolymphocytic leukemia. J Clin Oncol 1997; 15:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29352/abstract/21\">",
"      Johnson SA. Use of fludarabine in the treatment of mantle cell lymphoma, Waldenstr&ouml;m's macroglobulinemia and other uncommon B- and T-cell lymphoid malignancies. Hematol J 2004; 5 Suppl 1:S50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29352/abstract/22\">",
"      Doorduijn JK, Michiels JJ. Effectiveness of fludarabine in end-stage prolymphocytic leukemia. Leukemia 1994; 8:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29352/abstract/23\">",
"      Naranjo TA, Matutes El El, Mart&iacute;nez JJ, et al. Prolymphocytic leukaemia and Hodgkin's lymphoma. Eur J Haematol 2002; 69:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29352/abstract/24\">",
"      Andrieu V, Encaoua R, Carbon C, et al. Leukemic pleural effusion in B-cell prolymphocytic leukemia. Hematol Cell Ther 1998; 40:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29352/abstract/25\">",
"      Absi A, Hsi E, Kalaycio M. Prolymphocytic leukemia. Curr Treat Options Oncol 2005; 6:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29352/abstract/26\">",
"      McCune SL, Gockerman JP, Moore JO, et al. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Leuk Lymphoma 2002; 43:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29352/abstract/27\">",
"      Chaar BT, Petruska PJ. Complete response to alemtuzumab in a patient with B prolymphocytic leukemia. Am J Hematol 2007; 82:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29352/abstract/28\">",
"      Mourad YA, Taher A, Chehal A, Shamseddine A. Successful treatment of B-cell prolymphocytic leukemia with monoclonal anti-CD20 antibody. Ann Hematol 2004; 83:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29352/abstract/29\">",
"      O'Brien S, Kurzrock R, Duvic M, et al. 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood 1994; 84:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29352/abstract/30\">",
"      Matutes E, Catovsky D. Mature T-cell leukemias and leukemia/lymphoma syndromes: review of our experience in 175 cases. Leuk Lymphoma 1991; 4:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29352/abstract/31\">",
"      Hoyer JD, Ross CW, Li CY, et al. True T-cell chronic lymphocytic leukemia: a morphologic and immunophenotypic study of 25 cases. Blood 1995; 86:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29352/abstract/32\">",
"      Ho AD, Suciu S, Stryckmans P, et al. Pentostatin in T-cell malignancies--a phase II trial of the EORTC. Leukemia Cooperative Group. Ann Oncol 1999; 10:1493.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4545 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-1420615FBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_42_29352=[""].join("\n");
var outline_f28_42_29352=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS FOR TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5621835\">",
"      Asymptomatic early stage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5621842\">",
"      Symptomatic or advanced stage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5625291\">",
"      MANAGEMENT OF CLL/SLL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Management of asymptomatic CLL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Treatment of localized SLL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Treatment of symptomatic CLL or advanced SLL",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5625565\">",
"      - Pre-treatment evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5625744\">",
"      - Selection of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5625429\">",
"      Management of the complications of CLL and its therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      EVALUATING RESPONSE TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DURATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5625951\">",
"      RELAPSED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TREATMENT OF CLL VARIANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Prolymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - B cell PLL",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - T cell PLL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      T cell CLL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4545\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4545|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/23/10619\" title=\"table 1A\">",
"      Rai staging system CLL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/50/811\" title=\"table 1B\">",
"      Binet staging system CLL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 2A\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 2B\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/6/24680?source=related_link\">",
"      Epidemiology and clinical manifestations of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17671?source=related_link\">",
"      Evaluating response to treatment of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19974?source=related_link\">",
"      Evaluation for infection before hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35800?source=related_link\">",
"      Hematopoietic cell transplantation in chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35017?source=related_link\">",
"      Overview of the complications of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35431?source=related_link\">",
"      Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42361?source=related_link\">",
"      Pathophysiology and genetic features of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/39/12914?source=related_link\">",
"      Patient information: Chronic lymphocytic leukemia (CLL) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/10/6309?source=related_link\">",
"      Patient information: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/13/38098?source=related_link\">",
"      Patient information: Leukemia in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6362?source=related_link\">",
"      Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15466?source=related_link\">",
"      Staging and prognosis of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18680?source=related_link\">",
"      Treatment of T cell prolymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=related_link\">",
"      Treatment of relapsed or refractory chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_42_29353="Efavirenz: Drug information";
var content_f28_42_29353=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Efavirenz: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?23/34/24101?source=see_link\">",
"    see \"Efavirenz: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/45/40665?source=see_link\">",
"    see \"Efavirenz: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F164370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Sustiva&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F164371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sustiva&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F164400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiretroviral Agent, Reverse Transcriptase Inhibitor (Non-nucleoside)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F164374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      HIV infection (as part of combination; a preferred regimen for therapy-naive patients with tenofovir and emtricitabine [DHHS, 2013]):",
"     </b>",
"     Oral: 600 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for concomitant rifampin (only if patient weighs &ge;50 kg):",
"     </b>",
"     Increase efavirenz dose to 800 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for concomitant voriconazole:",
"     </b>",
"     Reduce efavirenz dose to 300 mg once daily and increase voriconazole to 400 mg every 12 hours.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F164390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/45/40665?source=see_link\">",
"      see \"Efavirenz: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage is based on body weight.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      HIV infection (as part of combination therapy):",
"     </b>",
"     Oral: Children &ge;3 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 kg to &lt;15 kg: 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 kg to &lt;20 kg: 250 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 kg to &lt;25 kg: 300 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 kg to &lt;32.5 kg: 350 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     32.5 kg to &lt;40 kg: 400 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;40 kg: 600 mg once daily;",
"     <b>",
"      Note:",
"     </b>",
"     Dosage adjustments may be necessary if patient receives certain concomitant medications. Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F164375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F164376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); however, undergoes minimal renal excretion.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F164377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild impairment (Child-Pugh class A): No dosage adjustment necessary; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Moderate-to-severe impairment (Child-Pugh class B or C): No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been adequately studied); use not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F164344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sustiva&reg;: 50 mg, 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sustiva&reg;: 600 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F164328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11368729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Efavirenz oral solution is available only through an expanded access (compassionate use) program. Enrollment information may be obtained by calling 877-372-7097.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F164347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer on an empty stomach. Dosing at or before bedtime is recommended to limit central nervous system effects (DHHS, 2013). Tablets should not be broken. Some clinicians recommend opening capsules and adding to liquid or food for patients that cannot swallow capsules; however, no pharmacokinetic data are available and this is not recommended (DHHS [pediatric], 2010).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F164345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV-1 infections in combination with at least two other antiretroviral agents",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F164398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Unless otherwise noted, frequency of adverse events is as reported in adults receiving combination antiretroviral therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (2% to 28%; children 16%), fever (children 21%), depression (&le;19%; severe: 1% to 2%), insomnia (&le;16%), anxiety (2% to 13%), pain (1% to 13%; children 14%), headache (2% to 8%; children 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (5% to 26%, grade 3/4: &lt;1%; children &le;46%, grade 3/4: 2% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: HDL increased (25% to 35%), total cholesterol increased (20% to 40%), triglycerides increased (&ge;751 mg/dL: 6% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (3% to 14%; children: &le;39%), nausea (2% to 10%; children 12%), vomiting (3% to 6%; children 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (children 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Impaired concentration (&le;8%), somnolence (&le;7%), fatigue (&le;8%), abnormal dreams (1% to 6%), nervousness (2% to 7%), hallucinations (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (&le;9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia (&gt;250 mg/dL: 2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (&le;4%), abdominal pain (2% to 3%), anorexia (&le; 2%), amylase increased (grade 3/4: &le;6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenia (grade 3/4: 2% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Incidence higher with hepatitis B and/or C coinfection: ALT increased (grades 3/4: 2% to 8%), AST increased (grades 3/4: 5% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reaction, ataxia, body fat accumulation/redistribution, cerebellar coordination disturbances, delusions, dermatitis (photoallergic), erythema multiforme, gynecomastia, hepatic failure, hepatitis, immune reconstitution syndrome, malabsorption, mania, neuropathy, neurosis, palpitations, pancreatitis, paranoia, psychosis, seizures, Stevens-Johnson syndrome, suicide attempts, suicidal ideation, visual abnormalities",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F164350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Previous significant hypersensitivity (eg, Stevens-Johnson syndrome, erythema multiforme, toxic skin eruptions) to efavirenz or any component of the formulation; concurrent use of bepridil, cisapride, midazolam, pimozide, triazolam, St. John&rsquo;s wort, or ergot alkaloids (includes dihydroergotamine, ergotamine, ergonovine, methylergonovine)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F164332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause CNS effects (eg, abnormal dreams, insomnia, impaired concentration, hallucinations, dizziness or drowsiness); symptoms usually begin within 1-2 days after starting efavirenz, and generally resolve within 2-4 weeks of continued therapy; avoid potentially hazardous tasks such as driving or operating machinery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercholesterolemia: Increases in total cholesterol and triglycerides have been reported; screening should be done prior to therapy and periodically throughout treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric effects: Serious psychiatric side effects have been associated with use, including aggressive behavior, severe depression, suicide, paranoia, and mania; use with caution in patients with a history of mental illness/drug abuse (predisposition to psychological reactions). Patients should be instructed to contact healthcare provider if serious psychiatric effects occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rash: May cause mild-to-moderate maculopapular rash; usually occurs within 2 weeks of starting therapy;  most resolve within 1 month with continued therapy. Discontinue if severe rash (involving blistering, desquamation, mucosal involvement or fever) develops; use is contraindicated in patients with a history of a severe cutaneous reaction (eg, Stevens-Johnson syndrome). Children are more susceptible to development of rash; prophylactic antihistamines/corticosteroids may be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Not recommended in moderate-to-severe hepatic impairment (Child-Pugh class B or C); use with caution in patients with mild hepatic impairment (Child-Pugh class A); including known or suspected hepatitis B or C infection; monitoring is recommended. Persistent elevations of serum transaminases &gt;5 times the upper limit of normal should prompt evaluation - benefit of continued therapy should be weighed against possible risk of hepatotoxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients with a history of seizure disorder; seizures have been associated with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Duplicate therapy: Concomitant use of other efavirenz-containing products should be avoided (unless needed for dosage adjustment with concomitant rifampin treatment).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Use with caution in patients taking strong CYP3A4 inhibitors, moderate or strong CYP3A4 inducers and major CYP3A4 substrates (see Drug Interactions); consider alternative agents that avoid or lessen the potential for CYP-mediated interactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: CNS effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy: Avoid pregnancy; women of childbearing potential should undergo pregnancy testing prior to initiation of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F164394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2B6 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (moderate), CYP2C9 (moderate), CYP3A4 (moderate);",
"     <b>",
"      Induces",
"     </b>",
"     CYP2B6 (weak/moderate), CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F164337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Efavirenz may decrease the serum concentration of Atazanavir.  Management: When used with efavirenz, the atazanavir regimen should be atazanavir 400 mg/ritonavir 100 mg daily for treatment-naive patients; treatment-experienced patients should not use atazanavir together with efavirenz.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Efavirenz may decrease the serum concentration of AtorvaSTATin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atovaquone: Efavirenz may decrease the serum concentration of Atovaquone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bepridil [Off Market]: Efavirenz may enhance the arrhythmogenic effect of Bepridil [Off Market].",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Efavirenz. Efavirenz may decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: Efavirenz may decrease serum concentrations of the active metabolite(s) of Buprenorphine. Efavirenz may decrease the serum concentration of Buprenorphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: Efavirenz may decrease the serum concentration of BuPROPion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of CarBAMazepine. This mechanism applies specifically to efavirenz.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caspofungin: Inducers of Drug Clearance may decrease the serum concentration of Caspofungin.  Management: Consider using an increased caspofungin dose of 70 mg daily in adults (or 70 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , up to a maximum of 70 mg, daily in pediatric patients) when coadministered with known inducers of drug clearance.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Efavirenz may enhance the QTc-prolonging effect of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citalopram: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with a moderate CYP2C19 inhibitor.  Patients using this combination should be monitored closely for evidence of citalopram toxicity (e.g., serotonin syndrome, QT prolongation, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Efavirenz may decrease the serum concentration of CycloSPORINE (Systemic).  Management: Increase monitoring of cyclosporine concentrations when starting, stopping, or adjusting doses of concurrent efavirenz, particularly within the first 2 weeks.  Cyclosporine dose adjustment may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inducers (Strong): May increase the metabolism of CYP2B6 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Moderate): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Strong): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of Efavirenz. Efavirenz may decrease the serum concentration of Darunavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dienogest.  Management: Avoid use of dienogest for contraception when using medications that induce CYP3A4 and for at least 28 days after discontinuation of a CYP3A4 inducer.  An alternative form of contraception should be used during this time.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dihydroergotamine: Efavirenz may increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergoloid Mesylates: Efavirenz may increase the serum concentration of Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergonovine: Efavirenz may increase the serum concentration of Ergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergotamine: Efavirenz may increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etonogestrel: Efavirenz may diminish the therapeutic effect of Etonogestrel.  Management: Use a reliable barrier contraceptive if efavirenz is used in combination with etonogestrel.  Continue using barrier contraception for 12 weeks after discontinuation of efavirenz.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Etravirine. This has been observed with the NNRTIs efavirenz and nevirapine. Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Etravirine. This has been observed with delavirdine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: Efavirenz may decrease the serum concentration of Everolimus.  Management: Closely monitor everolimus serum concentrations when starting, stopping, or changing doses of efavirenz, particularly during the first 2 weeks after any change.  Dose adjustment of everolimus may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: Efavirenz may decrease serum concentrations of the active metabolite(s) of Fosamprenavir.  Management: For once-daily fosamprenavir/ritonavir with efavirenz, an increased ritonavir dose to 300 mg/day is recommended.  No ritonavir dose adjustment is required if using twice-daily fosamprenavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Efavirenz may increase the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Efavirenz.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse drug reactions, consider increasing gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers.  Carefully monitor clinical response and development of adverse reactions.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Efavirenz may decrease the serum concentration of Indinavir.  Management: The appropriate dose adjustments for indinavir when used together with efavirenz are unknown. The use of higher unboosted indinavir doses is not likely an adequate approach.  Use of a ritonavir-boosted indinavir regimen could be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Efavirenz may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine.  Management: In patients with a resting heart rate over 60 beats per minute receiving a moderate CYP3A4 inhibitor, ivabradine initiation at an adult dose of 2.5 mg twice daily may be considered.  Monitor heart rate closely under these circumstances.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: Efavirenz may decrease the serum concentration of Lopinavir.  Management: Avoid once daily use of lopinavir/ritonavir with efavirenz.  Avoid use of this combination in patients less than 6 months of age.  See lopinavir/ritonavir prescribing information for specific recommended dose increases in particular patient populations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Efavirenz may decrease the serum concentration of Lovastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the metabolism of Methadone.  Management: Methadone dosage adjustments will likely be required with efavirenz and nevirapine, and may be necessary with rilpivirine as well.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylergonovine: Efavirenz may increase the serum concentration of Methylergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midazolam: Efavirenz may increase the serum concentration of Midazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of Efavirenz. Management: Use efavirenz with caution, and monitor for increased adverse effects, during and 2 weeks following discontinuation of mifepristone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: Efavirenz may enhance the adverse/toxic effect of Nevirapine. Nevirapine may enhance the adverse/toxic effect of Efavirenz. Nevirapine may decrease the serum concentration of Efavirenz.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NIFEdipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.  Management: Consider alternatives to nifedipine for patients who are using strong CYP3A4 inducers.  At least one specific brand of nifedipine (Adalat CC) lists this combination as contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Norgestimate: Efavirenz may decrease serum concentrations of the active metabolite(s) of Norgestimate.  Management: Use a reliable barrier contraceptive if efavirenz is used in combination with norgestimate.  Continue using barrier contraception for 12 weeks after discontinuation of efavirenz.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PACLitaxel: Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the metabolism of PACLitaxel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.  Management: Avoid use of perampanel with strong CYP3A inducers other than enzyme-inducing antiepileptic drugs (EIAEDs).  Increase perampanel starting dose to 4 mg/day when used with EIAEDs such as phenytoin, carbamazepine, or oxcarbazepine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Efavirenz may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Efavirenz.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Efavirenz may enhance the arrhythmogenic effect of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: Efavirenz may decrease the serum concentration of Posaconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pravastatin: Efavirenz may decrease the serum concentration of Pravastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proguanil: Efavirenz may decrease the serum concentration of Proguanil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quazepam: May increase the serum concentration of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltegravir: Efavirenz may decrease the serum concentration of Raltegravir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifabutin: Efavirenz may decrease the serum concentration of Rifabutin. Rifabutin may decrease the serum concentration of Efavirenz.  Management: If efavirenz is to be used with daily rifabutin, increase the planned rifabutin adult dose by 50%.  If used with regimens where rifabutin is administered 2-3 times per week, consider doubling the rifabutin dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Efavirenz. Management: Increase efavirenz adult dose to 800 mg daily in patients weighing over 50 kg (per U.S. manufacturer; CDC sets this at 60 kg, and Canadian manufacturer recommends the dose increase regardless of weight).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Rilpivirine. This mechanism applies to coadministration of delavirdine. Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Rilpivirine. This mechanism applies to coadministration of efavirenz, etravirine, and nevirapine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: Efavirenz may enhance the adverse/toxic effect of Ritonavir. Efavirenz may increase the serum concentration of Ritonavir. Ritonavir may increase the serum concentration of Efavirenz.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: May enhance the adverse/toxic effect of Efavirenz. Efavirenz may decrease the serum concentration of Saquinavir. Management: When used together with efavirenz, saquinavir should not be used as the sole protease inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sertraline: Efavirenz may decrease the serum concentration of Sertraline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Efavirenz may decrease the serum concentration of Simvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Efavirenz may decrease the serum concentration of Sirolimus.  Management: Closely monitor sirolimus serum concentrations when starting, stopping, or changing doses of efavirenz, particularly during the first 2 weeks after any change.  Dose adjustment of sirolimus may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Efavirenz.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Efavirenz may decrease the serum concentration of Tacrolimus (Systemic).  Management: Closely monitor tacrolimus serum concentrations when starting, stopping, or changing doses of efavirenz, particularly during the first 2 weeks after any change.  Dose adjustment of tacrolimus may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Efavirenz may decrease the serum concentration of Telaprevir. Telaprevir may decrease the serum concentration of Efavirenz.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Triazolam: Efavirenz may increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Efavirenz may increase the serum concentration of Vitamin K Antagonists. Efavirenz may decrease the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Voriconazole. Management: Consider avoiding when possible. Use efavirenz with voriconazole only if voriconazole is dosed at 400 mg every 12 hours and efavirenz is dosed at 300 mg daily (adult doses) throughout therapy. Avoid Atripla (efavirenz/emtricitabine/tenofovir).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F164365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may increase hepatotoxic potential of efavirenz and increase CNS depression. Management: Limit or avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: High-fat meals increase the absorption of efavirenz. CNS effects are possible. Management: Avoid high-fat meals. Administer at or before bedtime on an empty stomach.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease efavirenz serum levels. Management: Avoid concurrent use.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F164340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F164354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in primates receiving efavirenz. Efavirenz crosses the placenta. Based on data from the Antiretroviral Pregnancy Registry, an increased risk of overall birth defects has not been observed following first trimester exposure to efavirenz; however, neural tube and other CNS defects have been reported. Due to the low number of first trimester exposures and the low incidence of neural tube defects in the general population, available data are insufficient to evaluate risk. Other antiretroviral agents should strongly be considered for use in women of childbearing potential who are planning to become pregnant or who are sexually active and not using effective contraception. Nonpregnant women of reproductive age should undergo pregnancy testing prior to initiation of efavirenz. Barrier contraception should be used in combination with other (hormonal) methods of contraception during therapy and for 12 weeks after efavirenz is discontinued. Neural tube defects would occur following exposure during the first 5-6 weeks of gestation (most pregnancies are not detected before 4-6 weeks gestation). For women who present in the first trimester already on an efavirenz-containing regimen and who have adequate viral suppression, efavirenz may be continued; changing regimens may lead to loss of viral control and increase the risk of perinatal transmission. Pharmacokinetic data from available studies do not suggest dose alterations are needed during pregnancy. Hypersensitivity reactions (including hepatic toxicity and rash) are more common in women on NNRTI therapy; it is not known if pregnancy increases this risk",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum antiretroviral (ARV) drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV), also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F164381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F164355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Efavirenz is excreted into breast milk. Although breast-feeding is not recommended, plasma concentrations of efavirenz in nursing infants have been reported as ~13% of maternal plasma concentrations.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Maternal or infant antiretroviral therapy does not completely eliminate the risk of postnatal HIV transmission. In addition, multiclass-resistant virus has been detected in breast-feeding infants despite maternal therapy. Therefore, in the United States, where formula is accessible, affordable, safe, and sustainable, and the risk of infant mortality due to diarrhea and respiratory infections is low, complete avoidance of breast-feeding by HIV-infected women is recommended to decrease potential transmission of HIV (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F164356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken on an empty stomach.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F164353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Sustiva Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (30): $65.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (90): $785.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Sustiva Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (30): $785.90",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F164342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum transaminases (discontinuation of treatment should be considered for persistent elevations &gt;5 times the upper limit of normal); cholesterol and triglycerides (prior to therapy and periodically during); signs and symptoms of infection; psychiatric effects",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F164357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Efavir (IN, PE, PY);",
"     </li>",
"     <li>",
"      Filginase (AR);",
"     </li>",
"     <li>",
"      Stocrin (AT, AU, BE, BG, BR, CH, CL, CN, CO, CR, CZ, DE, DK, EC, EE, FI, FR, GB, GR, GT, HK, HN, IE, IL, IT, KP, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PL, PT, RU, SE, SG, SK, SV, TH, TR, TW, UY, VE);",
"     </li>",
"     <li>",
"      Sustiva (AT, BE, BG, CH, CZ, DE, DK, EE, FR, GB, GR, HN, IE, IT, MT, NL, NO, PL, RU, SE, SK, TR);",
"     </li>",
"     <li>",
"      Virorrever (AR);",
"     </li>",
"     <li>",
"      Virzen (CO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F164331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a non-nucleoside reverse transcriptase inhibitor, efavirenz has activity against HIV-1 by binding to reverse transcriptase. It consequently blocks the RNA-dependent and DNA-dependent DNA polymerase activities including HIV-1 replication. It does not require intracellular phosphorylation for antiviral activity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F164349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Increased by fatty meals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: CSF concentrations exceed free fraction in serum",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;99%, primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4 and 2B6 to inactive hydroxylated metabolites; may induce its own metabolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Single dose: 52-76 hours; Multiple doses: 40-55 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 3-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (16% to 61% primarily as unchanged drug); urine (14% to 34% as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Adkins JC and Noble S, &ldquo;Efavirenz,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1998, 56(6):1055-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/42/29353/abstract-text/9878993/pubmed\" id=\"9878993\" target=\"_blank\">",
"        9878993",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blank A, Hellstern V, Schuster D, et al, &ldquo;Efavirenz Treatment and False-Positive Results in Benzodiazepine Screening Tests,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 48(12):1787-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/42/29353/abstract-text/19432553/pubmed\" id=\"19432553\" target=\"_blank\">",
"        19432553",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services,&rdquo; February 12, 2013;1-267. Available at",
"      <a href=\"file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7&amp;ClassID=1\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, \"Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,\"  July 31, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, &ldquo;Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,&rdquo; August 16, 2010. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8731 Version 52.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-2.133.93.82-E575B2020D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_42_29353=[""].join("\n");
var outline_f28_42_29353=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164370\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164371\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164400\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164374\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164390\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164375\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164376\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164377\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164344\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164328\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11368729\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164347\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164345\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164398\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164350\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164332\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164394\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164337\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164365\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164340\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164354\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164381\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164355\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164356\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164353\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164342\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164357\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164331\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164349\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8731\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8731|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/34/24101?source=related_link\">",
"      Efavirenz: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/45/40665?source=related_link\">",
"      Efavirenz: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_42_29354="Osteoporotic fracture risk assessment";
var content_f28_42_29354=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Osteoporotic fracture risk assessment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/42/29354/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/42/29354/contributors\">",
"     E Michael Lewiecki, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/42/29354/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/42/29354/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/42/29354/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/42/29354/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/42/29354/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/42/29354/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoporosis is a common disease that is characterized by low bone mass with microarchitectural disruption and skeletal fragility, resulting in an increased risk of fracture, particularly at the spine, hip, wrist, humerus, and pelvis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/1\">",
"     1",
"    </a>",
"    ]. Osteoporotic fractures (fragility fractures, low-trauma fractures) are those occurring from a fall from a standing height or less, without major trauma such as a motor vehicle accident. There were an estimated nine million osteoporotic fractures worldwide in 2000, of which 1.6 million were hip, 1.7 million forearm, and 1.4 million clinical vertebral fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/2\">",
"     2",
"    </a>",
"    ]. Fractures of the hip and spine are associated with an increased mortality rate of 10 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Fractures may result in limitation of ambulation, depression, loss of independence, and chronic pain [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Properties that contribute to bone strength include bone mineral density (BMD), bone geometry (size and shape of bone), degree of mineralization, microarchitecture, and bone turnover [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/6\">",
"     6",
"    </a>",
"    ]. BMD measurements are available to many patients, and fracture risk has been demonstrated to increase with decreasing BMD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/6\">",
"     6",
"    </a>",
"    ]. Assessment of microarchitecture requires bone biopsy, microCT or microMRI, which are not routinely used in clinical practice.",
"   </p>",
"   <p>",
"    Non-BMD factors that contribute to fracture risk include advancing age, previous fracture, falls, glucocorticoid therapy, family history of hip fracture and current smoking (",
"    <a class=\"graphic graphic_table graphicRef76445 \" href=\"UTD.htm?2/21/2395\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. Incorporating risk factors that are independent of BMD increases the sensitivity of fracture risk assessment and thereby improves treatment intervention strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/11\">",
"     11",
"    </a>",
"    ]. Univariate and multivariate analyses suggest that age, prior fracture history, and BMD are the strongest predictors of fracture risk [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk assessment for osteoporotic fracture will be reviewed here. Detailed information regarding screening, prevention, diagnosis, and treatment is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40393?source=see_link\">",
"     \"Screening for osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33113?source=see_link\">",
"     \"Prevention of osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11128?source=see_link\">",
"     \"Diagnosis and evaluation of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36213?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of osteoporosis in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=see_link\">",
"     \"Treatment of osteoporosis in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF FRACTURE RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1994, the World Health Organization (WHO) established a classification of bone mineral density (BMD) according to the standard deviation (SD) difference between a patient's BMD and that of a young-adult reference population. This value is now commonly expressed as a \"T-score.\" A T-score that is equal to or less than -2.5 is consistent with a diagnosis of osteoporosis, a T-score between -1.0 and -2.5 is classified as low bone mass (osteopenia), and a T-score of -1.0 or higher is normal [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many studies have demonstrated that low BMD is associated with an increased risk of fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/12,14-20\">",
"     12,14-20",
"    </a>",
"    ]. Individuals with T-scores of &le;-2.5 have the highest risk of fracture. However, because there are more individuals with osteopenia than osteoporosis, the absolute number of fractures in subjects with BMD T-scores in the osteopenia range is greater than in those with T-scores in the osteoporosis range [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/7-9,21\">",
"     7-9,21",
"    </a>",
"    ]. Since most fractures occur in patients with T-scores better than -2.5, treatment strategies relying solely on BMD testing will miss many patients at risk for fracture.",
"   </p>",
"   <p>",
"    Assessment of clinical risk factors that are independent of BMD is important for fracture prediction. In addition to BMD, advancing age, prior history of fragility fracture, chronic glucocorticoid use, low body mass index (BMI), parental history of hip fracture, cigarette smoking, and excess alcohol intake are the risk factors that have been demonstrated to be most predictive of fracture (",
"    <a class=\"graphic graphic_table graphicRef76445 \" href=\"UTD.htm?2/21/2395\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Clinical risk factor assessment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Methodologies for combining BMD with clinical risk factors to quantify fracture probability offer attractive alternatives to relying on BMD testing alone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/22\">",
"     22",
"    </a>",
"    ]. Thus, assessment of fracture risk should include evaluation of both:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      BMD",
"     </li>",
"     <li>",
"      Clinical risk factors",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Expression of fracture risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Absolute risk (AR) is the probability of fracture, usually expressed as a percentage, over a specified period of time. Relative risk (RR) is the ratio of absolute risks of two populations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/20\">",
"     20",
"    </a>",
"    ]. RR tends to overestimate fracture risk in some populations and underestimate it in others [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/23\">",
"     23",
"    </a>",
"    ]. As an example, a 50-year-old woman and an 80-year-old with a hip T-score of -2.5 each have the same RR for hip fracture compared to an age-matched population with normal BMD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/20\">",
"     20",
"    </a>",
"    ], while the 10-year probability of hip fracture is much higher in the 80-year-old (",
"    <a class=\"graphic graphic_table graphicRef67119 \" href=\"UTD.htm?18/24/18827\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/24\">",
"     24",
"    </a>",
"    ]. For this reason, AR provides a better assessment of fracture risk and is a more useful clinical tool for identifying patients most likely to benefit from therapy. The preferred fracture risk expression for use in clinical practice is AR denoted as the 10-year probability of fracture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Fracture risk assessment tool",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2008, a World Health Organization (WHO) task force introduced a Fracture Risk Assessment Tool (FRAX), which estimates the 10-year probability of hip fracture and major osteoporotic fracture (hip, clinical spine, proximal humerus, or forearm) for",
"    <strong>",
"     untreated",
"    </strong>",
"    patients between ages 40 and 90 years using easily obtainable clinical risk factors for fracture (",
"    <a class=\"graphic graphic_table graphicRef76445 \" href=\"UTD.htm?2/21/2395\">",
"     table 1",
"    </a>",
"    ) and femoral neck BMD",
"    <span class=\"nowrap\">",
"     (g/cm2,",
"    </span>",
"    using dual energy x-ray absorptiometry [DXA]), when available [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    FRAX is based upon data collected from large prospective observational studies of men and women of different ethnicities and from different world regions in which clinical risk factors, BMD, and fractures were evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/12,24\">",
"     12,24",
"    </a>",
"    ]. FRAX has been validated in 11 independent cohorts, mainly comprised of women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/22\">",
"     22",
"    </a>",
"    ]. The statistical power of this large dataset allows estimation of fracture probability from an individual's set of risk factors. The country-specific FRAX prediction algorithms are available for some but not all countries online (",
"    <a class=\"external\" href=\"file://www.shef.ac.uk/FRAX/\">",
"     www.shef.ac.uk/FRAX/",
"    </a>",
"    ); click on Calculation Tool [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/26\">",
"     26",
"    </a>",
"    ]. The FRAX calculator is also available on current versions of DXA software. FRAX is a trademark of the WHO.",
"   </p>",
"   <p>",
"    Results from a large prospective cohort study suggest that FRAX can similarly predict fracture in women currently or previously",
"    <strong>",
"     treated",
"    </strong>",
"    for osteoporosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/27\">",
"     27",
"    </a>",
"    ]. In this analysis, the FRAX predicted risk and observed incidence of major osteoporotic fracture in both untreated and treated women were concordant. Only in the subset of women who were at highest risk for fracture, and who were highly adherent to their osteoporosis treatment, was the observed hip fracture incidence significantly less than the predicted risk. Thus, osteoporosis therapy does not preclude the use of FRAX for fracture prediction. However, FRAX is not intended to be used to assess the reduction in fracture risk in individuals on therapy.",
"   </p>",
"   <p>",
"    Other fracture risk assessment models are available, but most have not been validated in diverse populations, and they are not in widespread use [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Clinical application of fracture risk assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;When country-specific fracture data and economic assumptions are used with FRAX, thresholds for cost-effective pharmacological intervention can be calculated [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/24,30-35\">",
"     24,30-35",
"    </a>",
"    ], allowing clinicians to identify patients likely to benefit from therapy better than currently available qualitative methods. Treatment guidelines based upon FRAX are likely to lead to more drug treatment in older patients with slightly low T-scores and high risk of fracture, with less use of drugs to treat younger patients with slightly low T-scores and low risk of fracture.",
"   </p>",
"   <p>",
"    In the United States, cost-effectiveness modeling suggests that the 10-year hip fracture probability at which treatment becomes cost-effective (intervention threshold) ranges from 2.5 to 4.7 percent for women and from 2.4 to 4.9 percent in men, depending upon age and assuming annual treatment costs of $600 and a willingness-to-pay threshold of $60,000 per quality-adjusted life-year gained [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/30\">",
"     30",
"    </a>",
"    ]. For a 70-year old woman initiating therapy, the intervention threshold is approximately 4 percent. Using similar willingness-to-pay thresholds but country-specific intervention costs, the intervention threshold in 70-year old women from other countries ranges from 4 to 9.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intervention thresholds vary based upon country-specific health economic data, such as fracture-related treatment costs and willingness-to-pay thresholds [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/25\">",
"     25",
"    </a>",
"    ]. In most countries, the analysis is based upon five years of treatment with a bisphosphonate. The analysis in the US was based upon the incidence of hip fracture in Caucasian postmenopausal women and the expected cost of generic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    (before the actual cost was known) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/30,37\">",
"     30,37",
"    </a>",
"    ]. Since the current cost of generic alendronate in the United States is less than the estimated cost, the fracture probability at which this treatment is cost-effective is presumably less than what was calculated. Conversely, the use of more expensive non-generic drugs increases the fracture probability at which treatment becomes cost-effective.",
"   </p>",
"   <p>",
"    Guidelines for pharmacologic intervention based upon 10-year absolute fracture risk are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Candidates for therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of osteoporosis in men\", section on 'Candidates for therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2003321\">",
"    <span class=\"h3\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;FRAX is a useful clinical tool for assessment of fracture risk. As with all clinical tools, however, there are some limitations. Limitations include lack of extensive validation in treated patients, limitation to four ethnicities (Caucasian, Black, Hispanic, Asian) in the US, uncertainty regarding the range of error with fracture risk, and lack of validation with BMD measurements by technologies other than DXA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The FRAX algorithm uses femoral neck (FN) BMD",
"    <span class=\"nowrap\">",
"     (g/cm2)",
"    </span>",
"    for calculation of fracture probability in untreated patients. BMD input from non-hip sites has not been validated with FRAX and is therefore not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/25\">",
"     25",
"    </a>",
"    ]. For patients who have clinical risk factors for osteoporosis, low lumbar spine BMD, but normal FN BMD, FRAX is likely to underestimate fracture risk. Additional limitations, which may result in over or underestimation of fracture risk in an individual patient, include dichotomous (yes or no) input for clinical risk factors that are associated with variable risk depending on dose and duration of exposure (eg, glucocorticoids) and lack of consideration of all risk factors (eg, multiple fractures, falls, bone turnover). While there is evidence that hip, vertebral, and humeral fractures appear to confer greater risk of subsequent fracture than fractures at other sites, quantification of this incremental risk in FRAX is not possible.",
"   </p>",
"   <p>",
"    Thus, FRAX may underestimate fracture probability in individuals with a history of [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low lumbar spine but normal FN BMD",
"     </li>",
"     <li>",
"      Multiple fractures",
"     </li>",
"     <li>",
"      High dose glucocorticoid exposure (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      &gt;7.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or equivalent)",
"     </li>",
"     <li>",
"      Prevalent severe vertebral fractures",
"     </li>",
"     <li>",
"      A parental history of non-hip fragility fracture",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The magnitude by which FRAX may over- or underestimate fracture risk has been studied using large population databases, and procedures for adjusting FRAX probability have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. As an example, when there is discordance between lumbar spine and femoral neck BMD, the FRAX estimate for major osteoporotic fracture may be increased or decreased by one-tenth for each rounded T-score difference or offset between lumbar spine and FN (eg, when the lumbar spine T-score is 1.0 less than the FN T-score, the 10-year probability of major osteoporotic fracture can be increased by one-tenth) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/39\">",
"     39",
"    </a>",
"    ]. Another analysis using the UK General Practice Research Database showed that for patients exposed to high dose glucocorticoids (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    &gt;7.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or equivalent), the 10-year probability of major osteoporotic fracture may be increased by 15 percent and the 10-year probability of hip increased by 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/40\">",
"     40",
"    </a>",
"    ]. With these modifications, the FRAX probability of fracture can be refined. However, these correction factors have not been computed for the majority of countries represented by FRAX, including the United States. Thus, they should not yet be applied to US populations.",
"   </p>",
"   <p>",
"    The clinician should appreciate that intervention guidelines with or without the use of FRAX provide only general clinical guidance. Osteoporosis treatment should remain individualized through shared decision-making between patient and clinician. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Candidates for therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of osteoporosis in men\", section on 'Candidates for therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     METHODS OF MEASUREMENT OF BMD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low BMD is associated with increased risk of fracture, regardless of the technique used for measurement [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/12,14-20,41-52\">",
"     12,14-20,41-52",
"    </a>",
"    ]. However, there are discrepancies in T-score values at different skeletal sites and with different technologies. The increase in fracture risk per 1.0 SD decrease in T-score (fracture gradient) varies with the technique used and the skeletal site measured. Therefore, T-scores derived from different skeletal sites with different technologies are not interchangeable [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/10,53\">",
"     10,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In clinical practice, DXA is the only technology that can be used for diagnostic classification and for BMD input with FRAX and is the most useful technology for monitoring serial BMD changes. However, other techniques measuring different skeletal sites have demonstrated the ability to predict the likelihood of fractures. Therefore, when BMD testing by DXA is not available, then fracture risk assessment may be done using other technologies (measuring lumbar spine, hip, or peripheral skeletal sites) in combination with consideration of clinical risk factors. Clinical risk factor assessment alone may be considered for fracture prediction in world regions without access to any technologies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/22,54\">",
"     22,54",
"    </a>",
"    ]. The FRAX model allows estimation of 10-year probability of hip fracture and major osteoporotic fracture with clinical risk factors alone when BMD is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/25,26,55\">",
"     25,26,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dual-energy x-ray absorptiometry (DXA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;DXA measures bone mineral content (BMC, in grams) and bone area (BA, in square centimeters), then calculates \"areal\" BMD (aBMD) in",
"    <span class=\"nowrap\">",
"     g/cm2",
"    </span>",
"    by dividing BMC by BA. DXA is the most widely used method for measuring BMD because it gives very precise and accurate measurements at clinically relevant skeletal sites (ie, those with major clinical consequences when a fracture occurs) and can be used for diagnostic classification, input with FRAX, and monitoring the response to therapy. The major disadvantages of DXA are that the instrument is large (not portable), more expensive than most peripheral technologies, and uses ionizing radiation, albeit in a very low dose.",
"   </p>",
"   <p>",
"    Detailed information about DXA is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42583?source=see_link\">",
"     \"Overview of dual-energy x-ray absorptiometry\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Fracture prediction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many studies have demonstrated that low BMD measured by DXA at any skeletal site (spine, hip, or forearm) can predict osteoporotic (fragility) fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. Overall, there is an approximately twofold increase in risk of such fractures for each SD decrease in BMD (",
"    <a class=\"graphic graphic_table graphicRef51324 \" href=\"UTD.htm?14/12/14539\">",
"     table 3",
"    </a>",
"    ). As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study of 9700 older women, 2680 of whom were followed for an average of 15 years, the risk of vertebral fracture was inversely related to bone density at all measurement sites [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/56\">",
"       56",
"      </a>",
"      ]. The age-adjusted odds ratio (OR) of vertebral fracture for each SD decrease in DXA-measured BMD of the lumbar spine and total hip was 2.1 (95% CI 1.8-2.3) and 1.8 (95% CI 1.6-2.0), respectively.",
"     </li>",
"     <li>",
"      In a historical cohort study (mean observation 3.2",
"      <span class=\"nowrap\">",
"       +/-",
"      </span>",
"      1.5 years) of 16,505 Canadian women, each SD decrease in DXA-measured BMD of the hip or lumbar spine was associated with an increased risk of osteoporotic fracture at any site (hazard ratio 1.8 [95% CI 1.7-2.0] for total hip and 1.5 [95% CI 1.4-1.6] for spine) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although low BMD at any skeletal site can predict osteoporotic fracture, site-specific measurements are generally better for their respective sites. As an example, hip BMD is superior to BMD measured at other skeletal sites in predicting hip fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/12,14,16,18,19\">",
"     12,14,16,18,19",
"    </a>",
"    ]. A meta-analysis of prospective cohort studies with over 90,000 person-years of observation found that every one SD decrease in BMD at the femoral neck (FN) in women was associated with a relative risk of 2.6 (95% CI 2.0-3.5) for hip fracture and 1.6 (95% CI 1.4-1.8) for all fractures. A one SD decrease in lumbar spine BMD was associated with a RR of 2.3 (95% CI 1.9-2.8) for vertebral fracture and 1.5 (95% CI 1.4-1.7) for all fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a similar relationship between overall fracture, hip fracture, and FN BMD in women and men [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/9,15,57\">",
"     9,15,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High-trauma fractures (generally defined as fractures from motor vehicle accidents, sporting accidents, or falls from ladders or other raised surfaces) have traditionally been excluded from observational studies and clinical osteoporosis trials. Although the force to which bone is subjected varies with the level of trauma, the conventional view has been that even normal bone would fracture under most high-trauma conditions. Therefore, high-trauma fractures have not been considered a risk factor for osteoporosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Clinical risk factor assessment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, evidence suggests that low BMD also increases the risk of high-trauma fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. As an example, in two large prospective cohort studies of community-dwelling older men and women, a one SD decrease in total hip BMD was associated with similarly increased risks of high- or-low trauma fractures (age-adjusted relative hazard [RH] 1.4 [95% CI 1.2-1.7] and 1.5 [95% CI 1.4-1.6] for high- and low-trauma fractures, respectively, in women and 1.5 [95% CI 1.2-2.0] and 1.7 [95% CI 1.5-1.9], for high-and low-trauma fractures, respectively, in men) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the relationship between BMD and fracture appears to be similar, regardless of the cause of fracture, the studies are limited by the broad definition of high-trauma fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/58\">",
"     58",
"    </a>",
"    ]. There is a level of force at which normal bone would fracture, independent of BMD. The ability to accurately define traumatic fractures that are unlikely related to low BMD would clarify which patients with fracture require an evaluation for osteoporosis. Those who sustain fractures from a level of force at which normal bone would not ordinarily fracture require evaluation for osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40393?source=see_link\">",
"     \"Screening for osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11128?source=see_link\">",
"     \"Diagnosis and evaluation of osteoporosis in postmenopausal women\"",
"    </a>",
"    .) This relationship between force and fracture requires further investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Follow-up BMD testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;DXA is commonly used to monitor the effects of pharmacological therapy. Stability or an increase in BMD is considered to be a good response to therapy, whereas significant loss of BMD is cause for consideration of evaluation of factors contributing to suboptimal therapeutic effect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40393?source=see_link&amp;anchor=H20#H20\">",
"     \"Screening for osteoporosis\", section on 'Repeat BMD measurements'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link&amp;anchor=H31#H31\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Monitoring the response to therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The value of repeat DXA in predicting fracture risk may be lower in older patients who are unlikely to experience further dramatic declines in BMD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. In the Study of Osteoporotic Fractures (SOF), a repeat BMD measurement performed a mean of eight years after the initial measurement did not improve the overall predictive value of hip, spine, or nonspine fracture risk in 4124 healthy community dwelling women 65 years and older [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/63\">",
"     63",
"    </a>",
"    ]. However, these findings may not necessarily apply to younger women who may have accelerated bone loss (as in the early menopause), to women being treated for osteoporosis or low BMD, or to men [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Peripheral DXA (pDXA)",
"    </span>",
"    &nbsp;&mdash;&nbsp;pDXA devices are dedicated portable instruments that use the same technology as DXA to measure BMD at peripheral sites, such as the forearm, calcaneus, or finger. Evaluation of fracture risk prediction with these devices is confounded by technical differences, variation in the definitions of the bone regions of interest measured, and lack of standardized reference databases for calculating T-scores. Nevertheless, low T-score values at peripheral sites measured by pDXA devices are associated with increased fracture risk [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/20,41\">",
"     20,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peripheral DXA cannot be used for diagnostic classification, other than with measurement at the distal 33 percent (one-third) radius site, since the WHO criteria for BMD classification do not apply to BMD at skeletal sites other than the lumbar spine, hip, and forearm [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/66\">",
"     66",
"    </a>",
"    ]. Despite generally good precision with pDXA, it is not clinically useful to monitor therapy, since changes in BMD at peripheral skeletal sites in response to therapy are very slow [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Quantitative ultrasonography (QUS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;QUS does not measure BMD, but instead measures the transmission of ultrasound through accessible limb bones or the reflectance of the ultrasound waves from the bone surface. Parameters assessed by transmission ultrasound include broadband ultrasound attenuation (BUA), speed of sound (SOS), and calculated values such as quantitative ultrasound index (QUI) or stiffness index (SI). Reflectance ultrasound reports only SOS.",
"   </p>",
"   <p>",
"    Potential advantages of QUS compared with measurement of BMD include lower expense, portability, and lack of radiation exposure. Measurements are most commonly made at the calcaneus (heel), a skeletal site that is composed primarily of cancellous bone, similar to the spine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Fracture prediction",
"    </span>",
"    &nbsp;&mdash;&nbsp;QUS is a good predictor of osteoporotic fracture risk [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/41-49,67\">",
"     41-49,67",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a large prospective study of 6189 postmenopausal women over age 65, QUS of the calcaneus predicted hip fracture as accurately as DXA of the calcaneus or femoral neck [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/44\">",
"       44",
"      </a>",
"      ]. Each SD reduction in calcaneal BUA was associated with a doubling of the risk for hip fractures (relative risk [RR], 2.0; 95% CI 1.5-2.7).",
"     </li>",
"     <li>",
"      In a larger study of 14,824 patients that included younger women as well as men ages 42 to 82 years, calcaneal QUS also was a good predictor of total and hip fracture risk [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/43\">",
"       43",
"      </a>",
"      ]. BUA predicted fracture risk in all subgroups of patients, with a relative risk similar to the study above.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to predicting fracture risk, other studies have found that QUS is at least as good, and possibly better than clinical risk factors for predicting women at risk for osteoporosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, QUS appears to be a good predictor of fractures in men and women, and is at least as good as clinical risk factors for identifying patients at high risk for osteoporosis. However, QUS cannot be used for diagnostic classification, since the WHO criteria were established based upon BMD measurement by DXA and cannot be used with FRAX. In addition, there are no studies showing reduction in fracture risk for patients selected for therapy based on QUS measurements, and QUS cannot be used to monitor response to therapy, because changes are too slow to be clinically useful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40393?source=see_link\">",
"     \"Screening for osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11128?source=see_link\">",
"     \"Diagnosis and evaluation of osteoporosis in postmenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Quantitative computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quantitative computed tomography (QCT) measures volumetric BMD (vBMD) in",
"    <span class=\"nowrap\">",
"     mg/cm3,",
"    </span>",
"    most often at the spine. Unlike DXA, QCT can isolate trabecular bone from its envelope of cortical bone. Some studies have suggested that QCT of the spine may be a slightly better predictor of fracture risk of the spine than anterior-posterior spine DXA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/70,71\">",
"     70,71",
"    </a>",
"    ], perhaps because of the important contribution of trabecular bone to vertebral body strength [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/72\">",
"     72",
"    </a>",
"    ]. However, another study suggested that QCT of the spine is not superior to DXA of the hip in predicting non-spine fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    QCT cannot be used for diagnostic classification, since the WHO criteria for BMD classification do not apply to this technology, and it cannot be used with FRAX. It may be clinically useful to monitor changes in BMD over time for some patients with structural abnormalities of the spine that preclude the use of DXA. It has a potential role in monitoring the therapeutic effects of anabolic agents or other types of drugs with novel mechanisms of action. At the present time, QCT is primarily a research tool that has been very helpful in improving our understanding of the pathogenesis of osteoporosis and the skeletal effects of drugs used to treat osteoporosis. It is more expensive, less reproducible, and requires a higher radiation dose than DXA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Emerging technologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although DXA is the most commonly used technique to assess BMD, it has some limitations. DXA measures areal BMD, rather than volumetric BMD. In addition, it cannot distinguish between cortical and trabecular bone, and it cannot assess bone microarchitecture. Thus, new technologies have been developed which allow noninvasive three-dimensional evaluation of bone microarchitecture. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High-resolution microCT and microMRI measure peripheral sites (distal radius, tibia). Preliminary studies suggest that alterations in microarchitecture as detected by these techniques are associated with fracture [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/74-76\">",
"       74-76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hip structural analysis (HSA) uses information about bone geometry and mass distribution obtained from DXA scans of the hip to calculate parameters related to bone strength, such as hip axis length, neck-shaft angle, cross-sectional bone area, bone width, section modulus, moment of inertia, and buckling ratio [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Structural engineering models (SEMs) of the hip integrate DXA-derived hip data with applied forces to estimate hip fracture risk [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Finite element analysis (FEA) uses computer models of images and data from QCT of the spine or hip to assess bone strength [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While all of these technologies have provided insight into skeletal properties other than BMD that determine bone strength, their role in clinical practice has not been defined. These techniques are used primarily in research settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Older technologies for measuring BMD",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Single-photon absorptiometry (SPA) &mdash; In SPA, a single-energy photon beam generated from a radioisotope source is passed through a peripheral bone, usually the radius or calcaneus. Bone density is estimated from the degree of attenuation of this x-ray beam. Because the photon beam is single-energy, the machine cannot determine whether the beam was attenuated by soft tissue or bone. As a result, SPA can be used only at peripheral sites, such as the radius and calcaneus. Low BMD at the radius and calcaneus, as measured by SPA, is associated with an increased risk of fractures [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/17,50,51\">",
"       17,50,51",
"      </a>",
"      ], including hip fractures [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/52\">",
"       52",
"      </a>",
"      ]. It is currently rarely used in clinical practice and is included here primarily for historical context.",
"     </li>",
"     <li>",
"      Dual-photon absorptiometry (DPA) &mdash; DPA uses photon beams of two different energy levels from a radioisotope. Because the two photon beams are attenuated differently by soft tissue and bone, bone density can be accurately estimated despite varying amounts of soft tissue. This feature allows DPA to measure bone density at clinically important deep axial sites, such as the spine and hip. DXA has largely replaced DPA, which is now rarely used in clinical practice.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SKELETAL SITE TO MEASURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fracture risk can be predicted by measurement or estimation of BMD at many skeletal sites with a variety of technologies. Although BMD measurements at peripheral skeletal sites predict global fracture risk (ie, the risk of fracture at any skeletal site) as well as BMD measurement at the hip or spine [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/17,79\">",
"     17,79",
"    </a>",
"    ], the risk for fracture at a particular skeletal site is best estimated by measuring BMD at that skeletal site [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/80-83\">",
"     80-83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The International Society for Clinical Densitometry (ISCD) recommends that the WHO criteria be applied to BMD measured by DXA, using the lowest T-score of the lumbar spine (preferably L1-L4), FN, or total proximal femur. If BMD cannot be measured at either of these skeletal sites due to structural abnormalities, such as osteoarthritis or surgical artifact, then the distal 33 percent (one-third) radius should also be measured and considered for diagnostic classification [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend following ISCD recommendations (DXA of the lumbar spine and hip). However, the lumbar spine is less useful for BMD measurement in older individuals, in whom structural abnormalities, such as degenerative arthritis and disc disease, commonly result in BMD increases. In such patients, measurement of the hip alone could be sufficient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11128?source=see_link&amp;anchor=H12#H12\">",
"     \"Diagnosis and evaluation of osteoporosis in postmenopausal women\", section on 'Site of measurement'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=see_link\">",
"     \"Treatment of osteoporosis in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, it is important to note that FRAX was designed to calculate fracture probability with femoral neck BMD measured by DXA. The validity of FRAX with BMD measured at other skeletal sites and using other technologies has not been determined and therefore is not recommended. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Clinical application of fracture risk assessment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CLINICAL RISK FACTOR ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most fractures occur in patients who do not have osteoporosis. Although patients with osteoporosis are at the highest risk of fracture, there are more fractures in patients with low bone mass or osteopenia (T-score between -1.0 and -2.5) because there are so many more patients in this category [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/7,84,85\">",
"     7,84,85",
"    </a>",
"    ]. Therefore, assessment of clinical risk factors that are independent of BMD is important for fracture prediction.",
"   </p>",
"   <p>",
"    Some of these factors in Caucasian women and men include advancing age, previous fracture, glucocorticoid therapy, a family history of hip fracture, poor visual capacity, low body weight, neuromuscular disorders, and smoking (",
"    <a class=\"graphic graphic_table graphicRef76445 \" href=\"UTD.htm?2/21/2395\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/10,86,87\">",
"     10,86,87",
"    </a>",
"    ]. Similar risk factors were identified in a prospective study of 1435 Chinese women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many of these risk factors are easily discernible from a routine history and physical examination; taken together they are predictive of future hip fracture, even in the absence of BMD measurement [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. Advancing age and previous personal history of fracture are two of the most important BMD-independent risk factors for fracture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Advanced age",
"    </span>",
"    &nbsp;&mdash;&nbsp;For any given T-score the risk of fracture is higher with advancing age (",
"    <a class=\"graphic graphic_figure graphicRef54599 \" href=\"UTD.htm?23/31/24062\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Personal history of fracture as an adult",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of a fragility (low-trauma) fracture is another important risk factor for subsequent fracture in men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/56,91-95\">",
"     56,91-95",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 11 prospective cohort studies of fracture risk in men or women with prior fracture reported increased risks of any fracture (RR 1.8, 95% CI 1.6-1.9), osteoporotic fracture (RR 1.8, 95% CI 1.6-1.9), and hip fracture (RR 1.6, 95% CI 1.3-2.0) in both men and women, even after adjustment for BMD [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective cohort study of 4005 Australian men and women followed for 16 years, the RR of subsequent fracture in women with any initial low-trauma fracture (after age 60 years) was 2.0 (95% CI 1.7-2.2) and for men was 3.5 (95% CI 2.7-4.5) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/91\">",
"       91",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a longitudinal study (SOF) of 9700 older (age &gt;65 years at baseline) women, 2680 of whom were followed for an average of 15 years, the absolute risk (AR) of a new vertebral fracture in women with previous vertebral fracture ranged from 25 to 50 percent, depending upon T-score [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/56\">",
"       56",
"      </a>",
"      ]. The risk of new vertebral fracture was greatest in women with a total hip T-score &le;-2.5 and a previous vertebral fracture (AR 56 percent, 95% CI 44 to 69 percent). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Expression of fracture risk'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In women, a history of a high-trauma fracture may also be a risk factor for subsequent fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/60\">",
"     60",
"    </a>",
"    ]. In a nine-year study of 8022 women participating in SOF, women with a previous history of high- and low-trauma nonspine fractures had a similarly elevated risk of subsequent fracture compared with women who had not had such fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/60\">",
"     60",
"    </a>",
"    ]. The risk of a subsequent fracture was 34 percent (95% CI 7-67) and 31 percent (95% CI 20-43) greater among women with a history of high- and low-trauma fracture, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Glucocorticoid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A retrospective cohort study in 244,235 oral glucocorticoid users in the United Kingdom General Practice Research Database showed a dose-dependent relationship between chronic glucocorticoid use and fracture risk, with high doses (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    7.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or greater) having the highest risk [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/96\">",
"     96",
"    </a>",
"    ]. Low doses of glucocorticoids (prednisolone less than 2.5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    were also associated with increased fracture risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=see_link\">",
"     \"Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     History of fragility fracture in a first-degree relative",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parental history of hip fracture is associated with a twofold increased risk of hip fracture in women, regardless of BMD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Low body weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low body weight (less than 58 kg [127 lb]) is associated with increased risk of osteoporosis and fractures, possibly related to small bone size [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/97-100\">",
"     97-100",
"    </a>",
"    ]. Weight loss after age 50 years in women and increased height also raise the risk of hip fracture, while weight gain decreases it [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/98,101,102\">",
"     98,101,102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of weight loss may influence the effect on bone physiology. In one small, randomized trial, subjects who lost weight by calorie restriction had decreases in total hip BMD, whereas subjects who lost the same amount of weight via exercise without reduced caloric intake had no changes in BMD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Cigarette smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meta-analyses have shown that cigarette smoking is associated with reduced BMD and increased risk of fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]. The risk of fracture was increased with a smoking history and current smoking, but was higher for current smokers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Excessive alcohol consumption",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of fracture with excessive alcohol intake is dose dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/106\">",
"     106",
"    </a>",
"    ]. A meta-analysis of case-control and prospective cohort studies showed that alcohol consumption in excess of two drinks (approximately 28 g of pure alcohol) per day is associated with an increased risk of hip fracture (RR 1.39, 95% CI 1.08-1.79) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Medical diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many medical diseases are associated with low BMD and an increased risk of fracture, either due to underlying inflammation, malabsorption, renal excretion of calcium, or medications used to treat the diseases. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rheumatoid arthritis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=see_link\">",
"       \"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Inflammatory bowel disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30569?source=see_link\">",
"       \"Metabolic bone disease in inflammatory bowel disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Celiac disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link&amp;anchor=H21#H21\">",
"       \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\", section on 'Metabolic bone disease'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cystic fibrosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link&amp;anchor=H14#H14\">",
"       \"Cystic fibrosis: Clinical manifestations and diagnosis\", section on 'Musculoskeletal disorders'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Previous hyperthyroidism (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17593?source=see_link\">",
"       \"Bone disease with hyperthyroidism and thyroid hormone therapy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Type 1 and 2 diabetes (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/26/11687?source=see_link\">",
"       \"Bone disease in diabetes mellitus\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Renal disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link\">",
"       \"Pathogenesis of renal osteodystrophy\"",
"      </a>",
"      )",
"      <br/>",
"      <br/>",
"      End-stage renal disease is associated with an increased risk of fracture. In addition, moderate degrees of renal insufficiency (as estimated in patients with a stable serum creatinine) have been reported to be associated with an increased fracture risk in one study [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/108\">",
"       108",
"      </a>",
"      ], but not in another [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/109\">",
"       109",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Other risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors in addition to those described above (",
"    <a class=\"graphic graphic_table graphicRef76445 \" href=\"UTD.htm?2/21/2395\">",
"     table 1",
"    </a>",
"    ) include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vitamin D deficiency (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=see_link&amp;anchor=H2#H2\">",
"       \"Calcium and vitamin D supplementation in osteoporosis\", section on 'Efficacy'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Reduced functional mobility, recurrent falls, or use of walking aids (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22602?source=see_link\">",
"       \"Falls in older persons: Risk factors and patient evaluation\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Many drugs, including androgen deprivation agents, aromatase inhibitors, proton pump inhibitors, selective serotonin reuptake inhibitors, thiazolidinediones, and anticonvulsants (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=see_link&amp;anchor=H7#H7\">",
"       \"Side effects of androgen deprivation therapy\", section on 'Osteoporosis and bone fractures'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=see_link\">",
"       \"Drugs that affect bone metabolism\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Dementia",
"     </li>",
"     <li>",
"      Poor",
"      <span class=\"nowrap\">",
"       health/frailty",
"      </span>",
"     </li>",
"     <li>",
"      Previous fracture between the ages of 20 and 50 years (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/25/6553?source=see_link&amp;anchor=H9#H9\">",
"       \"Epidemiology and etiology of premenopausal osteoporosis\", section on 'Fractures'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      A previous history of breast cancer (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8202?source=see_link&amp;anchor=H1201327#H1201327\">",
"       \"Patterns of relapse and long-term complications of therapy in breast cancer survivors\", section on 'Musculoskeletal'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Possible risk factors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Depression has been associated with an increased risk of fracture in some studies [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/110\">",
"       110",
"      </a>",
"      ]. However, the relationship between depression and fracture is likely complex. Individuals with depression tend to have other risk factors for fracture, including medication use (selective serotonin reuptake inhibitors), increased frequency of falling, hypercortisolism, and lifestyle factors (smoking, alcohol). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Other risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mild asymptomatic hyponatremia (serum sodium &lt;135",
"      <span class=\"nowrap\">",
"       mEq/L)",
"      </span>",
"      was associated with an increased risk of fall-related fractures (adjusted odds ratio for fracture 4.2, 95% CI 2.2-7.7) in a case-control study [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/111\">",
"       111",
"      </a>",
"      ]. In the majority of cases, hyponatremia was either drug-induced (diuretics, selective serotonin reuptake inhibitors, and antiepileptic drugs) or was due to the syndrome of inappropriate antidiuretic hormone secretion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=see_link\">",
"       \"Drugs that affect bone metabolism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aortic calcification on CT scan (a marker of atherosclerosis) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/112\">",
"       112",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Elevated markers of inflammation [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/113,114\">",
"       113,114",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      High dietary retinol intake, which some but not all studies suggest increases fracture risk (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=see_link\">",
"       \"Drugs that affect bone metabolism\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Sedentary lifestyle [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/115\">",
"       115",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vitamin B12 deficiency (pernicious anemia) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=see_link\">",
"       \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      High homocysteine concentrations, which are associated with an increased risk of fracture in some but not all studies [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/116-123\">",
"       116-123",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Consumption of large amounts of caffeine: The association between excess caffeine and increased fracture risk has been variably reported as a definite association [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/88\">",
"       88",
"      </a>",
"      ], no association [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/124,125\">",
"       124,125",
"      </a>",
"      ], and an association only if the patient does not drink milk [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/126\">",
"       126",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Carbonated beverages may be associated with adverse skeletal effects in adolescents, possibly due to the displacement of nutritious foods and beverages, but the impact in older women is unclear. In one report, modest intake of carbonated beverages did not have adverse effects on BMD [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/127\">",
"       127",
"      </a>",
"      ], while in another, cola drinks (but not other carbonated beverages), were associated with lower bone density [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/128\">",
"       128",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40040?source=see_link\">",
"       \"Calcium requirements in adolescents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Bone turnover markers (BTMs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurements of BTMs may provide information about expected rates of bone loss and fracture risk that cannot be obtained from measurements of BMD (",
"    <a class=\"graphic graphic_figure graphicRef71125 \" href=\"UTD.htm?36/42/37550\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/129,130\">",
"     129,130",
"    </a>",
"    ]. Elevated BTMs have been demonstrated to be associated with increased risk of vertebral and nonvertebral fracture, independently of BMD, suggesting that BMD combined with a BTM may improve fracture prediction (",
"    <a class=\"graphic graphic_figure graphicRef77540 \" href=\"UTD.htm?8/59/9150\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/131,132\">",
"     131,132",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44487?source=see_link\">",
"     \"Use of biochemical markers of bone turnover in osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the relationship between BTMs and fracture risk has not been validated in all studies. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a subset of placebo patients in the Multiple Outcomes of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"       Raloxifene",
"      </a>",
"      (MORE) study, none of the BTMs (bone-specific alkaline phosphatase, osteocalcin or urinary C-telopeptide) that were measured influenced fracture risk [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/133\">",
"       133",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an observational study of 225 postmenopausal women followed for a median of 16.2 years, BTMs (osteocalcin, alkaline phosphatase, and urinary hydroxyproline) did not predict any type of osteoporotic fracture [",
"      <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While the use of BTMs in clinical trials has been helpful in understanding the mechanism of action of therapeutic agents, their role in the care of individual patients is not well established. Potential roles of BTMs in clinical practice include prediction of fracture risk, monitoring response to therapy, and as an aid in selection of drug for treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/42/29354/abstract/134\">",
"     134",
"    </a>",
"    ]. It is not clear which specific BTM is most useful for specific clinical situations. Biologic and within individual variability in BTM values have confounded their widespread use in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone mineral density (BMD) and clinical risk factors may be combined to provide a better estimate of fracture risk than BMD or clinical risk factors alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Fracture prediction",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Fracture Risk Assessment Tool (FRAX) estimates the 10-year probability of hip fracture and major osteoporotic fracture for an untreated patient (40 to 90 years of age) using femoral neck BMD",
"      <span class=\"nowrap\">",
"       (g/cm2)",
"      </span>",
"      and easily obtainable clinical risk factors for fracture (",
"      <a class=\"external\" href=\"file://www.shef.ac.uk/FRAX/\">",
"       file://www.shef.ac.uk/FRAX/",
"      </a>",
"      ) (",
"      <a class=\"graphic graphic_table graphicRef76445 \" href=\"UTD.htm?2/21/2395\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Fracture risk assessment tool'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      FRAX is calibrated for each country using country-specific fracture data and mortality data, then used with country-specific economic assumptions to develop treatment guidelines with thresholds for cost-effective pharmacological intervention. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical application of fracture risk assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With the use of the FRAX model, it is anticipated that intervention will be more effectively targeted to those at highest risk of fracture, ie, older patients with slightly low T-scores and high risk of fracture will be selected for drug therapy, while fewer younger patients with low T-scores and low risk of fracture will be treated. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical application of fracture risk assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical risk factor assessment alone may be considered for fracture prediction in world regions without access to any BMD technologies. The FRAX model allows estimation of 10-year probability of hip fracture (and major osteoporotic fractures) using clinical risk factors alone or in combination with femoral neck BMD. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Skeletal site to measure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Bone mineral density",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DXA measurements of hip or spine or peripheral measurements of BMD using different validated techniques can be used to predict fracture. However, T-scores derived from different skeletal sites with different technologies are not interchangeable. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Methods of measurement of BMD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest DXA measurement of BMD at the hip and lumbar spine. When either the hip or lumbar spine is not a valid skeletal site for BMD measurement, then the 33 percent (one-third) radius should be measured. In some patients, measurement of the hip alone could be sufficient. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Skeletal site to measure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Assessment of clinical risk factors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most robust non-BMD risk factors are age and prevalent fracture. Other validated BMD-independent risk factors for fracture include long-term glucocorticoid therapy, parental history of hip fracture, cigarette smoking, and excess alcohol intake (",
"      <a class=\"graphic graphic_table graphicRef76445 \" href=\"UTD.htm?2/21/2395\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Clinical risk factor assessment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/1\">",
"      Riggs BL, Melton LJ 3rd. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995; 17:505S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/2\">",
"      Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006; 17:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/3\">",
"      Ioannidis G, Papaioannou A, Hopman WM, et al. Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ 2009; 181:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/4\">",
"      Poole KE, Compston JE. Osteoporosis and its management. BMJ 2006; 333:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/5\">",
"      Adachi JD, Adami S, Gehlbach S, et al. Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women. Mayo Clin Proc 2010; 85:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/6\">",
"      Ahlborg HG, Johnell O, Turner CH, et al. Bone loss and bone size after menopause. N Engl J Med 2003; 349:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/7\">",
"      Wainwright SA, Marshall LM, Ensrud KE, et al. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 2005; 90:2787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/8\">",
"      Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 2004; 164:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/9\">",
"      Schuit SC, van der Klift M, Weel AE, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 2004; 34:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/10\">",
"      Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002; 359:1929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/11\">",
"      Kanis JA, Johnell O, Oden A, et al. Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 2002; 30:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/12\">",
"      Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int 2005; 16:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/13\">",
"      Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994; 843:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/14\">",
"      Stone KL, Seeley DG, Lui LY, et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res 2003; 18:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/15\">",
"      Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005; 20:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/16\">",
"      Leslie WD, Tsang JF, Caetano PA, et al. Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice. J Clin Endocrinol Metab 2007; 92:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/17\">",
"      Black DM, Cummings SR, Genant HK, et al. Axial and appendicular bone density predict fractures in older women. J Bone Miner Res 1992; 7:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/18\">",
"      Kanis JA, Gl&uuml;er CC. An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int 2000; 11:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/19\">",
"      Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 1993; 341:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/20\">",
"      Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/21\">",
"      Cranney A, Jamal SA, Tsang JF, et al. Low bone mineral density and fracture burden in postmenopausal women. CMAJ 2007; 177:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/22\">",
"      Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007; 18:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/23\">",
"      Kanis JA, Johnell O, Oden A, et al. Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 2000; 27:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/24\">",
"      Kanis JA, Oden A, Johnell O, et al. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 2001; 12:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/25\">",
"      Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008; 19:385.",
"     </a>",
"    </li>",
"    <li>",
"     WHO Fracture Risk Assessment Tool (FRAX). file://www.shef.ac.uk/FRAX (Accessed on June 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/27\">",
"      Leslie WD, Lix LM, Johansson H, et al. Does osteoporosis therapy invalidate FRAX for fracture prediction? J Bone Miner Res 2012; 27:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/28\">",
"      Ensrud KE, Lui LY, Taylor BC, et al. A comparison of prediction models for fractures in older women: is more better? Arch Intern Med 2009; 169:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/29\">",
"      Hippisley-Cox J, Coupland C. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ 2009; 339:b4229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/30\">",
"      Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 2008; 19:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/31\">",
"      Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008; 19:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/32\">",
"      Kanis JA, Borgstrom F, Zethraeus N, et al. Intervention thresholds for osteoporosis in the UK. Bone 2005; 36:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/33\">",
"      Kanis JA, Borgstr&ouml;m F, Johnell O, et al. Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int 2005; 16:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/34\">",
"      Borgstr&ouml;m F, Johnell O, Kanis JA, et al. Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics 2004; 22:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/35\">",
"      Kanis JA, Borgstrom F, Johnell O, Jonsson B. Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 2004; 15:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/36\">",
"      Borgstr&ouml;m F, Johnell O, Kanis JA, et al. At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 2006; 17:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/37\">",
"      Dawson-Hughes B, Tosteson AN, Melton LJ 3rd, et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 2008; 19:449.",
"     </a>",
"    </li>",
"    <li>",
"     The International Society for Clinical Densitometry, International Osteoporosis Foundation. 2010 Official Positions on FRAX. file://www.iscd.org/Visitors/pdfs/Official%20Positions%20ISCD-IOF%20FRAX.pdf (Accessed on July 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/39\">",
"      Leslie WD, Lix LM, Johansson H, et al. Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporos Int 2011; 22:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/40\">",
"      Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 2011; 22:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/41\">",
"      Bauer DC, Gl&uuml;er CC, Genant HK, Stone K. Quantitative ultrasound and vertebral fracture in postmenopausal women. Fracture Intervention Trial Research Group. J Bone Miner Res 1995; 10:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/42\">",
"      Schott AM, Weill-Engerer S, Hans D, et al. Ultrasound discriminates patients with hip fracture equally well as dual energy X-ray absorptiometry and independently of bone mineral density. J Bone Miner Res 1995; 10:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/43\">",
"      Khaw KT, Reeve J, Luben R, et al. Prediction of total and hip fracture risk in men and women by quantitative ultrasound of the calcaneus: EPIC-Norfolk prospective population study. Lancet 2004; 363:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/44\">",
"      Bauer DC, Gl&uuml;er CC, Cauley JA, et al. Broadband ultrasound attenuation predicts fractures strongly and independently of densitometry in older women. A prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1997; 157:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/45\">",
"      Hans D, Dargent-Molina P, Schott AM, et al. Ultrasonographic heel measurements to predict hip fracture in elderly women: the EPIDOS prospective study. Lancet 1996; 348:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/46\">",
"      Gl&uuml;er CC, Eastell R, Reid DM, et al. Association of five quantitative ultrasound devices and bone densitometry with osteoporotic vertebral fractures in a population-based sample: the OPUS Study. J Bone Miner Res 2004; 19:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/47\">",
"      Stewart A, Torgerson DJ, Reid DM. Prediction of fractures in perimenopausal women: a comparison of dual energy x ray absorptiometry and broadband ultrasound attenuation. Ann Rheum Dis 1996; 55:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/48\">",
"      Thompson P, Taylor J, Fisher A, Oliver R. Quantitative heel ultrasound in 3180 women between 45 and 75 years of age: compliance, normal ranges and relationship to fracture history. Osteoporos Int 1998; 8:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/49\">",
"      Mar&iacute;n F, Gonz&aacute;lez-Mac&iacute;as J, D&iacute;ez-P&eacute;rez A, et al. Relationship between bone quantitative ultrasound and fractures: a meta-analysis. J Bone Miner Res 2006; 21:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/50\">",
"      Seeley DG, Browner WS, Nevitt MC, et al. Which fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures Research Group. Ann Intern Med 1991; 115:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/51\">",
"      Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991; 114:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/52\">",
"      Cummings SR, Black DM, Nevitt MC, et al. Appendicular bone density and age predict hip fracture in women. The Study of Osteoporotic Fractures Research Group. JAMA 1990; 263:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/53\">",
"      Picard D, Brown JP, Rosenthall L, et al. Ability of peripheral DXA measurement to diagnose osteoporosis as assessed by central DXA measurement. J Clin Densitom 2004; 7:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/54\">",
"      Kung AW, Lee KK, Ho AY, et al. Ten-year risk of osteoporotic fractures in postmenopausal Chinese women according to clinical risk factors and BMD T-scores: a prospective study. J Bone Miner Res 2007; 22:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/55\">",
"      Leslie WD, Morin S, Lix LM, et al. Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporos Int 2012; 23:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/56\">",
"      Cauley JA, Hochberg MC, Lui LY, et al. Long-term risk of incident vertebral fractures. JAMA 2007; 298:2761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/57\">",
"      De Laet CE, Van Hout BA, Burger H, et al. Hip fracture prediction in elderly men and women: validation in the Rotterdam study. J Bone Miner Res 1998; 13:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/58\">",
"      Khosla S. High-trauma fractures and bone mineral density. JAMA 2007; 298:2418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/59\">",
"      Sanders KM, Pasco JA, Ugoni AM, et al. The exclusion of high trauma fractures may underestimate the prevalence of bone fragility fractures in the community: the Geelong Osteoporosis Study. J Bone Miner Res 1998; 13:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/60\">",
"      Mackey DC, Lui LY, Cawthon PM, et al. High-trauma fractures and low bone mineral density in older women and men. JAMA 2007; 298:2381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/61\">",
"      Huang C, Ross PD, Wasnich RD. Short-term and long-term fracture prediction by bone mass measurements: a prospective study. J Bone Miner Res 1998; 13:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/62\">",
"      Melton LJ 3rd, Crowson CS, O'Fallon WM, et al. Relative contributions of bone density, bone turnover, and clinical risk factors to long-term fracture prediction. J Bone Miner Res 2003; 18:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/63\">",
"      Hillier TA, Stone KL, Bauer DC, et al. Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women: the study of osteoporotic fractures. Arch Intern Med 2007; 167:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/64\">",
"      Kanis JA, Johnell O, Oden A, et al. Prediction of fracture from low bone mineral density measurements overestimates risk. Bone 2000; 26:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/65\">",
"      Duppe H, Gardsell P, Nilsson B, Johnell O. A single bone density measurement can predict fractures over 25 years. Calcif Tissue Int 1997; 60:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/66\">",
"      Binkley N, Bilezikian JP, Kendler DL, et al. Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference. J Clin Densitom 2006; 9:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/67\">",
"      Dobnig H, Piswanger-S&ouml;lkner JC, Obermayer-Pietsch B, et al. Hip and nonvertebral fracture prediction in nursing home patients: role of bone ultrasound and bone marker measurements. J Clin Endocrinol Metab 2007; 92:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/68\">",
"      Hodson J, Marsh J. Quantitative ultrasound and risk factor enquiry as predictors of postmenopausal osteoporosis: comparative study in primary care. BMJ 2003; 326:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/69\">",
"      Stewart A, Reid DM. Quantitative ultrasound or clinical risk factors--which best identifies women at risk of osteoporosis? Br J Radiol 2000; 73:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/70\">",
"      Yamada M, Ito M, Hayashi K, et al. Dual energy X-ray absorptiometry of the calcaneus: comparison with other techniques to assess bone density and value in predicting risk of spine fracture. AJR Am J Roentgenol 1994; 163:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/71\">",
"      Pacifici R, Rupich R, Griffin M, et al. Dual energy radiography versus quantitative computer tomography for the diagnosis of osteoporosis. J Clin Endocrinol Metab 1990; 70:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/72\">",
"      Genant HK, Engelke K, Fuerst T, et al. Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res 1996; 11:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/73\">",
"      Mackey DC, Eby JG, Harris F, et al. Prediction of clinical non-spine fractures in older black and white men and women with volumetric BMD of the spine and areal BMD of the hip: the Health, Aging, and Body Composition Study*. J Bone Miner Res 2007; 22:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/74\">",
"      Sornay-Rendu E, Boutroy S, Munoz F, Delmas PD. Alterations of cortical and trabecular architecture are associated with fractures in postmenopausal women, partially independent of decreased BMD measured by DXA: the OFELY study. J Bone Miner Res 2007; 22:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/75\">",
"      Boutroy S, Bouxsein ML, Munoz F, Delmas PD. In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab 2005; 90:6508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/76\">",
"      Majumdar S, Link TM, Augat P, et al. Trabecular bone architecture in the distal radius using magnetic resonance imaging in subjects with fractures of the proximal femur. Magnetic Resonance Science Center and Osteoporosis and Arthritis Research Group. Osteoporos Int 1999; 10:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/77\">",
"      Yang L, Peel N, Clowes JA, et al. Use of DXA-based structural engineering models of the proximal femur to discriminate hip fracture. J Bone Miner Res 2009; 24:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/78\">",
"      Orwoll ES, Marshall LM, Nielson CM, et al. Finite element analysis of the proximal femur and hip fracture risk in older men. J Bone Miner Res 2009; 24:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/79\">",
"      Siris ES, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 2001; 286:2815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/80\">",
"      Blake GM, Fogelman I. Peripheral or central densitometry: does it matter which technique we use? J Clin Densitom 2001; 4:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/81\">",
"      Eastell, R, Wahner, HW, O'Fallon, WM, et al. Unequal decrease in bone density of lumbar spine and ultradistal radius in Colles' and vertebral fracture syndromes. J Clin Invest 1989; 83:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/82\">",
"      Melton, LJ III, Atkinson, EJ, O'Fallon, WM, et al. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993; 8:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/83\">",
"      Cummings SR, Black D. Bone mass measurements and risk of fracture in Caucasian women: a review of findings from prospective studies. Am J Med 1995; 98:24S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/84\">",
"      Miller PD, Barlas S, Brenneman SK, et al. An approach to identifying osteopenic women at increased short-term risk of fracture. Arch Intern Med 2004; 164:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/85\">",
"      Miller PD, Siris ES, Barrett-Connor E, et al. Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment. J Bone Miner Res 2002; 17:2222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/86\">",
"      Robbins J, Aragaki AK, Kooperberg C, et al. Factors associated with 5-year risk of hip fracture in postmenopausal women. JAMA 2007; 298:2389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/87\">",
"      Liu H, Paige NM, Goldzweig CL, et al. Screening for osteoporosis in men: a systematic review for an American College of Physicians guideline. Ann Intern Med 2008; 148:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/88\">",
"      Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/89\">",
"      Sambrook PN, Flahive J, Hooven FH, et al. Predicting fractures in an international cohort using risk factor algorithms without BMD. J Bone Miner Res 2011; 26:2770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/90\">",
"      Kanis JA, Johnell O, Oden A, et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001; 12:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/91\">",
"      Center JR, Bliuc D, Nguyen TV, Eisman JA. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 2007; 297:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/92\">",
"      Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000; 15:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/93\">",
"      Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004; 35:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/94\">",
"      Hodsman AB, Leslie WD, Tsang JF, Gamble GD. 10-year probability of recurrent fractures following wrist and other osteoporotic fractures in a large clinical cohort: an analysis from the Manitoba Bone Density Program. Arch Intern Med 2008; 168:2261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/95\">",
"      Gehlbach S, Saag KG, Adachi JD, et al. Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women. J Bone Miner Res 2012; 27:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/96\">",
"      Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/97\">",
"      Ensrud KE, Cauley J, Lipschutz R, Cummings SR. Weight change and fractures in older women. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1997; 157:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/98\">",
"      Ensrud KE, Lipschutz RC, Cauley JA, et al. Body size and hip fracture risk in older women: a prospective study. Study of Osteoporotic Fractures Research Group. Am J Med 1997; 103:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/99\">",
"      Langlois JA, Visser M, Davidovic LS, et al. Hip fracture risk in older white men is associated with change in body weight from age 50 years to old age. Arch Intern Med 1998; 158:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/100\">",
"      Green AD, Col&oacute;n-Emeric CS, Bastian L, et al. Does this woman have osteoporosis? JAMA 2004; 292:2890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/101\">",
"      Langlois JA, Harris T, Looker AC, Madans J. Weight change between age 50 years and old age is associated with risk of hip fracture in white women aged 67 years and older. Arch Intern Med 1996; 156:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/102\">",
"      Meyer HE, Falch JA, O'Neill T, et al. Height and body mass index in Oslo, Norway, compared to other regions of Europe: do they explain differences in the incidence of hip fracture? European Vertebral Osteoporosis Study Group. Bone 1995; 17:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/103\">",
"      Villareal DT, Fontana L, Weiss EP, et al. Bone mineral density response to caloric restriction-induced weight loss or exercise-induced weight loss: a randomized controlled trial. Arch Intern Med 2006; 166:2502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/104\">",
"      Ward KD, Klesges RC. A meta-analysis of the effects of cigarette smoking on bone mineral density. Calcif Tissue Int 2001; 68:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/105\">",
"      Kanis JA, Johnell O, Oden A, et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int 2005; 16:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/106\">",
"      Kanis JA, Johansson H, Johnell O, et al. Alcohol intake as a risk factor for fracture. Osteoporos Int 2005; 16:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/107\">",
"      Berg KM, Kunins HV, Jackson JL, et al. Association between alcohol consumption and both osteoporotic fracture and bone density. Am J Med 2008; 121:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/108\">",
"      Ensrud KE, Lui LY, Taylor BC, et al. Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med 2007; 167:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/109\">",
"      Jassal SK, von Muhlen D, Barrett-Connor E. Measures of renal function, BMD, bone loss, and osteoporotic fracture in older adults: the Rancho Bernardo study. J Bone Miner Res 2007; 22:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/110\">",
"      Mezuk B, Eaton WW, Golden SH. Depression and osteoporosis: epidemiology and potential mediating pathways. Osteoporos Int 2008; 19:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/111\">",
"      Gankam Kengne F, Andres C, Sattar L, et al. Mild hyponatremia and risk of fracture in the ambulatory elderly. QJM 2008; 101:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/112\">",
"      Schulz E, Arfai K, Liu X, et al. Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 2004; 89:4246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/113\">",
"      Schett G, Kiechl S, Weger S, et al. High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med 2006; 166:2495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/114\">",
"      Cauley JA, Danielson ME, Boudreau RM, et al. Inflammatory markers and incident fracture risk in older men and women: the Health Aging and Body Composition Study. J Bone Miner Res 2007; 22:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/115\">",
"      Gregg EW, Cauley JA, Seeley DG, et al. Physical activity and osteoporotic fracture risk in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1998; 129:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/116\">",
"      van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 2004; 350:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/117\">",
"      McLean RR, Jacques PF, Selhub J, et al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 2004; 350:2042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/118\">",
"      Dhonukshe-Rutten RA, Pluijm SM, de Groot LC, et al. Homocysteine and vitamin B12 status relate to bone turnover markers, broadband ultrasound attenuation, and fractures in healthy elderly people. J Bone Miner Res 2005; 20:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/119\">",
"      Sato Y, Iwamoto J, Kanoko T, Satoh K. Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease. Am J Med 2005; 118:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/120\">",
"      Gerdhem P, Ivaska KK, Isaksson A, et al. Associations between homocysteine, bone turnover, BMD, mortality, and fracture risk in elderly women. J Bone Miner Res 2007; 22:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/121\">",
"      P&eacute;rier MA, Gineyts E, Munoz F, et al. Homocysteine and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int 2007; 18:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/122\">",
"      McLean RR, Jacques PF, Selhub J, et al. Plasma B vitamins, homocysteine, and their relation with bone loss and hip fracture in elderly men and women. J Clin Endocrinol Metab 2008; 93:2206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/123\">",
"      Leboff MS, Narweker R, LaCroix A, et al. Homocysteine levels and risk of hip fracture in postmenopausal women. J Clin Endocrinol Metab 2009; 94:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/124\">",
"      Lloyd T, Rollings N, Eggli DF, et al. Dietary caffeine intake and bone status of postmenopausal women. Am J Clin Nutr 1997; 65:1826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/125\">",
"      Wu CH, Yang YC, Yao WJ, et al. Epidemiological evidence of increased bone mineral density in habitual tea drinkers. Arch Intern Med 2002; 162:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/126\">",
"      Barrett-Connor E, Chang JC, Edelstein SL. Coffee-associated osteoporosis offset by daily milk consumption. The Rancho Bernardo Study. JAMA 1994; 271:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/127\">",
"      Kim SH, Morton DJ, Barrett-Connor EL. Carbonated beverage consumption and bone mineral density among older women: the Rancho Bernardo Study. Am J Public Health 1997; 87:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/128\">",
"      Tucker KL, Morita K, Qiao N, et al. Colas, but not other carbonated beverages, are associated with low bone mineral density in older women: The Framingham Osteoporosis Study. Am J Clin Nutr 2006; 84:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/129\">",
"      Christiansen C, Riis BJ, R&oslash;dbro P. Prediction of rapid bone loss in postmenopausal women. Lancet 1987; 1:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/130\">",
"      Hansen MA, Overgaard K, Riis BJ, Christiansen C. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ 1991; 303:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/131\">",
"      Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000; 15:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/132\">",
"      Delmas PD, Eastell R, Garnero P, et al. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 2000; 11 Suppl 6:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/133\">",
"      Johnell O, Kanis JA, Black DM, et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. J Bone Miner Res 2004; 19:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/42/29354/abstract/134\">",
"      Srivastava AK, Vliet EL, Lewiecki EM, et al. Clinical use of serum and urine bone markers in the management of osteoporosis. Curr Med Res Opin 2005; 21:1015.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2061 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-0AA24E0359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_42_29354=[""].join("\n");
var outline_f28_42_29354=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ASSESSMENT OF FRACTURE RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Expression of fracture risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Fracture risk assessment tool",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Clinical application of fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2003321\">",
"      - Limitations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      METHODS OF MEASUREMENT OF BMD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dual-energy x-ray absorptiometry (DXA)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Fracture prediction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Follow-up BMD testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Peripheral DXA (pDXA)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Quantitative ultrasonography (QUS)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Fracture prediction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Quantitative computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Emerging technologies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Older technologies for measuring BMD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SKELETAL SITE TO MEASURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CLINICAL RISK FACTOR ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Advanced age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Personal history of fracture as an adult",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Glucocorticoid therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      History of fragility fracture in a first-degree relative",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Low body weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Cigarette smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Excessive alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Medical diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Other risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Possible risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Bone turnover markers (BTMs)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Fracture prediction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Bone mineral density",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Assessment of clinical risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2061\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2061|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/31/24062\" title=\"figure 1\">",
"      Fracture probability age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/42/37550\" title=\"figure 2\">",
"      Bone markers and bone loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/59/9150\" title=\"figure 3\">",
"      BMD bone markers and hip fx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2061|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/21/2395\" title=\"table 1\">",
"      Risk factors for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/24/18827\" title=\"table 2\">",
"      RR vs absolute risk fx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/12/14539\" title=\"table 3\">",
"      Relative Risk of fracture",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/26/11687?source=related_link\">",
"      Bone disease in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17593?source=related_link\">",
"      Bone disease with hyperthyroidism and thyroid hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40040?source=related_link\">",
"      Calcium requirements in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36213?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11128?source=related_link\">",
"      Diagnosis and evaluation of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=related_link\">",
"      Drugs that affect bone metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/25/6553?source=related_link\">",
"      Epidemiology and etiology of premenopausal osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=related_link\">",
"      Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22602?source=related_link\">",
"      Falls in older persons: Risk factors and patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30569?source=related_link\">",
"      Metabolic bone disease in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42583?source=related_link\">",
"      Overview of dual-energy x-ray absorptiometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18954?source=related_link\">",
"      Overview of the systemic and nonarticular manifestations of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=related_link\">",
"      Pathogenesis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=related_link\">",
"      Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8202?source=related_link\">",
"      Patterns of relapse and long-term complications of therapy in breast cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33113?source=related_link\">",
"      Prevention of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40393?source=related_link\">",
"      Screening for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=related_link\">",
"      Side effects of androgen deprivation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=related_link\">",
"      Treatment of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44487?source=related_link\">",
"      Use of biochemical markers of bone turnover in osteoporosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_42_29355="Causes of wide QRS tach";
var content_f28_42_29355=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of a wide QRS complex tachycardia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Ventricular tachycardia (VT)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Any type of supraventricular tachycardia (SVT) with a",
"preexistant bundle branch block or a rate-related (functional) bundle",
"branch block",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sinus tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Atrial tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Atrial flutter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Atrioventricular nodal reentrant tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Atrioventricular reentrant tachycardia (orthodromic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any SVT which occurs in a patient receiving an antiarrhythmic drug, primarily class IA or IC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Any SVT with antegrade conduction via an accessory pathway (Wolff-Parkinson-White syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sinus tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Atrial tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Atrial flutter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Atrioventricular reentrant tachycardia (antidromic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electronic pacemaker in certain specific settings",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_42_29355=[""].join("\n");
var outline_f28_42_29355=null;
var title_f28_42_29356="Clinical features of preseptal and orbital cellulitis";
var content_f28_42_29356=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F55123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F55123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of preseptal and orbital cellulitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"40%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"30\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical feature",
"       </td>",
"       <td class=\"subtitle1\">",
"        Preseptal cellulitis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Orbital cellulitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eyelid swelling with or without erythema",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eye pain/tenderness",
"       </td>",
"       <td>",
"        May be present",
"       </td>",
"       <td>",
"        Yes; may cause deep eye pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain with eye movements",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proptosis",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Usually, but may be subtle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ophthalmoplegia +/- diplopia",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vision impairment",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        May be present*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chemosis",
"       </td>",
"       <td>",
"        Rarely present",
"       </td>",
"       <td>",
"        May be present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever",
"       </td>",
"       <td>",
"        May be present",
"       </td>",
"       <td>",
"        Usually present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukocytosis",
"       </td>",
"       <td>",
"        May be present",
"       </td>",
"       <td>",
"        May be present",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * An afferent pupillary defect may signal impending visual loss.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Seltz LB, Smith J, Durairaj VD, et al. Microbiology and antibiotic management of orbital cellulitis. Pediatrics 2011; 127:e566.",
"      </li>",
"      <li>",
"       Durand ML. Periocular infections. In: Principles and Practice of Infectious Diseases, 7th ed, Mandell GL, Bennett, et al. (Eds), Churchill Livingstone Elsevier, Philadelphia 2010. p.1569.",
"      </li>",
"      <li>",
"       Chaudhry IA, Shamsi FA, Elzaridi E, et al. Inpatient preseptal cellulitis: experience from a tertiary eye care centre. Br J Ophthalmol 2008; 92:1337.",
"      </li>",
"      <li>",
"       Botting AM, McIntosh D, Mahadevan M. Paediatric pre- and post-septal peri-orbital infections are different diseases. A retrospective review of 262 cases. Int J Pediatr Otorhinolaryngol 2008; 72:377.",
"      </li>",
"      <li>",
"       Nageswaran S, Woods CR, Benjamin DK Jr, et al. Orbital cellulitis in children. Pediatr Infect Dis J 2006; 25:695.",
"      </li>",
"      <li>",
"       Sobol SE, Marchand J, Tewfik TL, et al. Orbital complications of sinusitis in children. J Otolaryngol 2002; 31:131.",
"      </li>",
"      <li>",
"       Givner LB. Periorbital versus orbital cellulitis. Pediatr Infect Dis J 2002; 21:1157.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_42_29356=[""].join("\n");
var outline_f28_42_29356=null;
var title_f28_42_29357="Resiliency strategies LD";
var content_f28_42_29357=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Strategies to enhance resilience and success in children and adolescents with learning disabilities",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Exhibit belief in the child's or adolescent's positive attributes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Find words to describe the attributes of the child or adolescent in positive terms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Identify the child's or adolescent's areas of strength and highlight those skills and their contribution to the family's well-being",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Accept the unique pattern of the child's or adolescent's strengths and weaknesses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Emphasize effort rather than achievement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Emphasize the value of education",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Establish realistic expectations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Praise success and avoid frustration by matching tasks to the child's or adolescent's level of functioning and interests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Align expectations with child's or adolescent's capabilities, considering personal temperament, moral development, and learning style",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Communicate realistic expectations and celebrate effort to achieve a skill or goal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prepare the child or adolescent for new situations to ensure success",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Match expectations to child's or adolescent's temperament",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Teach socially acceptable methods of requesting information or stating personal desires",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recognize the individual's unique learning style",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monitor books that the child chooses to read independently to prevent undue frustration; helping the child to choose books at his or her \"independent\" reading level (99 percent accuracy); reading the age-appropriate books that are beyond the child's independent reading level aloud to the child",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use many senses to assist a child to learn information",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Provide the child or adolescent with the opportunity to assume responsibility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encourage independence (in situations where the child or adolescent is likely to be successful) to enhance self-esteem",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Give the individual household and personal tasks that are within the ability of the individual",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Permit the individual to experience the management of money, considering age and ability to self-regulate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assist children and adolescents to manage their modes of transportation independently, as appropriate for age and level of self-regulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encourage decision-making",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Improve social skills and provide opportunities for successful social interaction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keep children abreast of current events",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Involve children in community service",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encourage activities of interest rather than age outside of home and school",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid intensive competition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Be consistent about rules and limits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keep rules to a minimum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seek to educate and negotiate rather than dictate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apply logical consequences",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use positive reinforcement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use rewards only when needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reward effort and initiative, as well as achievement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Enhance family dynamics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Permit parents to provide support for each other as they navigate educational decisions, school communication, advocate for their child, and make social decisions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use a team approach to parenting, including shared responsibility for decision-making and child management",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Give siblings adequate time and attention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Listen to feelings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Look for outside support when necessary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Parent support groups",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Individual, marriage, and family counseling",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Smith C, Strick L. Strategies for Promoting Personal Success. In: Learning Disabilities: A to Z: A parent's complete guide to learning disabilities from preschool to adulthood, The Free Press, a division of Simon &amp; Schuster, Inc., New York 1997. p.257.",
"     <br/>",
"     <ol>",
"      <li>",
"       Lock RH, Janas M. Build Resiliency. Intervention in School &amp; Clinic 2002; 38:117.",
"      </li>",
"      <li>",
"       Lerner J. Learning Disabilities: Theories, Diagnosis, and Teaching Strategies, Houghton Mifflin Company, Boston 2000.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_42_29357=[""].join("\n");
var outline_f28_42_29357=null;
var title_f28_42_29358="Nasolacrimal duct cyst";
var content_f28_42_29358=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bilateral nasolacrimal duct cysts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomography image of bilateral nasal lacrimal duct cysts (c) causing upper airway obstruction in this neonate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_42_29358=[""].join("\n");
var outline_f28_42_29358=null;
var title_f28_42_29359="2D TTE Parasternal short axis coronary arteries";
var content_f28_42_29359=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Two-dimensional transthoracic echocardiogram (2D TTE) from the parasternal short axis view at the level of the coronary arteries",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 260px; height: 261px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEFAQQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5mMgB4XA/L+VKHy3IHNRA+poOeevStnYESF8sMhenoKQyZ7DP0zmo89aMgqaLoB5k9Qp5z0o385xlvU96YTntSfgRSbsIXPHFKGwOMUw9D296M+o4/KlzXGPLZHIA/DvSZpucY7mg8H8P8n60czAdnnpTk5YDApnc454ra0jw5q+q29vPY6fcTWs90LFJlT5DMQCI93rgg/SqTbFsdT4e+FHirX/C0fiDS9OW4sZSwjRZF81wrbSVTqeQenpVB/hz4u3lD4Z1jdnHFk/+FfZ/gPZpvh3TNJSC5UWMEcOGt2UhAMZ4xyTnP5116lWPBOU4wD/OiU+TSUSUnLVM+JLH4HeNLnRLi+bTWjdF3R25z5k3qAOxA55/nXl9xC8MrxyIyMhKsrDBU9wfev0uAx0+tfLn7TPw5I8Q6bqnhrT1eTU28iW1to/nebOQ4HfP9KqMlU0irNfiDTg1fZnzdnijdgf/AFqfdQSW1xJbzo0c0TlHRuqsDgg/Qiowe4qG2tChWbjgD/Gr+t6W+kzWySSxyi4tYrpGTptkXcB9R0/Cs49OPxzW94hNxJ4d8M3EykJ9llhjcnO9VmcfpkD8KI6piejRzG9v7x/Ojcx6sfzptFZ3KHF2OcsTnrzS724+Y8e9MopAO3tnO459c0u9+Pmbj3plFADy7nqzH8aQOwIIY5HfNNooAeXYjBY4+tJub+8fzptFAD/McDh2wevNJvbGNxx9abRQA7c394/nRTaKALoz2pSR9KToCRmlPXGMnFbPYSG96Pzoz3wPzoPHAGBUgHPr370hGc4+lBOF4+Xjr/n8KG4OP5UmMb1OQBgflQORx680vOeoPpTR93J69vpSQxeDx60Hg88Z6ik5PrnpTjgADtQA70HTFdN4X068u7bzUup4rdJCyxxOQdwAG8Dp3Az/AIVg21lcXJhMcT7JZVgWQqQgc443dM85xXt+p+DvFfhGzFjqJh/sdI8RSWhWVnX2I5xk85FdGHpqUrSMasnGN0aHwo8beIre9/sl7l0sZEZRLP8AvWXGeh+vrX0Dpsmv/wBnJeXFxDcb0Vj5Ixu4+8PXivmCC5FnYLe3Gqi11Jpyu2RQCUx94e39RV22+K2r2+pRpJr1zqtkqGJ7d0CoR2JI55zitqlGKStYyhVb3ufWsEqHdMZ0KooV1A5Bx3/OvNvjH4fm1qxujBvaYwGKORWKCLuWPuPUVwGheNvEfiENb2ETW3lqZYpV+aQR9gc+nvW/HomtzXAj1bxJfahA+Xa0jK4EhPAyOgPelRoOnLmurDqVeeNkj5G1G3ks9QuLeZ1eWKQozqc7iD1z3qsOR261618WvCmpymXVl0+GKO0zHKIAAFQE4Zjnk/rXlN5a3NnIsV5bTW7socJNGUJUjIOD2PXPesK9N05WWxrTnzrzIGIxz+hpzTStDHE8hMSZKL2XPXFRMeT70h6An0rGxqRUUUVIgooooAKKKKACiiigAooooAKKKKACiiigC6OMUdO3NA4o7YrZ7CQnbn/JoAB780Y6cZpeuMGpQDSc+oBA/wD1UcAY6jvSEjHHb1o9MfpUsYhHbpim54Jxz7U4fXI9KTqMHgUFIAevHSnA+x5700Ek/wA6liTzJVSPliQoAyadhPQ2dG1OaOzFletczaPHMbj7Oj4RZyoXzMeuABXRXWuXcOnBdP1GWKyLbTtfcwY8kZPOOlW/Dmn6N9hktNRe5aZFJjSOPndjoe9dX/wh8mtaXbT2Wl6W+4ABkuShZuwKkgCu6FLljbQ4pz5nseZvGVKSfaUkVkLM82CC3XA781paXrdnYuqLBZo0hLSNKpYg+o9B9Kq+JPCuo6fqjRTxW1uR1VZQwUfXPNZElpFJmKCVpLhflbO0Kcc/KT+NK8oPRWKtGS1Z3MXii8cQz2979mQJ5UrJxhfcj1/OvWbL4k6N4d8GxrFfW8up3cQLR28RIhXHBZmGSc18zw3EtvMsJCvHu3FG6E9Oa6GXUJtQiCSNbpGgIjDABf8AeyOT9Kanz6Pclx5dg8ReJdWlZ4ZrlZYrgmRo0+4zMepHriuX1fVb/V7pbjU7ya7uEjWESTNuIRRhVHsB0qC4YkENIrncfz9qgYALkY57Vy1XzO50U4qKGMef5ZpCKD1xnpQfYGszUjoooqBBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAF0dc4ozwCORjrQP8AIpAeMnp39q1ewgxxQeuPem9AOceho43dOeOMZqB2FPf+YPSk7HJJX0B4pD3/AIj3FAz1JJ9h/hQxhwOn5djSYHHIx6UEE5OO/wCdKAMYbOaQwGBkiul0W+vzDbKlsr21nG8SvHbruAZt7bpMZznoxOR0Fc0ilmG0kn+tdrF9mt9Kgk0uYl9m24RWbJbtuQ8H8BiuihG7vcwrOyNh9fsZJhMbMtMyYE9uCXT1Df41csdWsoTHcXBkkWHlVZtu706YOa5WwuIIIpxd3VzDCx+ZVhUvux1zjGPY1TE1obxWvSZoRgKynB+pA6H8K6/aPqzn5CbXNVTWJ5FWFolUsYyX+5k5xknmuaLFehxz69P85rW1R7BZybJzJGckEjBQn69azRE0sDMBHhTjJZV/SuWq+Z76nRCyXkRqxVg24AjmrCTB5JDI8bEjI4wM/h0qpKvltt/jHGAc/wD66IwqscvyOm0ZzWUW07GjSauXWsy8bSquYlwGZWGBVEkL/DxV1lmhgBKOASCCTz09PSqMp5+UdeuRV1ETHUu3ur3V1o9hpkrRG0smkaACJAwLnLZYDc3PqTjtWd3OKVVBBJOD2GOtN9+1Zmi0GUUUVmIKKKKACiiigAooooAKKKKACiiigAooooAu+tJil7cUh7+3NaS2EJ6nNB+n09KOhP50ADHcGoGIW54AJ9u1GTnvgZzxigncehNBweh7/Wmxjcbjwc+x70q98c+uP/rUD5iucnPTmtfwzot1r2tWemWEMk89xIFCRjJx3P5d6aTbsDY+0a9v5bNpI9yRRrbROkCgbASew+Y89eTV6e+uLe6ea2+zxLH8rIi5GfxGc/Svqv4e/DRNIns7yP7KLcYZLaaPMsB9eeDnr3q7438AeGtT8T2j6lolnG0lyWQwyFTdqsTM4kVSAvzACuz3Y+6nqczu/eaPkvU75r6NZLqaSPaApj8ocn6gfzrNjso1C+ZP5dtLnEhiY5Pp0zX1D4b8E+HvENzdXEGgNFbyeTaGCEl1t5GU7phkn5AQvX1PHSvHNd8JvE88cOPJjmdVRY3bbtOOcfnxWrpufm1/Xf5Gako7bM88ltzH8s7s0RzgiEqc468jNdh4I0rwDc29y3i3UdZt5QoMEdumNx75Owj+Vc+0B2TW94z4QfumwwYn0/8A11FYRI8FyL0S7kTepAIJPp+XrWNtdi29DM1GG2ivZhYytNAHPllh82M8Z96pSb1UFiMHkeoqdmAJCKAATg85x6VDJk9ea55tXN47CeazsTIzMfXNDdsHAPXODQgUEfKc/X9Kkcp5eFQ7h15yPpU6DbsVe9aVvrV/baPe6VbzhLC8kjlniEa/O0edhzjIxuPAOOaziOTx9R6UcdqB7kdFFFZgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAXKOD60D64/xpvUdKtvQAzg9fzpOcnAHPT0oyR14zige/UipGHfk/59aUZGM9uCabjr0xnpS8HovP6UwH4/DOa+rfgWvhfU7u2vtA0O602/i06K1lldlImcf6yRRkn5j34OK+XNJszf6jBbh44/MfaWkbCqO5ya+nPh5bXul3FodCv7K8smUJHDI6rJbnHY/xV0UKbkmzCrJJpHu8VvPYsC9wzrnOWwAfbceBWFf2vn6oL2TU7K3xcedFHLG2V+Xa6g9wwPOPwqeY63r2mwLbCG1jdjHcmZfmAHdc8HPrVdfBVzviU6zJcWsWVENwgc4PUBsZFKNo/FKzBtvaN0X4/Dt9FOktne2ttbiWGVYoUdVAjUgJkfeU55zVn/hFdPm0m2sruNXaJNrSRDaXJ5JrLtPC2oac8j2NxC0RbcsEssjbfUKScD8a39B/tNbdk1co0oY4ZRjjsP8A69TOUoq8ZFxjF6SieXeKvguL+dpdF1CK0Rm+eMx5Yj/ePpXn1/8AALXZ5XMc0bZG0kOAWGeua+pgPzpkrLFGWc7VXk/Sn9bna0kmDoRWq0Pg/wAYfDHWvDk8qXsMa7T8qo25iD0NcFd20ttKY5VKsp54r9Hb6exmhEk0ls9owIdioOfbd2rxT4jaR4es7PUIU8GXmpM+WjvYpUQr6YB9PpVpQq7Jp/eZtyp7u6PkUgjgZPekYnOfStrWNHvbS6lLWk8cROVDDBA7VlRW8ksipFG8jngBVySfQCsZU3F2NYzTVytjk4HHtT1t5Su4IwX+8RxXpng3SfC3hqC41D4jWtzPc7c2emRMQxbsX9BXLeLvFc/iAwRm0tbS1t8rBDBHt2qTwCe9VyKK9/fsJTcn7p3fhT4NW2v+CtD1U6xeW9/q1tfXEa/Yg9rB9lcgiWXeCgYAYO09/TmkPhPbm60+8XV5D4auNAfXZb/yRui2DDw7c4LiQovX+L8K5TUPHet3fgrRvCwnFtpemCdVW3Z0a4E0m9hMN21sHpwMAnrViP4j67H8NJPA6m2OkNKZPMKHzlUuHMYbOAhcbiMZz37VjY0OKxRjFO/xpKdgsJijBpaWiwDcGjFKaKLCExSkYo+lAzmlYYmDijBpw6UlPlEJiilPJJ5oosgLXQkc+9N5yeen60p+uP6UdcYwPehgNOPp9TScDuBxxQDz68+tIOvpzQUL7ZxkVLAYlnjNwrGEMN4Q4bbnkA9M9aiJJelXk4/Gla4F+5W2l1K6bTo547JpnNusrBnWPPyhiOCcYyR3rt/BurzWBheRoZ1DAxqzbHU+n0rhbCYwTA7d6dGGcHHsexrqdJtLO8gYNKDHkFklT/V+4PrXXQXbc5ap9MeCPixDI0Nvq1lNYSSMVRi2+OXHGVNekeGNUXUmm23nzK5/dOm1mHrjr+NfIJmXTFt3hvru3XjOed6Z6LyR/KuwtPHMTSJb/ZpJmTa0UwBV9vp74+tazw0ZXtoRCrJWPq47xlWZRnIHHNQXF5HCjecdpXrtbke/0rnvB2sS3Ojpc3rW3lbfldTtYexXnn8ai8WapGdMuJtLawN0inK3ykBvYYrhjSfNys6nNct0yPxX450ax0u5eO9SdQCkixH5gCOea8d1X4iSQws2m3riz2gRRNNjYfqetY3i3xJqOs2KLaw2iysWDosQRVx7+n868S12/uZrpjJKgcH5kTkZ4ru5Y4eO1/U5eaVWW523iHxtq97qLXBv0Bz6lf0HBr074Q/FgXcg03xDbpdzzt5aF24A6dK+bHvZHt0iKp8pOGxya1fB+ty6NrdpdQ8urjPy5yP6Vk6qk7dC1T5Ufanif4ZaLrVjK0Nna29w43YVM5I7ZzXk9zoekfCXTbjX7FZLvxC4KQxNb+ZBCT1+lez/AA/8ZWviHT7aOZiuoNH5jLsAQjtg102p2FveWdyktvHI0kbIMoC3I7Z71EcROMuSr/X/AACnSjJOUD85vEOp3Ws6rc3+oEPdTuWc4wMn09B7VmlGJyy8deldh4+0qfRdfurG9t5LaaOQjLjPGeue9cpJgscliOoJoqwtJ3HTleKsQbcscevenJH13DJHOParsLW6hT5DS84wT145/wD102WEsSqRMvPGe9RyeZfPqVtQe2lv7iSxheC0aRjFE8m9kTPClsckDvVcVJKm1sYx6jNRVD1KWwDNKPrigdaOtIYlHalNJz26UAGaBRRSEKe9J+FFB9hVAAGe4/GijNFSBYGMA8dc00n9KcR14/Gg4yQPrz/WmMb0OKQnBOcZFBHX9O1Hfgj8qBot6VFZyX8CapPNbWLNiSaGMSMgx1CkjPOO9VkwD1yMdfSmnHPPvTwygDA/DNNCaJomMcgdWKsOVIq615ISsluwjk/iZBtz9fWs0DPA6frV63cJGZAEZu4I6e/tWsHfQzkupqWmpPAS4dlLnD5clc+vI4/Cung1u0uY1bUL6ZnQbFDLvX6Dnn8a5Oy1KQjEdvAwHBWQByw/GmSXLrI80VpFH82WaPA2H2/+tXTGfLt+RzyhfoetfD/xfpthfhbi9e0izjyymzcMYGCDxWn4s8U2t1GY9KM09srE/vZTHHnuO+frXjFrrAZDHLZQyOc/PtBJz6ZqaXxAk6eUYBbxtwylyUPuRj/GrVZJXbJdJ9EQ+JNTuZruVGZVjJztWQtjp19a59m59T3NXbxEM5CSwNzkFOB9BxS6To95rWpw2Gmx/abydwkUakKWPYc8Vx1LzlodMLRiZwJBPQmpYi24beWzxzWxc+E9Zt5pIZdPcSRsUYblPIOD39ax2jeKZ1fIdWKkZ6EcVEqcoW5lYpTjLZn0h+zRZ3c+u2+pXd5aLFCpjSGQkuc/3RivqMEEZBz9K+CPhx4mXSdWtzLcTq5cAOXIWP3wOtfcnhq6F9o1tcLI0qugO5lCE/gKMQk0pIVF2vGx5T+0H4B1PxWbe68PaVHcXCRn7TKHCscHoATzx6V81an8P/E9lZvd6ho+oxWy9JHhwF69c9K+/wDFeZ+IZbm6+JR0+4upnsVj85bUynyyyxF1ymcEbgDjv9M1rRn7VcslsjOpDkd09z5D0nSrhdNeVo4QQ2BuX5/bHH1rIlSaKZYmfzCTn5eg/GvsHw7pEfiK5udSm0i2FzcCGwm5EStDIMPcICMb/lGAOOPc15Trvwi1OecXlpDCbS5y0bBlXHOOQeB/+qunli/dT1RipNavqeKaktusUscaRtJnJkDcZ9BVTX49IjuohoUl7JbGCMyG7VVYTbR5gG3+HdnHfFd3rfgW4sZmScIsIydqfMc+7cj8ua43W9IlsR5pDGMnDcfcPbPpn3rGtRmvesa0qkXpcwsUVMQcr7dMUwrz647iuQ6RhGAeaQ9KeVA6nn+VHUYx/jTAYKKU0cUrAIaKX15zR3ApgN/CilA96KLCJ16fyoGQOVzSk8HOBnr/AI0mfQgn1pDE+nrwc4q5YWkd5JMsl3bWgjheUNOWAcqMhF2g/M3QZwPcDmqWcHn8c0o5OOpI4oBoCMEgcDvSYOevJByaCMZGB+NB/Uc0DAjABB4FPDblIPB659ajznjPfrQOvp9aYWJ2J24IGT3z0qSJwFwSQe3Gf8/hVZORjNBJU4GMY/KqUmtSHHoXo7qWPhHRxnptH9RTGnWUDzTnHTaoGKqKQGBJpxTeMqOB1GRT52xcqQ5wuRgj6HivSfgHEqfEKC7dVkNnaXV0sZwQzJA5X9e/avMiWVsZPX0zXqP7Ol41j8S7e58tJfJsbyTy36Ptt3bB+uKlPXYclpue76n4Rsda1TVrq6mltbm7WJ9Oih2hJp2txK6HjoMrycdetfImpsp1O7KkkGZyCfrX3K0x1HWIr6NY0j02WHUbxU4EUUlkACB1PIIwOcCvhjUB/wATG74x++f+ZrorTbgr+X9fr8zClFKTsXfDtzDbanbvcZMO8b8KGIGe2eK+7fhn4kste0VPsSzokQCgzBVLcdQAcfpXwbo12trfQSSBSiODtKBh1r62+FfxM0kWQtr0eW4GfMEcY49ggB/Ss3HnptLcpy5Zps9wHTv+dZepaMuoSI8t5cxmORZU8tYwVI6fNsyR7E8jg5rGt/HNtf3UVvpVjd3RY8uyFAozycHn9K3rqOe8tyqqYlZe5wze2O3FYqE6bV9DVyjNaamPeaPp8lyXuNYujJHNFPsUxfI8f3MKE4A9Mc981T1LQ21D+zLGDcdNg+eWWVissvOQOMcEk9h7U2Xw5q8urxyW91DYWWSJMBZJSuOxOf1zXYW8It4FQFnIABZ+ST7mtZVOS1pXM4Q5r3VkYeqeGtO1KIW4t1hjXGdsQA/AkdfcZ965rxR4K8Ead4Y1KPWYo7awki8uSXd+8DHowJB+bPSu5vPMS2lmnuWt440JJjC5Ax1yQRXyB8XviBdeJ7uTTUkMWj2rn5Ac+YR/Ezdz7Dj2p05VJL4tETUUFpbU8v8AEmnabpz2w0zVk1FpFZpUEDxm2IYgKxYAMcc5HFYhwBx0x61YvZFmuWZCSucZPf3qs2COevrWU7czsawvbUZnJxTSc8ccelK2cev07U08dO9BYfypKPU0tIAPPOaO/pQOaSqEAHuBRQSM+lFICxjDE/oDmmkfN6nsKdgd89Me1IDx36+nFJjRbs9OuLuzv7iExCKyjEku+UIcFgvyg8scnoO3NU9v8qMYb8ePejqVGDg0hjep4BzmlYDORn8aXPp+IzR0XvnFMBp9+vfNAyOhowcE9qMDmgaFAyDwBS9epOfehV7Zq3BZzyqHiidlPAIGapJt6EuSQ22txM2FdVY/3q6LQ/D8NxdRx6yZ7eJvuumMH86PD/hy4u75YdsZlJ+Xe20fSvp/4a/C2xgtYLnXbAz3AUFZBL5oUew7V1whGEeaf9fI5pScnaJ87698PJbdwdIla8iIzkISFPoWHFYmn2ms+HdUW6itZxLGrLwGwQykEHHsTxX33pGg2Wk2JsrS2XyCxb5gvGfw6Vekit4bck20TKMZAiXn9KyqVqN7xTXpp/wxcadS1mz4PPj3xFGroGkQSKEkAkkHmADAVueQBwAeAK46eC5uJ5JngYNIxcgKcAk1+iTaNpNwq/a9NsZBkth7dB16duuDj86c2i6Hd2jQLpunPCQVISFeB9RU+1py+Jv+vmNU3Hax+eemaZcT3cabMMTwrg819A+DvhnrVzoAuLMiGZzlZIoiOO/J6/hXtOn/AAw8P2eoy3UMMnmScbcDA+mRW9e+IPD+golpeatY2rRrhYXlG7A9vWr9vCn/AAtWQ6bl/E0Mb4feG7zRbBUvZYmIGCNrbyfcmuzUBegwPzrkf+E90uaOSSwiuruFMAyImBn2zTYPiFooiaW+m+xKM5MvTj+tYVKdWb5nE1hOnBWTOxHXqKhu7qCzhea7mSGJAWLO2ABXM3fxD8L2toty2sQNuX5I1OWf8K+c/jD8TG1t5re3knitlYhSsuB9Md6IUJS1eiCdZLSOrO5+Lfxp02PTrrTNGR5zIDG7uNoPpgdfxr5a1nV7vU599wwH+yo2gUkzXFwS8W9ochWlbpnrgmqs8TgGTlowdpdR8oOM4zWknaPLHRGcVd3luQDPPPXjGat3OmtFo0Oofa7NhJO0H2ZZQZ0wM7ynZT0BquIpDGZRG3lZ27tvGfTNa9j4en1LSrma1Qvc26mVogpLMg6t+FRGDk9DRyUdWc6cY4pDk9TTivAzjpmmkVJYlFKQOwo7HnikAnainH+VIetUIT8aKPpRSAsYIHPUnnFdH4c8Hat4i0TXNV01YXtdHSNroPJtYhyQNo79DmueXIyf/wBVdP4JhtpJ7hdRe7jspFC74idm7PVgD82Owq6cOeSRM5cqbGan4XmsrGOXckqAcyxNuA/3h/Ca5uSIhscY68V2WuaLd2WZ9NnNzAecxthsepWuVmbzcl1+cjkjjHNbVYJPYzpSfcpkc5OO9KQcDJBH1qRwwyDjp6Uxs9SR/SuZqxuncj/r60YpTncTk9e9J2pFEigcs3b1PStbS7ho5V3SRKBwCxORWMOck8d81IvLYByR/KrhLlZnONz6N+DGt6Zb6jI8mjtNKFCiWJPMOfoa+kdM1O2liZ/KaDB5DR7T0z0+hFfBfg7xDqeiXG6wvWjPXb15r6i+EPi/xBrjOkzLOgA3GYgbOOo9a6asfbR5uqMIP2crHtMTrKiuM4PqOazdfNzHpk39nxyNOR8ojQNzz1ya0CzJEWZRkDkA4/WvAPjJ8WbrT0kstLkkgyCpaGX7x9cgVy0YOUr9EbVZJK3VnGeLPiB4j0LUbm01iFEctwzjcV9AADWRL8Y9fsoQLS+urdSvCRgKv15zXletavc6revdXlzcTTsfvyOWNZxupGURuwbHQtyR7V0VKsXdW0MIUnuem3fxe8b36TRzeILoW7cFFx0+oGa4qTWLme+aS5Z5ZC333Yk/XNYXmsjHa2Pam+YW5ZuB+JFYqSj8KNfZ9WepDxv9j0yK3tklmlxguZOV/CqA1tLmaWSeCF3lUhjMSTz/ABD0NcAkjrhw3zAYp8MjFhksw/St1iWzL2CR6Kz2SWb20N3EHkZQpJz+f51yOtJGjbFmSVxkkq3ygn0/SqcssiqwaVI2zwijO4VUkQbN7SjPoeTTqVeZWsEKdne5674as7XXvgHJoMGuaDZ6mniY3vlajqEdsTELUJuAcgn5jj8D6V19heeET8LT8PJfEelrdTaUb0uxUQjUCfOANxu28ALEV9vwr5tL4HHPuTTQQxAxz71yM6Uj6d0S58It8NV+HjeINONzLpf21mJTyhfk+aM3G7bkDbFt9vwrrPhB4GiuNCiunDQWcyhXReGn9Q7dcew4r5O8P20txewrHbyzHcCqIDgnNfcfwn0zV7fQIZ9XJgVx+7tf+ef/AOutoydOm5J2MJJSmkeB/Eb4C3lhqHiTU9LvrKDR7VPtVtDO+JJUIyyD/d5HPWvAXQAYJ5zX3z8Y/h/beO/ClxAi7NWtlaazlz1YDOw+ob+dfBt1C0Nw8T/Kykg85we9ZOXMuY0V07FPoOtAHWl7D16c04ct6g9/61JoMPuKTinHvnrnNNPWmA2ilzRRZCNm+0fULGw02+vLZorXUUaS1kJBEqq21iADkYPHOK63wB4ot9LMdlfxiS0BYoSoYqx68e5/KuE6E4GR05q9aDzHBjcK6njccfqOa2pScWnEzmk1Znu9x4Z0nX9Pa4sUeCUPxPbElT9V4Oc98V5VrWlCzvvK1FRnj96UIBGepyOa9M+FnjdbGWO11e1KzoTiUACR8joT0cfU/hXceNtf8Ma7ppjvrCMucKs0SgNkdAV4wM+ma72/abo40nDqfLl7ZhWP2f50A79R/U9aom3cIXC5UdSK6jXbYW186QKzx9VIOePY9T+NYN3KCfmXawOSFODnPeuSpTSep0wm2UGjyAF/KoyvHPFTsCGORg+9NYHoQTXM0bpjNjHpg8dqdsHAJKnHIPam5OQeeaaXLf8A6qQ7M0bGzlmO6B13jgAkgn8a6XTNc17QXVjc3MCjn91KDx26GuNE0kZCqSp/EVLHdzxkOHJ6Hnn+daxnFLYylBs9M1T4oaxeaeYl1zUlbjIlnZh/9avOLzUrmZnMtxKzNndluT65qGa688jzFTI7hQM1WcAHA6fXNKU76L8rDjTS3FMjY4OPpTck8MeM02g1maB0HFKrbTnvSUfU0wJRIR1wB9OakUu3KcDGCScVXxxntUq5PO3p3zQTYlG5nCIDJI/AUDJJ9MCprrTru1RWurOeEMDjzEI7+h961/D2vXujrI2mwQlj1d0DHP0P9Kg1/UdQ1O583UpvMY9EVun4dq1cY8t2Z8zvYxJUCAZx9AataVZSXl3HDAgZz13NtAHc5pbezmnkCRooP+2wUD65ret9HjR2b7VvZcHIAjUjv9cfWlCm2/Ic6iSseofCjQdNXV7aN7oXF4Hw7xjEMPpnufwNfW9kqJax+XIGjVclyeOnqe1fNPwcTV5o/s/h3T7dynW4kUhDz3Y5yPpX0FFZywWKNq1z9onRSfKt12R5x0C5JOD7/hV4pJ8sbmdFtXdjVe7ijh83zQFzhW67j6D+9+FfGPxv8DJb+NtUutEaxhs3t2v3gkukj8vBwyDJ+Z887Rzg9K9p8aaxLp01x9qlaLzBhIUOZNuO/ZfrivBvFdrqHiS2umith5UDGQTH7ikDJG71xVQwvJB9bkTr8010PLGwBk984pvAPf6d6WT6cjrTM9B6VyHYkDHPf2prf55peO1JjPtTBjaKXB9KKVhGkqoAH6HP3W6fnVy3gt3EZ3PA+DlieM/UV0FpolhqR/0G62yHrC4Cuv8ARvw5qQaNPoWolLqNhGSA8MicEHoMdQf1rtVJ77o5nUT06kGmz3cEscV3EJYicgnnB7EMO9duNLttWsh57yC4UEic5Vxnpkj5ce+d1dX4M0Xwzqlv5c0ca4Yb8zbDEcfwknnntzXaXngM2Nms2jubi3YFSoAkwOoG0c9e9dMOSPu3MZcz1seB6lFPpgaTZDdRAbUMZyuOh46j6t19elUvt+jajAYb2w8ucsNk8ZBAAHcA5/Sun8eW+oWl++2Jg+MGMINyjrlgo/nXDJO7SSmaKF3xjLRlWxnoMYA+uKVT3ZWQR1V2R3NrbREFIBNCWwCxKsPwHP8AjVO8sbUwlxFJH6GNwwz7gnd+lXJ5IJGVUWS1fJ/eMS659KqPLHs2bYQQc70c5b356VhJo1V1sY0kQJO2RWx6nB/I1AwIyegq9cwPkugLR9c5DH8xVFwTx61yzSR0xdxjDnvjvmnEKo+VsmmkDtwB+tIRUFh06Uhpe2aQ0DE+ua7/AMZfDuXRvi83gbTbpr2Y3FvbxztHsLGWNGyRk4A3nv0Ga4DAzXquo/GzVr3xL/wkX/CO+GbfX+cahDbzCUEwmIHmUjhSMcdQKRLMX4t+BYvA+sWUWn6n/a2lX1v59veiPYHIYo64yeQV/UVwpyK67xX8Qtc8WeHNP0nxA8F6bGd54bx0InUOAGjyDt2cA/dzkDmuROPxpgIPzxVmBXmJ8tG467R0qADqcDB9a1dLjg35kQsQOm/b/Q5/+vVQjdkSdkWbYBSYY2IBI5kIC5we9DCJ2wpUHOCCDxzjr3q7HHDJMY7fTvtAJHIBXbxyP/r1fVY7a5ibUNOtkhzlk3nP411KNzmvqFpoIu4S8TL8g5ZnwjY6DPbr3q9p2mNbXflWcEbzrgNLgyGL3B6Yzx0p2taudZihsrO0t7OCHIBVic813/w/07T5jGt4019jh44ztgGPU9T9K2iot6IhuVtTuPg7ZrYmTy5pbq5ueXijO0KV7uv9Riu/8U6+lnI9gJluNQcZSyiOxm46MTyR9MVqQXy6V4bAgt47aFY/kiACpn25/Wvnf4g+INSvtYlS4v7SJEIVI4gSIwPXJyGrG3tZuTVki5PkVh3iLVrRZppJ4mv70/M8YJ8qH2Pf2xXF+KvEV9exLaLawwwwjb5KkhEPbjsa6rw7o3iTXYfsukwtFbuwEspBRSc8sTznNei6X8MHeP7LNIt3MuA8UI2xr6F3/PgAmumbj9p2MEnfRXPlqPQNS13WBbaPZNdTztIVjgAG4opd8AnqFBOK5txg/Wvqj4jfDSOy05oGkDtKrfZktVwscmDku3BIA4z3FfMd9aS2V3LbTrtlibawB9PSuGvTUbTjqmdlGo37r6FLr2xSgdR044pzDBOPwOabjHNYG4m3PcD60Uhxn0opAacF3LCfm+YA9ckMPoRXcab4u3Rxw6lH9uiAJHnnEiduGH3q4NZcuN4B7ZxyKspmIhigZOu09DXTCTjrFmEoKSsz1zw9r+g2N2hE13YybvlIXeuf9pcZAr3HwabC6eCS0n4b5VfTp9vmHGSzRNuJ59CK+QobyE7jJFICf4lOT/8Aqr0X4b+MLLSb8Nc2ZmtuMyQEkxgf7Oetbe15lZ/1/mZKPK72PpnxR4NfWLIvHJDLdnjfIvlcd93XOP6V5l4j09vDsf2PxPpC3FuRhbiBdwxyMlu2ff0r2fw34m0XVrKI6dqEcgxgKx2sB7g1oajpVhrFrJDdxLNBNzIEbG/64rKli5QfLPY0nh4y1jufHPiXwzpWpbpdDu1jUDLQydEGPXtXD6v4blsNzq6ug6mNsgf419H/ABC+Fq2TTf8ACOw3jwSNvMUab1B7AV89+JdKvLS5lguYLiAhti+dkAnOMYrpqJTjzJXMouUXy7HKOk0bfxFTzyODUMj7m3HaM+g4rek0W9ijU3em3DRuMrIoJyPqOKz7u3SBfnt3ibrjfk/lXJOnJLXQ3Uk2ZrIMn5g30HSo8du/Wpm68HIHrTWHBzyB19awehqmQ0nansDznrTM8Uiw7j1pDSkcetJ+NAgoNKKB0H9KYEkCNI6hAM+gr1fwV4LjubZbnWNb0rTIR82wsXnk+gA/rXkyEbufzr0rwRqaltsMlvp8ZwG+ckg8c9Px+uK6MO1zanPWvY0Nb07RbW7lj023urkA486W32xflXGXbujSRqVGSSMckD2PavenutBksZhfXZvmkQHzJbtmUE9PlIxwe1ef6taXWtSTLpsFt5SjgRxKjuBxjjrXXOCktNzmjK25y/hy0W7vIkbkDjDZ2gnvjFfTvww0C0a2X+zxNLKsYzNIcJCc/wAPrXJfCj4WzvOtzrtkoiPIjaYgkdj8vQ19B6TpsGnWscFsgjjjGAqjj8T1P1Nc9WqqUeVbm0Kbm79DBm8GW9zBN9uuZbmWYbWLDII+h6fWuP0/4I6b/bX9oalcCRFbKQBdw2+hzwPqK9d6e1OP3sHgGuX6zUV1f8Do9hC9zPttJsraxWzt4fLtVAXy0OM/UirUzGC3ZbWANtH7uIfKPz7VLnAOTgd/pXF+MvGaaHBK0aRlcbUZm6t3H9ayip1HbcKjjTV9jnfiXrzsE02H9/qEwO1Y/wDVRAckM3r9Aa+WvibBFda/FHp0f2m7/wBXLJFk+c5OFCr7fdHc13Xi3x3fX9xPbQbreI5Mkp+UkH09PwrzG+nkB82w3W0MbiWOYHbI7g5DBuucjIr0ZpRp8iOSLbnzHM3dvNaXE1vdRSxTxOY5YpF2sjA4KkHoQRVckA8YqxfzzXF1PPdyyzXEzmSSWVizOxOSxJ6knqTVU1wnathCeeDRSUUhFpc57VZt7qWLABDDPIcZBquCDxnj+VC9wMY7etXF21E1fc1LaeNtzcxSk4BXofXPoK27ac2UkcssUbIOVmg4Bz6f/XrnLYjKcZyfunkD/wCvXZ6DosksHmWiyyAL+8UFW56nC9eldVK70MKlkeseGNWhvbIvqAnt5dm1Li1G5s8fex2rpfD8uqWN27R639otolwRBgFMn+Pn5v8A61eY+HdDZHzo2rNYXrJ81vdZjMhPs2Bz7V1toIdwk8T2kVtcEqqT2zFfM5xyBxjmutxvujnTa2PW9P1qa7tYXttUtfOUZ3lyque+VPANYWoHxBc6nnVdA0jULbdt80/vMrn2zya3rTwHpGqaWGleXewB3JIGCg9uKnh8E3Gl2kltomrSQ2rc+VNyCfqK5VUpwbs/zX4o3cJyWquTP4J8N6lAYmh+z74/9RDMAI8+3rXmvi34EeHHhnls9f8Asb/eAnAcD1zjmrHiO+1rRnlt7zw48mRuS5spCVA9+9cpqPjSK4ge2voo7eUDgzKynH1q4wqPeV0ZycekbM8e8Q+CJNMmkSPUILhEyQ4XaHHrzXJS2EwGcb1HdRkV6p40vY2cfZ7aEtknzVl3DBHevN9RuHy298OeojOP5VFeEEaUpye5kSYBwykH8qiI6ntViRiw+f5vcnmoZB82R09Aa43odSYykpT09aQ0hij60vOOOxpO1OAwTnp7imIWNSW+7n261u6ZZX0zCPZJCn94Jtx9Se1ZtuHBHlHn34A/Gum0rUp0ZFe5WJBwwQ7iSOlb04q+phUk7aF2Lw5GJFNxeyPMP+WSAswweRnpXrXw98Pa0tvHJolt5RjUgTXUf7wHpuCnrVLwPo0d5rNlNDq5trIYaSV0CKSOo+bqa+k7U2uk6cptB5oC5aRnEakdzuNdE5KirRV2zGMXU1bGeE9FbS7MPdFWvJADIygjn6Hoa3SwAyWAQ9yeDXn2r+NBO81tpRSWWNfultsZ46Fu/wCFeaavrGoMZsa68YCqQiRlVjPfGT8wrmWGnVfNN2NXXjBWifREl3bxlUe4hDO21RvGSad56MshVtwQZYjnaPevi/WvEm1Rb2eo6lcOhy5RtqFs9a7HQ/iVdx28P2myudTnhACebL5cMfHRl6tSlg+idw+st7o+hPEXiey0uxZgfOkPAC8qCR3rxXxmbjUtt1Duu7uVD1TCxgHkegGOax7/AMSSa0on13Vra2SHkIh+aIZ4C46fU5rjtb8ZW9xHJb2mpXv2ZM4fduYnoenXPrXVRpxorzMKs3Ufkc94lSDRZpRfTJqN8c7IVbdCn49TXF393LezM93Jub+FE4ArV1i6tp5pDCmwnk7myzcdSe30rNhmhifMcKzOoyCfuD1z61jUfM7dDSCsr9TNljJQv/PvUMiPHjerLuGRkYyPUVPczlmJJG4+nb2qXVtYv9WFkNRuZJxZ262luGx+7iUkhB7Asfzrml5HSr9TPoooqRlsEc84PvS85HvUSnBPHA9KcGX0wCad9AsSxOyEFWK/Q5rsvDOozI6vbTR+cONytsZPcgnBrisj61cRHI3KjYA++vOB68dPxrelLl2M5x5j219Y+0SLHq8bS7BgTXMWw49nwB154pZ727iY/ZWNxbgAJHIylUz6E8+nevIrTX9VtHbZelgV2jzcNx32g9K1IJ5L9JHmWLc4ULuDA/hgjFdka99LHNKk0evaH458Q+HI1ljiYQIuWiUiSMc8ZI5H4mu60343tLGFudKWSZeCId2S30NeAWlzLpHySXMckY48q6bgflj9c1pT+IrZozKdMETtgieJ9pb65zUyp05u8lqClKPwnpPjH4yxTQoq2klrcDuFJB789xXn+t+PLjVrR0e2tgCCVddufyPNVbnW7Ce0K3dlf6eeG3NtYP7/AHc1yOqW4ljL2TwvnrtU7sfQmnfkVoMXxO8ircX5vLkicrHGcnO3Jz6cVnTJFIfLSeADruK4P50i2Zkl+S4jjkxkiX93+p61Mmnp90pDL2/dThifyrnd5bm2i2KtxZxQqC1xE7k/dTnH5VROcfLnNbiaQrsQ1vcR+7cL+eK0F8KF1ys1uM5ChrlVb8eKl0nLpYpVEtzjzuY9yevSkCNzx+ddHf6Elm/72eFRjPy3Kv8AoAKz3itUAJMp/wB1wP6GodNrctVE9jLIKnB6mnclQeprVaOzVN6x3GexZgy/oKrNIrFQkaIAME460nC3UfNfoV03DHOOMHmtTTlhV133Bh4zmNNxqnjeMFgWHYL1qRVcLjEaheMFvmPvTirES1Pd/h34l8PeGlEsdjBfXSqQJry4C7ec5wal8Z/FHU9cllglvLOO025WO2+dT04OD1/GvDbOMTlVhhmuGA3BCcjHetqysZ5VAtrFonIClpmwgI69q6Yyu72MJK2lzsbnxDaNAstxcedIHGA0oK4xyNg7Z965/UfEt3qCrDZq7IBjYqkKnpivSPC3wbTU1juL6+m1F2xtSyhzGueu5mIxj6H6V3s/w38P6FYPHrmrxwKoJjtEOAB2DD+LnPoKtz6SdhKHVI+bhBPJKxO2Q/xxg5AqxduIURHmkmYfKIYfkx9T6e9bfjVNLtrlit5dxW5GYo44ggYA8YAbgVwJkillP2S0lkizzuf+Z/pSnaOgorm1NO4a2K7ChkbBxDk4B/3u9UI3lZkjEYjOM+XGmO38Q9adJqkNr8iLFGD8pSL5iPxNQXHiiVYEi0y3SzOPmmB3Sk9yHwCM+lYynFbs0UZPZFvUNPtdNiL6lLi4ZQVgUgk+5PpXN3F48p+XCLjAA4wKgd2ldnkYszHJYnJNN4rnnU5ttDaMLb6hkYoPXilx7fpSGsyxM0UN1ooGSscAdTnmgHJFFFWUhdxBIzn61JDM6HKMyk9wcfnRRRe2qBpMsx3O6XY6KRjqvGasrhZV2bkzjoaKK1i220zKUUWphPbeWDcGR2UvvI5GO3WkuQ6RmZnDsWwSw/lzxRRW0oq7X9bGfVEVvJcbQwuZfmKg5OeO1S3SSCcFJSpVckjvzRRTik4il8RfEFvMsUbpIZD/ABlwR27Y9/WtFfDzAyeXdqoVQR+66DrgfN7UUVphYqrfnM29LjLXw+biaRZrreQQMlD6f71St4bKk+XfSJghRhPY+9FFdHsYdjNzZl3eipbyOJ5nnVBwD8v9T6VkXVvD5iLErJkcktnviiiuKtFRlZdzog2zoNI8HpfLlrvZyB/qs9/96uv0r4XW1/Ktv/aLRlhncIc4P03UUV0QpQulYXM2j07wd+zbpFxYwXt/rl5MrkkxRxCPj0zuP512V78HfAmgaPcXMmitfvApYmac7n/H/wCtRRXnVJtTcVsjZxXK2eEeO77R59YltNI8NaZp1vDtx8gkfIHXdgHOT79Oc1i+HvEV3o8u61jt2fACtLHuKgemfXNFFd1N+6mcq1imzsdS+Mni42qoLuJI1j/5Zx7WOQB1zXG2et6zrouLu51a7UhMsu8ncM4wTnpRRRBWlZbBLZtnFazq8ZvGaKyjMnKlp283P0BHFZFzql5ccPO4XGNqnaMfQUUVwSqSe7OmEVyplP1pPSiiszQUHilPTNFFIQuOaaaKKECEye1FFFMZ/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The origins of the right (RCA) and left (LCA) coronary arteries can be seen on the short axis precordial view, obtained through the aortic root (Ao) just above the valves; there is a vague \"pinwheel\" relationship of the sweep of the arteries. Additionally, the left atrial appendage (LAA) is seen just inferior to the LCA and the pulmonary valve (PV) just superior.",
"    <div class=\"footnotes\">",
"     LA: left atrium.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_42_29359=[""].join("\n");
var outline_f28_42_29359=null;
